

Author Index

(Italicized page numbers refer to comments in General Discussions)

Abrams, W. B., 98
Apostolides, A., 254-266

Blackburn, H., 36, 58, 66, 236-242
Blaufox, M. D., 254-266
Blumenthal, S., 28-32, 36-37
Borhani, N. O., 254-266

Cooper, R., 110, 388
Curran, J. P., 320-330
Curry, C. L., 363-372
Cutter, G., 254-266

Dustan, H. P., 460-462
Daugherty, S., 254-266

Ferguson, D. C. E., 222-235
Fitz, A. E., 267-288
Fodor, G., 200
Frohlich, E. D., 58, 68-73, 109-110, 125,
267-288

Gibson, E. S., 390-403
Goldman, A. I., 267-288

Haber, P., 463-465
Hammond, J. J., 147-160
Hawthorne, E. W., 292, 363-372
Haynes, R. B., 390-403
Hunt, J. C., 373-380, 389

Johansen, H. L., 203-219
Johnson, A. L., 390-403
Julius, S., 38-52, 58

Kannel, W. B., 16-17, 58, 128-139,
144-146, 161-164
Kass, E. H., 36, 110, 201, 253, 291, 318-
319, 412-419, 423
Kilcoyne, M. M., 33-35, 36
Kirkendall, W. M., 146, 147-160, 176,
200-201, 359, 361

Klimt, C. R., 250-252, 253, 289
Krug, S., 411

Labarthe, D. R., 3-14, 16-17, 37, 58,
422-423
Langford, H. G., 16, 98, 145, 175, 198-
199, 200, 289-290
Laragh, J. H., 165-174, 175-177
Lavin, M. A., 267-288
Levy, R. I., 441-457
Lewin, A. J., 254-266

Marston, M.-'V., 404-409
Melman, K. L., 112-122, 125-127
Meneely, G. R., 201, 361
Miall, W. E., 18-25, 422-423, 458-459
Miller, M., 98, 253, 318
Moser, M., 16, 126, 331-332, 360, 388,
410-411
Moses, C., 84-95, 410-411

Neri, L. C., 203-219

Ostfeld, A., 107-108, 109-110
Overturf, M. L., 147-160

Page, L. B., 2⁶, 83, 175, 200, 290-291,
361-362
Paul, O., 59-63, 66
Perry, H. M., Jr., 1-2, 220-221, 267-
288, 290-292, 472-475
Petursson, S. R., 320-330
Pickering, G., 27, 289-290, 439, 466-471
Polk, B. F., 254-266, 290

Ramirez, E. A., 81-82, 98, 110-111
Reader, R., 15, 67, 146, 309-317
Redmond, D. P., 222-235
Remington, R. D., 244-249
Richman, H. G., 267-288
Roberts, R. S., 390-403,
Robertson, J. I. S., 64-65, 66, 126, 144,
176-177

Sackett, D. L., 390-403
Saunders, E., 37, 96-97
Schwartz, G. E., 222-235
Schnall, P., 109, 360, 439-440
Schnaper, H. W., 267-288, 381-385, 388
Schoenberger, J. A., 420-421
Schork, M. A., 38-52
Shapiro, A., 98, 109-110, 123-124, 126,
175-176, 222-235, 318
Sheiner, L. B., 112-122
Slotkoff, L. M., 200
Smith, W. M., 74-80, 83, 291-292, 293-
308, 319, 472-475
Sondik, E. J., 441-457
Stamler, J., 140-143, 144-146, 201-202,
263, 318-319, 333-358, 360-361
Stamler, R., 410, 439
Stason, W. B., 424-436, 439-440

Steele, B., 267-288
Strasser, T., 243, 291, 319, 440
Syme, S. L., 99-106, 109, 111

Tarazi, R. C., 53-57
Taylor, D. W., 390-403, 410-411
Thomsen, G. E., 363-372
Thurm, R. H., 201
Tobian, L., 178-197, 200-201, 410
Tuckman, J., 66, 253, 423

Ward, G. W., 437-438
Wardell, W. M., 320-330
Weinstein, M. C., 424-436
Weiss, S. M., 222-235
Wilber, J., 16, 109, 386-387, 388, 440

Subject Index

A

Adrenal disorders, 365

Adrenal hormone levels, 161

Adrenergic-neurone blocking drugs, 326-328

Age factors, 4, 12, 58

in antihypertensive therapy, 70-72

complications of hypertension and, 59
in interventions, 11

low-renin hypertension and, 162

Albany Civil Servant Study, 140

Aldosterone

in malignant hypertension, 162

in primary hypertension, 161

salt taste threshold and, 200

American Heart Association, Committee on Ethics of, 418

Angina pectoris, 78

Angiotensin, 161

Animal protein, 201-202

Antihypertensive drugs, 89-90

benefit-risk ratios in, 355

for children, 31-32

in clinical trials, 313, 315

consumption patterns of, 320-329

evaluation of, 225

holistic treatment and, 145

in mass treatment, 346-347

for mild hypertension, 68-72

side effects of, 283-286

adverse, 84-98

patient compliance and, 100-101, 410-411

placebo effect and, 107

in Stepped-Care Program, 296

utility function of, 112-127

See also specific drugs

Arterial endothelium, changes in, 148

Arterial pressure, 34

Arterial wall metabolism, 148

Aspirin Myocardial Infarction Study (AMIS), 444, 450

Association of American Medical Colleges, 251

Asymptomatic hypertension, 376

Atherosclerosis, 128-139, 145-147

antihypertensive treatment and, 359

blood pressure and, 128-129

role of vasoactive agents in, 147-148

in PHS hospital trials, 78, 79

Autoregulation of blood flow, 182-183

B

Baroreceptor reflex activity, 33

Behavioral modification, 224-232, 331

Behavioral problems, 99-101

Beta-adrenergic blocking agents, 64, 66

national consumption patterns of, 322-323, 327

Biofeedback, 225-227, 230-231

Blacks

antihypertensive therapy for, 70, 71

blood pressure in, 33

plasma renin activity in, 151-154

See also Race factors

Blood lipids, 128-139

Blood pressure, 3-10, 164, 333-336

body weight and, 239-240

borderline elevations of, 135

in children, 36-37

lability of, 29

measurement of, 34

control of

by biofeedback, 225-227

complication rates and, 81

educational program for, 68-69

nonpharmacologic, 340-346

by relaxation therapies, 228-229

as coronary risk factor, 152, 293, 297-299

effect of exercise on, 224, 237-238

endocrine or renal problems and, 374-375

genetic factors and, 19-24

labile elevations of, 135

mechanisms in regulation of, 161

in prediction of hypertension, 41-42

race and, 33, 257-259

regulation by kidneys of, 161

risk of coronary heart disease and, 135

self-monitoring of, 400

sodium intake and, 223

effect of salt loading, 191-194

stress and, 224, 231

variability of, 467-469

See also Diastolic pressure; Systolic pressure

Blood pressure reference curves, 37

Borderline hypertension, 7

neurogenic, 45-46

non-neurogenic, 46

pathophysiology of, 44-46, 53

predictors of, 58

Borderline hypertension
progression to moderate or severe hypertension from, 59-60

Bronchitis, 203

Bulbar input, 33

Cadmium, 204, 208-209, 220-221

Calcium, 200
in water supply, 204, 206-208

Cardiac examination, 366

Cardiac output, response to salt loading of, 191-194

Cardiovascular system
disease of
magnesium and, 211
mortality rate from, 79
risk profile in, 133-134
water hardness and, 203, 220-221

neural control of, 33-34

Casual blood pressure elevations, 16-17

Central resetting of arterial pressure, 34

Cerebrovascular complications, 60-61

Chicago Heart Association Industry Study, 140

Children
detection and control of hypertension and hyperlipidemia in, 137-138
precursors of adult hypertension in, 28-37

Chlorthalidone, 291-292

Cholesterol, 130-134, 140, 142

Cigarette smoking, 259, 262, 347-348
as risk factor, 138-143, 152, 293, 297-298

Clinical trials, 318-319
analysis and dissemination of results of, 454-457
costs of, 418, 423, 450, 458-459
design and management of, 244-253
end points in, 423, 461
ethical considerations in, 412-419, 451
financing of, 250, 253
planning of, 441-459
treatment benefits measured in, 439
worldwide, summary of, 309-316
See also specific studies

Clonidine hydrochloride, 92, 94, 96, 163

Cold pressor test, 40

Community high blood pressure treatment centers, 386-387

Community health workers, 103-104, 109

Compliance, *see* Patient compliance

Complication rates, 81

Comprehensive care, 347-348

Congenital malformations, 203

Cooperative trials, *see* Clinical trials

Coronary Artery Surgery Trial (CAST), 442, 444

Coronary Drug Project (CDP), 443

Coronary heart disease, 78, 79
as complication of hypertension, 60
mild, 64

hypertension, blood lipids and cigarette smoking as co-risk factors in, 128-139
prevention of, 293

risk factors in, 149-156, 293, 297-299

Coronary Primary Prevention Trial (CPPT), 443-444, 447, 450, 454

Cost-effectiveness, 426-432
individual patient and, 440
of nonpharmacologic treatment, 437-438
of screening, 432-434

Costs
of clinical trials, 418, 423, 450, 458-459
of treatment, 417-418
direct, 425
manpower impact, 425-426
savings in cardiovascular treatment costs, 426

Counselling, 31

Cushing's syndrome, 365, 367

Data management, 276-277

Decision theory, 112-115

Defense reflex, 289-290

Diagnosis
of hypertension in children and adolescents, 34
of mild hypertension, 363-370, 373-380

Diastolic blood pressure
as risk factor, 293, 297-299
pharmacologic treatment and, 334, 336

Diet, 109, 110, 223, 348, 350-351
low salt, 178, 331
magnesium in, 213-215
potassium in, 361
rice-fruit, 201
See also Obesity

Diet-Heart Study, 319

Diuretics, 183
national consumption patterns of, 322-323, 326-327

Doctor-patient relationships, 337-340, 352, 375-376

Double Masters test, 78

Drug therapy, *see* Antihypertensive drugs

Eating habits, *see* Diet

Electrocardiogram abnormalities, 78, 152

End points in clinical trials, 313, 461
Environmental modification, 224
Epidemiology, 47, 140
 salt intake and, 178-179, 207-208
 socioeconomic conditions and, 360
 water hardness and, 208-210
Essential hypertension, 194
 nutritional therapy for, 378-379
 volume-dependent hypertension and, 163
Ethical considerations
 in clinical trials, 412-423, 451
 in patient compliance, 390
Exercise, 223-224, 237-238
 in mass treatment, 345
 in prevention, 241
Extracellular fluid volume, 180-185
 regulation of blood pressure and, 161
 salt intake and, 193, 194, 201
European International Working Group
 on Drug Utilization, 321
European Working Party on Hypertension
 in the Elderly (EWPHE), 310, 311, 315

Familial aggregation, 30
Family history
 in diagnostic workup, 363-364
 in prediction of hypertension, 30, 42
Family support, 396, 407
Feasibility trials, *see* Clinical trials; *specific studies*
Fibrinoid arteriolar necrosis, 128
Follow-up visits, 295
Food and Drug Administration, U.S.,
 250, 320
Framingham Heart Study, 70, 129, 130,
 140, 340, 426, 427, 447

Glucose intolerance, 152
Group d'Etudes sur l'Epidemiologie de
 l'Atherosclerose (GEEA), 310, 311
Guanethidine sulfate, 91, 93, 96

HHealth and Nutritional Examination
 Survey, 425
Health beliefs, patient compliance and,
 395-396, 405
Health education, patient compliance and,
 399-400, 405-406
Heart failure, 61-62
Heart rate, 42
Hemodynamic heterogeneity, 34

Hi-Blood Program, 463-465
High density lipoprotein (HDL), 130-
 131
High-renin hypertension, 161-163, 166-
 167
Howard University Hospital Family
 Planning Clinic, 366
Hydralazine, 118, 163
 adverse effects of, 91, 92
Hypercholesterolemia, 142-143
Hyperkinetic state, 47-48
Hypertension Detection and Follow-up
 Program (HDFP), 7, 99, 222,
 247, 249, 250, 254-264, 309-311,
 443, 444
 design of, 289, 292
 drug regimen in, 291-292
 ethical considerations in, 415-416
Hypertension Education Program, 460
Hypertension Pretreatment Data Base,
 376-379
Hypertension Screening and Treatment
 Program, 463
Hypertensive evaluation, 368-369
Hypertensive personality, 101, 225
Hypokalemia, 223
Hypotensive drugs, *see* Antihypertensive
 drugs

Iatrogenic complications, 62-64, 123-
 124, 275
Impotence, 120-121, 290
Infant mortality, 203
International Atherosclerosis Project, 140
International Society of Hypertension,
 311, 458
Inter-Society Commission for Heart Disease
 Resources, 337, 352, 363
Intravenous pyelogram, 369-370
Isometric exercises, 224
Isotonic exercises, 224

Joint National Committee on Detection,
 Evaluation and Treatment of Hypertension,
 80, 304, 331, 374

Kaiser-Permanente Health Plan Clinics,
 102
Kempner rice diet, 201, 223
Kidneys
 blood pressure regulation by, 161
 natriuretic capacity of, 194-195
 salt intake and, 180-181, 183-186, 194

Labile hypertension, 58
Laboratory evaluation, 377, 379
in diagnostic work-up, 367-368
Latent disease, 374, 379
Lead in water supply, 204, 206-207, 211
Left ventricular hypertrophy, 79
Lipids, 128-139
Lipoproteins, 130-134
Los Angeles Civil Servant Study, 140
Low-renin hypertension, 161-163, 166-167

Magnesium
in diet, 213-215
in water supply, 211, 213-215
Malignant hypertension
aldosterone production in, 162
renin and, 167
Malignant neoplasm, 203
Mass treatment, 333-362
comprehensive care in, 347-348
defining candidates for, 333-336
medical practice and, 348-354
nonpharmacologic approaches to, 340-346, 359-360
pharmacologic treatment in, 346-347, 359
pretreatment measures in, 336-340
Medical history, 363-365, 376-377
Medical Research Council, 290, 422
Men of 1913 study, 140
Methyldopa, 163
adverse effects of, 89-90, 96
national consumption patterns of, 326-327
Midwest Railroad Study, 140
Mild hypertension
benefit of treatment for, 68-72
complications of, 59-64, 66
definition of, 3-17
diagnostic work-up for, 363-370, 373-380
intervention trial in, 74-80
as sign of latent disease, 374-375
See also Borderline hypertension; Essential hypertension
Mild Hypertension Study, 464
Mineralocorticoid hypertension, 181
Minnesota Business and Professional Men's Study, 140
Mortality, 8-10, 16
systolic blood pressure and, 334
water hardness and, 203, 211-215

Multiple Risk Factor Intervention Trial (MRFIT), 293-304, 309, 443, 444, 450, 452, 454
Multiple logistic function, 303
Multirisk factor analysis, 151-152, 157
Myocardial infarction, 76-79, 290

NNational Health Survey, 4, 29, 42
National Blood Pressure Study (NBPS), 155, 310, 311
National Cancer Institute, 244
National Cooperative Pooling Project, 9, 140
National Cooperative Study on Renovascular Hypertension, 364
National Heart Institute, 244
National Heart and Lung Institute, 99, 363, 414, 415
National Heart, Lung and Blood Institute, 21, 26, 28, 222, 254, 267, 373
clinical trials by, 441-457
See also Veterans Administration-National Heart, Lung and Blood Institute study
Hypertension Education Program of, 460
National High Blood Pressure Education Program, 72, 324, 354, 363, 381, 384, 454, 455
National Institutes of Health (NIH), 441-451
Nephritis, 203
"Neurogenic" borderline hypertension, 45-46
Neurohumoral heterogeneity, 34
Nitrates, 204-205, 211
Non-drug management, *see* Non-pharmacologic treatment
"Non-neurogenic" borderline hypertension, 46
Non-pharmacologic treatment, 80, 222-242, 340-346
behavior modification in, 224-232, 239-240
diet in, 223
physical exercise in, 223-224, 237-239, 241
salt restriction in, 240-241
Norsk Medisinaldepot, 321
Nutritional therapy, 378-379
See also Diet

Obesity, 30, 53, 108, 223, 259, 262
control of, 331, 360
in mass treatment, 340-346

Obesity
in prediction of hypertension, 42
prevention of hypertension and, 461–462

Optic fundus, 366

Oral contraceptives, 365–366

Packaging of medications, 401

Paramedical personnel, 381–389

Patient behavior, 99–101

Patient compliance, 2, 109, 231–232, 332, 337–340, 347, 390–402, 404–407, 410–411
clinical significance of, 393–394
cost-effectiveness and, 430–431
health beliefs and, 395–396
measurement of, 391–392, 404–405
socioeconomic factors in, 411
strategies to improve, 397–402

Peoples Gas Company study, 333, 340, 341

Peripheral resistance, 191–194

Personality assessment, 101

Pharmacologic treatment, *see* Antihypertensive drugs

Pheochromocytoma, 365, 367

Physical examination, 366

Physical exercise, *see* Exercise

Placebo effect, 107, 225

Placebo trials, ethical considerations in, 415, 422–423

Plasma renin activity
antihypertensive drugs and, 167
determination of, 368–369
in reduction of cardiovascular risk, 147, 149

Potassium, 198–201
in diet, 361

Prazosin hydrochloride, 92, 94

Prediction of hypertension, 38–58
by descriptive characteristics, 41–42
multiple factors in, 42–44
by provocative tests, 40–41
renin and, 147–157, 161

Pregnancy, 71, 365

Pretreatment data base, 376–379

Prevention of hypertension, 239–242, 461
exercise in, 241
primary, 355–356
salt restriction in, 240–241
weight control in, 239–240

Preventive medicine team, 387

Primary aldosteronism, 163, 365, 367

Primary endpoints, 76–77, 247

Primary hypertension
aldosterone production in, 162
atherosclerosis and, 128–130
childhood precursors of, 28–37

Primary prevention, 355–356

Primitive societies, 107–108
salt intake in, 178–179, 198–200, 223

Private practice, outcome evaluation of, 386

Progesterone levels, 161

Propranolol, 64, 66
adverse effects of, 90, 91
as renin inhibitor, 163, 164

Prostaglandins, 161

Provocative tests, 40–41, 48–49

Psychological factors, 41, 42

Psychosocial factors, 101–104

Psychotherapy, 225, 231

Public Health Service, U.S., 115, 117

Race factors, 256–259, 261
antihypertensive therapy and, 70, 71
blood pressure and, 297–299
body weight and, 239
plasma renin activity and, 151–154
in prediction of hypertension, 42
rate of hypertension and, 102–103
renovascular hypertension and, 364
See also Blacks

Rauwolfia alkaloids, 325–328

Relaxation therapies, 227–231

Renal hormone levels, 161

Renal papillary plasma flow, 186–191, 194

Renal parenchymal disease, 183, 364, 370, 374

Renin, 46, 161–164
inhibitors and stimulators of, 163
as predictor of cardiovascular damage, 166
as risk factor, 149–156
as vasoconstrictor agent, 147–148
vasoconstriction induced by, 165–166

Renin-dependent hypertensive disease, 149

Renin-sodium profiling, 165–173

Renovascular hypertension, 167, 364–365

Reserpine, 118, 163, 290, 328
adverse effects of, 87–88, 96
drug interactions with, 88–89

Response to exercise, 40–41

Risk factors, 164, 303
in coronary heart disease, 293, 297–299
of drug side effects, 397, 410–411
duration of therapy and, 365

Risk factors
family support and, 396
health beliefs and, 395-396, 405
in patient noncompliance, 394-397
renin as, 149

Roentgenographic evaluation, 367-368

St. Thomas' Hospital Trial, 310, 315

Salt intake, 108-110, 163, 178-195
blood pressure and, 198-199
from drinking water, 206-207
eating habits and, 361-362
epidemiologic studies of, 178-179, 207-208
experiments on, 178-185
kidneys and, 180-181, 183-194
prevention of hypertension and, 240-241, 461-462
renin and, 149
restriction of, 223, 360
See also Sodium

Salt loading, 55

Salt taste threshold, 200

Screening, 268-272, 281-283, 291, 293-297
cost-effectiveness of, 432-434

Self-monitoring, 400

Sex factors
antihypertensive therapy and, 70, 71
in clinical trials, 291
systolic pressure and, 33

Serum cholesterol, 130-131, 140, 142, 152, 259, 262, 293, 297-298

Side effects, 283-286
adverse, 84-98
patient compliance and, 100-101, 410-411
placebo effect and, 107

Seven Countries Study, 240

Society of Actuaries, 8

Socioeconomic factors, 101-104
in patient compliance, 411

Sodium
antihypertensive drugs and, 167-168
calcium and, 207
regulation of blood pressure by, 161
water softening and, 208
in water supply, 204, 211
See also Salt intake

Sodium retention, 163

Soft water, 208

"Soldier's heart," 469-470

Spironolactone
adverse effects of, 86-87
extracellular fluid volume and, 183

Stepped care, 254-256, 261-262, 296

Stress, 41, 101-104, 109
socioeconomic conditions and, 360, 440

Stroke, 76-78, 139
blood pressure level and, 157
decline of mortality from, 146
vasoconstriction and, 165

Suprabulbar projections, 33-34

Systolic blood pressure
mortality and, 334
risk of coronary heart disease and, 135

Target organ damage, 74, 259, 263
assessment of, 164
in definition of hypertension, 4, 12
intervention and, 11

Tecumseh Study, 140

Therapeutic compliance, *see* Patient compliance

Therapeutic trials, *see* Clinical trials

Thiazides, 64, 290, 368
adverse effects of, 85-86, 96, 98, 144
drug interactions with, 86, 96
effect on myocardial infarction of, 290
extracellular fluid volume and, 183

Tracking correlations, 30, 36

Transient hypertension, 58

Transport Workers Study, 140

Treatment Trial for Mild Hypertension, 310, 311, 315

Triamterene, 87, 88

Triglycerides, 130

Urinalysis, 374, 377, 379

Urine sodium measurement, 165

Utility function, 112-127

Vasculotoxic agents, 147-148

Vasoactive agents, 148

Vasoactive kinins, 161

Vasoconstriction
extracellular fluid volume and, 182
renin-induced, 165-167
salt intake and, 185, 194

Very low density lipoproteins (VLDL), 130-131

Veterans Administration, 267, 463-464

Veterans Administration Cooperative Study, 10, 15, 38, 60, 72, 111, 115, 117, 118, 165, 222, 250, 254, 267, 309, 373, 414-415

Veterans Administration Cooperative Study
comparison of PHS Hospitals Trial and, 75, 76, 79
coronary heart disease in, 137, 144-145
limitations of, 69-71
significance of, 68-69

Veterans Administration-National Heart, Lung and Blood Institute Feasibility Trial, 310
administration of, 277-280
data management in, 276-277
design of, 289-292
iatrogenic events in, 275
loss to study in, 275-276, 285, 286
morbid events in, 275, 283-286
sample size for, 267-268
screening in, 268-272, 281-283, 291
study population criteria for, 269
treatment in, 272-276, 283

Volume excess hypertension, 167

Water hardness, 204
cardiovascular disease and, 211, 220-221
epidemiology of hypertension and, 208-210
mortality and, 203, 211-215

Weight control, 239-240
See also Obesity

Western Collaborative Group Study, 140

Western Electric Company Study, 59-61, 340, 341

Whitehall Study, 140

Women
in clinical trials, 291
in Public Health Survey, 83
risk of coronary heart disease in, 135
See also Sex factors

World Health Organization, 7, 311, 321, 458

Zinc, 211



Author Index

(Italicized page numbers refer to comments in Discussions)

Agnati, Luigi F., 346-369

Baldessarini, Ross J., 198-206

Baliga, B. Suren, 96-105

Barofsky, A.-L., 174

Baumgarten, H. G., 3-24, 36-56, 56, 84, 94, 107-117, 117-118, 133, 145, 171, 175-177, 189, 206, 258, 260-261, 262-288, 423-436

Björklund, Anders, 3-24, 305-327, 370-384

Bobillier, P., 576-589

Bonetti, E. P., 595-620

Bosin, Talmage R., 134-145

Breese, G. R., 160-170, 171-174, 241, 260, 664-665 (Moderator), 664

Browning, Ronald A., 437-456, 456

Bruckwick, Eleanor, 182-188

Campaigne, Ernest, 134-145

Campbell, Alexander, 198-206

Carruba, Michele O., 172, 242-258, 258, 478

Clemens, James A., 399-410, 410, 478

Clineschmidt, Bradley V., 222-241, 241

Cohen, Gerald, 74-84, 84

Collu, Robert, 411-422, 422

Coscina, Donald V., 172, 206, 241, 456, 479, 627-644, 664-665

Creveling, C. R., 56, 57-73, 145

Da Prada, M., 56, 118, 146, 173, 260, 385, 595-620, 665

Donelson, Alan C., 134-145

DuCret, R. P., 590-594

Fuller, Ray W., 147-157, 158-159, 172, 175-177, 178-181, 241, 259-261 (Moderator), 260

Funderburk, W. H., 302-303

Fuxé, Kjell, 346-369, 386

Gál, E. M., 84, 105, 119-127, 127, 158-159, 175-176, 241

Gargiulo, Giuliana, 242-258

Gershon, M. D., 385

Gerson, Sylvia C., 198-206

Giambalvo, C. T., 173-174, 189, 478, 524-531, 589, 664

Göthert, Manfred, 457-476, 477

Growth, John H., 159, 207, 510-523

Gustafsson, Jan-Åke, 346-369

Hallman, H., 328-345

Hancke, J. L., 423-436

Harvey, John A., 259, 289-302, 303-304, 385-386 (Moderator), 385, 664-665

Heikkila, Richard E., 74-84, 133

Hoebel, B. G., 478-479, 590-594

Hoffman, William E., 437-456

Höhn, K. G., 423-436

Horn, A. S., 128-133, 133, 158

Jacobs, Barry L., 207, 479, 497-509, 664

Jacoby, Jacob H., 1-2, 146, 258, 261, 387-398, 478-479 (Moderator), 478, 664

Jonsson, G., 328-369, 665

Jouvet, M., 576-589

Kaufman, Nathan, 480-496

Keane, P., 576-589

Keller, H. H., 595-620

Klemm, H. P., 3-24, 36-56, 107-117

Klupp, Niels, 457-476

Köhler, Christer, 385, 645-663

Lachenmayer, L., 3-24, 107-117, 262-288, 385

Lorens, Stanley A., 532-535, 665

Lovenberg, W., 3-24, 182-188, 188-189, 221

Lundberg, J. J., 262-288

Lytte, Loy D., 1-2, 175-177 (Moderator), 480-496

McGinty, J., 241, 385

McGuffin, Jodie C., 222-241

MacKenzie, R. G., 590-594
Maickel, Roger P., 134-145, 145-146
Massari, V. J., 259
Meek, James L., 190-196, 259, 261
Meshul, C. K., 84, 221
Messing, Rita B., 480-496
Meyer, J., 410, 422
Mølgård, K., 262-288
Moskowitz, Michael A., 96-105, 105-106, 259
Mueller, R. A., 160-170
Munro, Hamish N., 96-105
Myers, R. D., 385, 478, 556-575, 665

Natelson, B., 479
Nisticò, Giuseppe, 242-258
Nobin, Anders, 305-327, 370-384, 385
Norelli, C., 590-594
Nowak, Thaddeus S., Jr., 96-105

Ögren, Sven-Ove, 346-369, 645-663

Pettibone, Douglas J., 480-496
Pflueger, A. Barbara, 222-241
Pieri, L., 595-620
Pieri, M., 595-620
Pollare, T., 328-345
Pujol, J. F., 478, 576-589, 589, 664

Radulovacki, M., 146, 196-197
Rapport, Maurice M., 85-94
Reinhard, J. F., Jr., 476
Renaud, B., 576-589
Rogers, Richard B., 134-145
Ross, Svante B., 645-663

Rotman, A., 57-73
Rubin, Deborah, 96-105

Sachs, Ch., 328-345
Sanders-Bush, Elaine, 127, 158, 175-176, 208-221, 221, 260
Sankar, Dr., 95
Schlossberger, H. G., 3-35, 107-117
Sherman, A. D., 119-127
Silbergeld, E. K., 95
Simonton, Ronald L., 437-456
Smith, G., 422
Snodgrass, S. R., 524-531
Sperk, Günther, 198-206
Srebro, Bolek, 645-663
Stein, J., 260
Steranka, Larry R., 208-221
Stewart, R. Malcolm, 198-206, 206-207, 260-261, 410

Tamir, Hadassah, 56, 73, 85-94, 94-95, 171, 188, 422
Thomas, Ronald F., 387-398
Totaro, James A., 222-241
Trulson, Michael E., 497-509, 590-594, 664

Uretsky, N. J., 524-531

Wiklund, Leif, 262-288, 370-384
Wishousky, Theodore I., 222-241
Wuttke, W., 410, 423-436, 479

Zacchei, Anthony G., 222-241
Zemlan, Frank P., 590-594, 621-626

Subject Index

Italicized page numbers refer to material in figures or tables.

The list of terms which precedes the index proper was adhered to strictly to bring about consistency in constructing the index. Under each chosen term are various synonyms, initialisms, etc. each preceded by "=". The reader is cautioned to check here for the various alternatives which may occur in the text itself, as different authors may use different terms. None of the alternatives appear in the index itself as references, because they may not have been needed alone as main headings and/or subheadings under other main headings.

<i>N</i> -Acetylnorfenfluramine	Desmethylimipramine
=FE ₃	=Desipramine hydrochloride
Adrenocorticotropic hormone	=DMI
=ACTH	=Norpramine®
Amine precursor uptake decarboxylase	Deuterium oxide
cells	=D ₂ O
=APUD cells	=Heavy water
6-Aminodopamine	5,6-Diacetoxypytrptamine
=6-ADA	=5,6-DACOT
3-(<i>β</i> -Aminoethyl)-5,6-dihydroxybenzo[<i>b</i>]-	5,6-Dihydroxyindoleacetic acid
thiophene	=DHIAA
=5,6-DHT-S	5,6-Dihydroxytryptamine
3-(<i>β</i> -Aminoethyl)-5,6-isopropylindendioxybenzo[<i>b</i>]thiophene	=5,6-DHT
=IPST	=5,6-HT
Aurintricarboxylic acid	5,7-Dihydroxytryptamine
=ATA	=5,7-DHT
Avoidance behavior	=5,7-HT
=CAR	3,4-Dimethoxyamphetamine
=Conditioned avoidance response	=3,4-DMA
Bacterial pyrogen	=P ₃
=Pyrifer® VII	6,7-Dimethyl-5,6,7,8-tetrahydroptanine
<i>p</i> -Bromoamphetamine	=DMPH ₁
= <i>p</i> -BA	Dopa
=4-Bromoamphetamine	=Dihydroxyphenylalanine
Catechol <i>O</i> -methyltransferase	=DOPA
=COMT	L-Dopa
Catecholamines	=Levodopa
=CA	Dopa decarboxylase
<i>p</i> -Chloro- <i>N</i> -methylamphetamine	=DDC
= <i>p</i> -CMA	Dopamine
<i>p</i> -Chloroamphetamine	=DA
= <i>p</i> -CA	Dopamine β -hydroxylase
= <i>p</i> -Chloro- α -methylphenylethylamine	=DBH
=4-Chloroamphetamine	Fenfluramine
<i>p</i> -Chloronorephedrine	= <i>N</i> -Ethyl- α -methyl-3-trifluoromethyl-
= <i>p</i> -Chloro- β -hydroxyamphetamine	β -phenylethylamine
=P ₂	= <i>N</i> -Ethyl- α -methyl- <i>m</i> -(trifluoromethyl)phenylethylamine
=PCNE	=FE
<i>p</i> -Chlorophenylalanine	=FEN
= <i>p</i> -CPA	<i>p</i> -Fluoroamphetamine
Chromatography, high-pressure liquid	=4-Fluoroamphetamine
=HPLC	

Fluoxetine	=FLU	3-Methoxy-4-hydroxyphenylethylene-glycol
	=Lilly 110,140	=MOPEG
	=3-(<i>p</i> -Trifluoromethylphenoxy)- <i>N</i> -methyl-3-phenylpropylamine	3-Methoxy-4-hydroxyphenylethylene-glycol sulfate
Follicle-stimulating hormone	=FSH	=3-Methoxy-4-hydroxyphenylglycol sulfate
Glutathione, reduced	=GSH	=MOPEG-SO ₄
Growth hormone	=GH	5-Methoxy-6-hydroxytryptamine
	=Pituitary growth hormone	=5-M-6-HT
	=Somatotropin	α -Methyl-5-hydroxytryptamine
	=STH	= α -Methyl-5-HT
Harmaline	=HAR	=Serotonin, α -methyl
Homovanillic acid	=HVA	Michaelis constant
5-Hydroxy-6-methoxytryptamine	=5-H-6-MT	=K _m app
6-Hydroxydopamine	=6-HD	Monoamine oxidase
	=6-OHDA	=MAO
	=2,4,5-Trihydroxyphenylethylamine	Monoamine oxidase inhibitors
5-Hydroxyindoleacetic acid	=5-HIAA	=MAOI
Hydroxyl radicals	=·OH	Norepinephrine
2-[β -(4-Hydroxyphenyl)ethylamino-methyl]tetralone	=HEAT	=NA
6-Hydroxytryptamine	=6-HT	=NE
5-Hydroxytryptophan	=5-HTP	=Noradrenaline
Isoprenaline	=Isoproterenol	Norfenfluramine
Lisuride maleate	=Lysenyl®	=NFE
	=Lysuride acid maleate	= <i>m</i> -Trifluoromethylamphetamine
Lu 10-171	=1-(3-Dimethylamino)propyl-1-(<i>p</i> -fluorophenyl-5-phthalancarbonitrile hydrobromide	Pentylenetetrazol
Luteinizing hormone	=LH	=PTZ
<i>d</i> -Lysergic acid diethylamide	=LSD	Perchloric acid
Maprotiline	=MAP	=PCA
Maximal velocity	=V _{max}	Peroxidase, horseradish
Melanocyte-stimulating hormone	=MSH	=HRP
5-Methoxy- <i>N,N</i> -dimethyltryptamine	=5-MDMT	1-Phenyl-3-(2-thiazolyl)-2-thiourea
		=PTTU
		Piperocaine
		=Metycaine®
		Prolactin
		=LTH
		=Luteotropin
		=Pituitary lactogenic hormone
		Reserpine
		=RES
		Ribonucleic acid
		=Messenger RNA
		=RNA
		Serotonin
		=Enteramine
		=5-HT
		=5-Hydroxytryptamine
		Serotonin-binding protein
		=SBP
		Subcommissural organ
		=SCO
		Thyroid-stimulating hormone
		=Thyrotrophin
		=Thyrotropin
		=TSH

<i>m</i> = Trifluoromethylbenzoylglycine	Tyrosine hydroxylase
= FE ₂	= TH
Tritium	Zimelidine
= ³ H	= (z)-3-Dimethylamino-1-(4-bromo-
= T	phenyl)-1-(3-pyridyl)propene
Tryptophan	= H 102/09
= TP	

Acetazolamide

effect of 5,7-dihydroxytryptamine or a raphe lesion on anticonvulsant action, 448—450, 452

effect on maximal electroshock-induced hindleg extension in rats, 449, 449, 450

after a raphe nuclei lesion, 450, 450

Acetylcholine, 519

effect of *p*-chloroamphetamine on, 260
raphe lesion lowering forebrain concentration, 453

Acetylcholinesterase, 538**N-Acetylnorfenfluramine**, 120, 125—126**Activity level**, 542—543

effects of

5,7-dihydroxytryptamine, 544

p-chloroamphetamine, 543—544

p-chlorophenylalanine, 543

selective raphe lesions, 543

novel vs. familiar environment, 543

Adenosine triphosphate

as inhibitor of serotonin-binding protein capacity, 91

Adrenal gland, 392**Adrenal-pituitary axis. See Pituitary-adrenal axis****Adrenal steroids**

blocked by dexamethasone, 621, 622
release stimulated by serotonin or 5-hydroxytryptophan, 392

Adrenalectomy, unilateral

and depletion of serotonin with *p*-chlorophenylalanine, 392

Adrenergic receptors, α - and β -, 391, 458

β -antagonists. *See* Pindolol

Adrenocorticotrophic hormone, 391—393

hypersecretion occurring after lesions of ascending serotonin pathways, as shown by increased basal corticosterone secretion, 362

Aggressive behavior

more prevalent in rats pretreated with *p*-chlorophenylalanine than 5-hydroxytryptophan, 486

Aldehyde dehydrogenase, 18**Amine precursor uptake decarboxylase cells**, 284**Amines**

influence of various antagonists on positive chronotropic effects in guinea pig right atria, 462, 464

6-Aminodopamine, 76—77

mechanism of action, 80

3-(β -Aminoethyl)-5,6-dihydroxybenzo[*b*]-thiophene

ability to lower stored norepinephrine, 143

and behavioral changes in rats, 136, 139—140

stability, 145

3-(β -Aminoethyl)-5,6-isopropylindendioxybenzo[*b*]thiophene

biochemical and behavioral effects in rats, 140—141

d-Amphetamine, 479, 510, 527—531, 542

and brain serotonin concentration, 92

and protein synthesis, 105—106

effect on protein synthesis, 101—104

effects, 251—252, 254—256

hyperthermia induced by, 252, 254—256

increased responsiveness to, 385—386

Amphetamines, halogenated. *See* Halogenated amphetamines**Anorexia**, 484—485. *See also* *p*-Chloroamphetamine; *p*-Chlorophenylalanine and serotonin; Fenfluramine; Fluoxetine

amphetamine-induced in rats, 593

fenfluramine-induced enhanced after 5,7-dihydroxytryptamine treatment in rats, 593—594, 593

Antimycin A and oxygen consumption, 81

Apomorphine, 389, 391, 479, 510, 524, 527—531, 596, 605, 613, 615

inducing locomotor activity and stereotyped behavior in rats, 348

ineffective in producing myoclonic syndrome in rats, 511

stimulation of dopaminergic receptors to cause hypothermia or hyperthermia, 252

Aromatic amino acid decarboxylase inhibitors. *See* RO4-4602**Ascorbic acid depleted by serotonin or 5-hydroxytryptophan**, 392**Atropine**, 515, 518, 529**Aurintricarboxylic acid**

effect on polysomal profiles, 102, 103

effect on protein synthesis, 101—102, 101

Avoidance behavior, 544—545

5,6-dihydroxytryptamine effects, 544

5,7-dihydroxytryptamine effects, 544—545

by rats, 657—658, 658

discriminated, 545

one-way, signaled or unsignaled, 545

p-chloroamphetamine effects, 544—545

p-chlorophenylalanine effects, 544—545

selective raphe lesion effects, 544

two-way (shuttle), 544

Bacterial pyrogen, 254
Behavior. *See also* Aggressive behavior;
Avoidance behavior; Behavior, rotational; *p*-Chloroamphetamine; Crossing behavior of rats; 5,6-Dihydroxytryptamine—a and behavioral changes; Locomotor activity; *d*-Lysergic acid diethylamide-induced behavioral syndrome in rats; 5-Methoxy-6-hydroxytryptamine; Mounting behavior; Rearing activity; Seizure susceptibility changes; Sexual behavior
as determined by injection of 5,7-dihydroxytryptamine in rats, 347—349, 366
changes and percent reductions in regional serotonin concentrations after discrete electrolytic brain stem lesions, 533, 534, 537, 542, 544
contacts with objects by rats, 652, 652
effects of *p*-chloroamphetamine on rats, 658—660, 659
effects of serotonin depletion, 546, 547
exploration of field by rats, 654, 654, 655
possibly related to route by which 5,7-dihydroxytryptamine was injected into rats, 638, 640
scoring in rats, 514—515
studies with rats, 497, 649—658
Behavior, rotational
after nigrostriatal lesions in rats, 524
after serotonin-pathway lesions in rats, 529
after treatment with 5,6-dihydroxytryptamine and 5,7-dihydroxytryptamine in rats, 605, 608, 614—616
correlation between size of lesion in the median raphe nucleus and vigor of the rotation, 526
effects of serotonin neurotoxins in rats, 524—531
in rats, 596
injected rats tested with amphetamine, 524—526
injected rats tested with apomorphine, 524—526
time course, 526
Benserazide causing marked sexual stimulation in rats, 613
Benzodiazepine action over inhibitory γ -aminobutyric acidergic system and reduction of serotonin turnover, 363
Benztropine
effect on retention of radioactivity in rat brain, 108, 110, 114—116
4-Benzylxy-5-methoxyindole synthesis, 25—26, 26
4-Benzylxy-5-methoxytryptamine formate ultraviolet spectra, 29, 31
Blood platelets, 617
after incubation in plasma at 37°C, 597
from rabbits and guinea pigs, 615
serotonin content after incubation in plasma with 5,6-dihydroxytryptamine, 5,7-dihydroxytryptamine, or metaraminol, from rats, 609, 609
storage pool deficiency, 616
ultrastructural aspects after incubation in plasma with 5,6-dihydroxytryptamine, 5,7-dihydroxytryptamine, or metaraminol, from rats, 609, 610, 611, 616
Blood pressure, arterial
hypertension in rats, 471—472
pretreatment with neither reserpine nor cocaine decreased the pressor effect of 5,6-dihydroxytryptamine, 457, 459
pressor effect of 5,7-dihydroxytryptamine considerably less than of 5,6-dihydroxytryptamine, 458
Body temperature. *See* Temperature, body
Body weight. *See* Weight, body
Brain. *See also* Hippocampus; Hypothalamus; Locus ceruleus; Serotonin—brain concentration; Serotonin—in brain
5-hydroxyindoleacetic acid content in rats, 649
areas B8 and B9, 623
bulbospinal system of rats, 372
regrowth, 377
content of monoamine metabolites after 5,7-dihydroxytryptamine injected intraventricularly in rats pretreated with desmethylimipramine, 597, 600, 613
diencephalon functionally analyzed for serotonin system, 347—349
dorsal accessory nucleus of the inferior olive of rats, 378, 380—381
enzymatic activity, 188—189
fluorescence histochemical studies in rats, 376—379
hypothalamus reactive to serotonin agonistic properties of quipazine, 390

Brain—(cont'd)
inferior olive of rats, 377—379, 378
after administration of 5,6-dihydroxytryptamine, 379, 382
medial hypothalamic lesions
after 5,7-dihydroxytryptamine in rats, 640—642
or sham surgery with measures of food and water intake and body weight in rats, 627, 633, 633, 636, 638
midbrain raphe lesions in rats, 629, 641
midbrain stained with thionine showing lesion involving dorsal and median raphe nuclei in rats, 441, 441
pathology in rats, 631
raphe-lesioned rats for monoamine analyses, 444, 446, 447, 450, 451
schematic representation in rats, 329, 329
serotonin content, 665
decrease in rats, 503
in rats, 646—647, 649
in various regions after *p*-chloroamphetamine treatment in rats, 646—647, 647
increase in rats, 665
of B9 region, 297
uptake in different regions affected by *p*-chloroamphetamine and zimelidine plus *p*-chloroamphetamine, in rats, 647, 648
telencephalon functionally analyzed for serotonin system, 347—349
topography of area perfused with 5,6-dihydroxytryptamine in rats, 576, 577
tryptophan concentrations and 3-(β -aminoethyl)-5,6-dihydroxybenzo[*b*]-thiophene, 146

Brain lesions. *See also* Behavior; Behavior, rotational; Dopamine; Norepinephrine
of medial forebrain bundle in rats, 529
of substantia nigra, 527
relation with dopamine neurons, 524

Brain metabolism of serotonin depleters, 119—126

Brain mitochondria
binding of radioactivity to after intraventricular injection of [¹⁴C]-5,6-dihydroxytryptamine and [¹⁴C]-5,7-dihydroxytryptamine, 11—12
interaction of 5,6-dihydroxytryptamine and 5,7-dihydroxytryptamine in rats, 74—75, 81—82, 81

Brain stem serotonin and norepinephrine levels after 5,6-dihydroxytryptamine or 3-(β -aminoethyl)-5,6-dihydroxybenzo[*b*]thiophene in rats, 136, 138, 139

p-Bromoamphetamine, 150, 158, 178, 289—291, 296—297
cf. *p*-chloroamphetamine in exerting neurotoxicity, 176
duration of reversibility of serotonin depletion, 148, 149, 154

2-Bromolysergic acid diethylamide, 203, 204
blocking myoclonic syndrome in rats, 511

p-Bromomethamphetamine, 150

Bufotenine as inhibitor of serotonin-binding protein capacity, 86, 88, 93

C cells of thyroid. *See* Thyroid C cells
Carbidopa to block 5-hydroxytryptophan effects, 410
Carbonic anhydrase inhibitors, 438, 452
Castration
did not affect mounting behavior in male rats, 603
of rats, 486
Catalase
inhibition of tryptamine conversion not antagonized, 41
Catechol O-methyltransferase, 17, 19, 36, 53
Catecholamine neurons, 600
effect of 5,6-dihydroxytryptamine on, 346
Catecholamines, 254—255, 540, 542, 586—587, 613, 616, 631
behavioral tolerance, 212
effect of *p*-chloroamphetamine on, 209
fluorometric estimation in brain, 244
histofluorescence, 244
metabolism, 212
uptake blockers. *See* Desmethylimipramine; Protriptyline
Centrally acting drugs. *See* Drugs, Centrally acting
Cerebrospinal fluid
circhoral luteinizing hormone pattern in ovariectomized injected rats, 427, 431
serum luteinizing hormone, prolactin, and monoamine levels in ovariectomized rats treated in hypothalamus, 427, 428
Chlorimipramine, 289, 372—373, 373, 374—375, 376

Chlorimipramine—(cont'd)
and serotonin-binding protein, 95
and serotonin uptake, 222
blocking of anorectic effects of fenfluramine, 241
blocking of uptake of 5,7-dihydroxytryptamine into adrenergic sites, 56
inhibiting serotonin transport, 20
inhibiting tyrosine hydroxylase activity
increase in locus ceruleus by 5,6-dihydroxytryptamine treatment in cats, 584—585, 585
pretreatment as a control for 5,7-dihydroxytryptamine in rats, 349
unavailable to protect serotonin fibers from 5,6-dihydroxytryptamine, 613

6-Chloro-2-aminotetralin, 153—154

p-Chloro-*N*-methylamphetamine, 147, 224, 546

m-Chloroamphetamine, 150, 154

o-Chloroamphetamine, 150

p-Chloroamphetamine, 147, 158—159, 178—179, 289—291, 296—297, 302—304, 385—386, 403, 481—486, 488—490, 511, 514—515, 529—530. *See also* in subheads under other main headings, e.g. Avoidance behavior—*p*-chloroamphetamine effects
abnormal behavior production, 212—213
administration, 123
and amino acid incorporation, 105—106
and concentration of serotonin and tryptophan hydroxylase in brain nuclei, 190
and glutathione levels, 215
and neurotoxicity, 153—154
and reduced glutathione in brain, 121, 123
and sexual behavior in female rats, 621 and tryptophan 5-hydroxylase activity, 126
brain concentration after injection of *p*-chloroamphetamine or *p*-chloro-*N*-methylamphetamine in rats, 150—151, 151
cf. fenfluramine, 239
correlation between turnover decrease in cortical serotonin and increase in striatal dopamine in rats injected unilaterally into median raphe nucleus or substantia nigra, 526—527, 527

early changes in norepinephrine and dopamine and dynamics after injection, 209, 210
effect in newborn animals, 172
effect of acute drug treatment on the postural syndrome induced in rats, 515, 517, 519
effect of fluoxetine on serotonin decreases after injection, 214, 214
effect of increasing doses on the postural syndrome induced in rats, 515, 518
effect of pretreatment with cysteine or diethylmaleate on long-term effect, 215—216, 216

effect on
mast cells and enterochromaffin cells, 385
mating behavior induced by estradiol benzoate in female rats, 621, 622
proestrous surges of luteinizing hormone and prolactin in female rats, 402, 402
serum levels of luteinizing hormone, prolactin, and growth hormone in male rats, 400, 401, 409

effect on brain
B9 region in rats, 290—291, 292—293, 294
B9 region in rats pretreated with fluoxetine, 292, 294
serotonin, norepinephrine, and dopamine in rats, 291, 291

effect when injected into median raphe nucleus in rats on serotonin and 5-hydroxyindoleacetic acid levels and serotonin and norepinephrine uptake, 525—526, 525

fluorescence histochemistry of neurotoxic action, 357—358, 357

hypothalamus and spinal cord resistant to depletion of serotonin after administration, 213
in discrete brain nuclei, 191—192
inducing anorexia, 478
influence of administration route on brain levels, 120, 120
influence on brain concentration of serotonin and 5-hydroxyindoleacetic acid, 148, 148
inhibition of protein synthesis, 103—104
injection effect on motor activity in rats, 210, 211
injection increasing dopamine turnover, 589
injection of rats, 515, 516

p-Chloroamphetamine—(cont'd)
interaction with fluoxetine in mice, 216, 217
long-term biochemical and behavioral effects in rats, 645-660
long-term biochemical effects, 213-216
long-term neurotoxic effect on mating behavior and forebrain monoamine levels in female rats, 621, 622
mechanism of action, 177
metabolism, 126
metabolite accumulation after brain injection, 120, 121
neurotoxic effects, 259, 480
neurotoxic metabolites and age of animals, 175-176
neurotoxicity, 125, 127, 175, 186-187, 261
producing decrease in brain serotonin and 5-hydroxyindoleacetic acid content, 289
reduction of brain serotonin and 5-hydroxyindoleacetic acid, 119
reduction of resting levels of thyroid-stimulating hormone in estrogen-primed ovariectomized rats, 394
selective neurotoxic damage to the brain, 351
Sidman avoidance, 211-212
species differences in mice and rats, 216
stereoisomers, 211
structure, 148, 149
subcellular distribution of metabolites after brain injection, 121, 122
synaptosomal uptake of serotonin after single injection, 213, 213
tolerance, 212
toxicity and metabolism, 215, 221
use to regulate body weight in human beings, 485
p-Chloroamphetamine analogs, 152, 154
See also 3-Phenylpiperidines, chlorinated
isomers, 158
structure, 148, 149
p-Chloroamphetamine and serotonin actions on serotonin neurons, 141-142, 153-154
attempts to increase serotonin depletion by, 192-193
changes in central serotonin neurons, 284
depletion of serotonin, 259
duration of reversibility of serotonin depletion, 148, 149, 154
effect on brain serotonin content when *p*-chloroamphetamine neonatally administered in rats, 163-164, 164
effect on content of brain regions in rats, 292, 295
effect on peripheral stores, 260
effect on serotonin neurons, 208
newborn rat brain serotonin, 241
reduction of brain serotonin in rats, 390-391
p-Chloroamphetamine homologs, 152
p-Chloromethylamphetamine, 187
biochemical effects, 213, 217
tissue distributions of, 177
p-Chloronorephedrine, 126
metabolite of *p*-chloroamphetamine in brain, 120
none detectable in brain or liver after administration of iprindole, 124
p-Chlorophenylalanine, 145-146, 217, 388-389, 391-393, 405-406, 409, 444, 456, 487-488, 498, 515, 519, 532, 578, 590, 596, 664. *See also* in subheads under other main headings, e.g. Avoidance behavior—*p*-chlorophenylalanine effects
and supersensitivity, 258
chronic administration did not induce to various compounds, 503
lacking, 505
effect on brain monoamine concentrations in rabbits, 247, 249
effect on growth hormone secretion in rats, 422
failure to block suckling-induced prolactin release, 433
in discrete brain nuclei, 193-194
induction of transient hyperphagia, 627
lowering of body temperature, 478
may increase locomotor activity in rats, 659
microinjection in rats, 571
mounting behavior in male, female, castrated, and ovariectomized rats alone or in combination with 5-hydroxytryptophan or haloperidol, 603, 603, 614
pretreatment with neither enhances nor antagonizes 5,7-dihydroxytryptamine-induced hypothermia in rats, 489
preventing rather than enhancing audiogenic seizures in mice, 438

p-Chlorophenylalanine and serotonin
blockade of central nervous system
serotonin synthesis, 242—243, 252,
254—256

blockade of central serotonin syn-
drome, 212

depleting brain serotonin content, 510

effect on serotonin in brain nuclei, 194,
195

inducing reductions in brain serotonin
associated with insomnia, 483

inhibiting serotonin synthesis, 423, 437

inhibiting tryptophan hydroxylase, de-
pleting brain serotonin causing
reduction in food intake and loss
in body weight, 556

mechanism of action of serotonin neu-
rons, 259

p-chlorophenylalanine decreasing brain
serotonin biosynthesis and causing
anorexia and hypodipsia, 484

reduction of brain serotonin in rats, 390

serotonin and tryptophan hydroxylase
concentration in brain nuclei, 190

total insomnia following inhibition of
serotonin biosynthesis, 576

p-Chlorophenylalanine methyl ester hy-
drochloride, 479

brains injected later with fluoxetine in
rats, 229, 233

Chlorpromazine and prevention of lethal
hyperthermia, 261

Chlorpromazine effect on brain dopamine
concentration, 173

Cholesterol, 623—624

Choline acetylase
effect of *p*-chloroamphetamine on, 260

Choline acetyltransferase, 538, 540

Chromatography, high-pressure liquid,
190—191

Cinanserin as putative serotonin receptor
antagonist, 485

Cinanserin blockade of serotonin re-
ceptors, 623

Circadian rhythm, 587

Clonidine, 391, 393

Clorgyline, 48

Clozapine as inhibitor of serotonin-bind-
ing protein capacity, 92

Cocaine, 462, 468, 471

Cold environment, exposure to, 393—394

Corpus striatum synaptosomes from rats,
128

Corticosteroids
diurnal elevation in cats, rats, and man
reduced by *p*-chloroamphetamine,
393

Corticosterone
elevation after lesions of the raphe
nuclei induced with 5,6-dihydroxy-
tryptamine, 392

suppressed by intraventricular or in-
tracerebral injection of serotonin,
392

Covalent binding
of 5,6-dihydroxytryptamine to atrial
protein, 65

of 5,7-dihydroxytryptamine to atrial
protein, 65, 65, 71

oxygen requirement for, 65, 67

p-chloroamphetamine or fenfluramine,
127

Covalent interaction of one or more ox-
idation products of an amine with
intraneuronal proteins, 57

Cross-linking of protein
oxygen dependency on, 68

requirement for two active nucleophilic
sites, 70

Crossing behavior of rats, 656, 657

Cushing's disease therapy, 392—393

Cycloheximide, 203, 205, 207

N-Cyclopropyl-*p*-chloroamphetamine as
inhibitor of monoamine oxidase,
150—152

Cyproheptadine, 284, 390, 462, 515,
518—519, 539

as blocker of serotonin receptors, 392

as inhibitor of serotonin-binding pro-
tein capacity, 91

as serotonin receptor antagonist, 484

pretreatment neither enhances nor an-
tagonizes 5,7-dihydroxytrypt-
amine-induced hypothermia in
rats, 489

Cytochrome P-450, 221

Cytotoxicity
and mitochondrial damage, 71

and oxidative phosphorylation, 71

molecular mechanism involving au-
toxidation of quinone from 5,6-di-
hydroxytryptamine and superoxide
and hydroxyl radicals, 85

selective target organelles for, 71

CZ-74 (drug) as inhibitor of serotonin-
binding protein capacity, 86, 88,
93

Decarboxylase
inhibition by RO4-4602, 589

inhibitors, 437

Deoxycorticosterone acetate-saline hyper-
tension in rats, 471

Desmethylimipramine, 118, 198, 324, 342—343, 388—390, 393, 400, 403, 418, 424, 426, 433, 515, 518, 595—596, 602—603, 605. *See also* in subheads under other main headings, e.g. 5,7-Dihydroxytryptamine—pretreatment of adult rats with desmethylimipramine and serotonin-binding protein, 95 and uptake of various substances in rat brain tissue, 200, 201 and/or 5,7-dihydroxytryptamine treatment of newborn and their effect on amine uptake *in vitro* in rat brain, 336—337, 336 antagonizing accumulation of 5,7-dihydroxytryptamine into norepinephrine neurons, 16—17 as protective agent, 80 blocking brain norepinephrine transport sites, 107 blocking uptake of 5,7-dihydroxytryptamine into adrenergic sites, 56 effect of pretreatment on long-term depletion of brain and spinal cord serotonin and norepinephrine before injection of 5,7-dihydroxytryptamine, 314—315, 316—317 effect on 5,7-dihydroxytryptamine-induced changes in serotonin and norepinephrine uptake *in vitro* in rat brain cortex, 334, 335 effect on actions of 5,7-dihydroxytryptamine on newborn rat brain, 165, 165 effect on retention of brain radioactivity in rats, 108, 110—111, 114—117 increasing the norepinephrine output evoked, 467 intraperitoneal injection in rats, 628—629 pretreatment, 541, 547 antagonizing brain norepinephrine, 4 before injection with 5,7-dihydroxytryptamine, 485 before intracerebroventricular injection of 5,7-dihydroxytryptamine, 472 in rats, 640—642 including amines in rat brain cortex, 200, 200 with 5,7-dihydroxytryptamine intracisternally or intraventricularly, 13 used to protect norepinephrine neurons from neurotoxic effects of 5,7-dihydroxytryptamine, 440

Deuterium oxide, 29, 33

Development of serotonin neurons. *See* Serotonin neuron development

Developmental plasticity of serotonin neurons. *See* Serotonin neuron development

5,6-Diacetoxytryptamine as serotonin neurotoxin, 4, 306

Dibenamine pretreatment causing degenerative changes in the ultrastructure of cardiac nerves with 5,6-dihydroxytryptamine, 471

4,5-Dibenzylxyloindole synthesis, 25—26, 26

Dibenzylxyloindoleacetonitrile synthesis, 29

4,5-Dibenzylxylotryptamine hydrogen oxalate ultraviolet spectra, 31

5,6-Dibenzylxylotryptamine hydrogen oxalate ultraviolet spectra, 31

5,7-Dibenzylxylotryptamine hydrogen oxalate ultraviolet spectra, 31

β,β -Difluoro-4-chloroamphetamine, 289—291

β,β -Difluoro-*p*-chloroamphetamine, 152—154

5,7-Dihydroxyindoleacetaldehyde role in augmenting 5,7-dihydroxytryptamine toxicity, 54, 55

5,6-Dihydroxyindoleacetic acid, 17—18, 54

binding to rat hypothalamus homogenates, 38—39, 43—45, 52, 53 identified by thin-layer chromatography, 46

5,7-Dihydroxyindoleacetic acid, 54, 118 binding to rat hypothalamus homogenates, 38—39, 43—45, 52, 53 identified by thin-layer chromatography, 46

Dihydroxyindoleamines effect on protein synthesis, 99, 100, 103

Dihydroxymethoxyindoleacetaldehyde synthesis, 27

4,5-Dihydroxytryptamine impairment of serotonin uptake, 306 rapid autoxidation preventing application as selective neurotoxic agent, 29

4,5-Dihydroxytryptamine hydrochloride synthesis, 28, 28

5,6-Dihydroxytryptamine, 17, 107, 178—179, 198, 252, 254—256, 289, 297, 305, 385, 389, 393, 476, 485, 488, 566, 568, 570—573, 638, 665. *See also* in subheads under other main headings, e.g. Avoidance behavior—5,6-dihydroxytryptamine effects

5,6-Dihydroxytryptamine—(cont'd)
 α methylation counteracting impairment of serotonin uptake, 307
 and axonal degeneration after intraventricular injection, 370
 and behavioral changes, 135—136, 145—146
 in rats, 139—140
 and cardiac lesions, 57
 and cross-linking of protein, 60—61, 69
 and selective cytotoxicity, 57
 as tool for morphologic studies of central indoleamine neurons, 322, 323, 342
 as tool for studying sleep mechanisms in cats, 576—587
 binding to rat hypothalamus homogenates, 38—39, 43—45, 51
 biochemical effects when intracisternally injected, 199—200
 brain lesions, 557—558
 breakdown at biologic hydrogen ion concentration and 37°C, 53
 chemical properties, 29, 33
 chromatography, 60—61, 61, 68—69
 covalent binding to protein oxygen dependency, 60, 68
 effect alone and in combination with 5-hydroxytryptophan or 6-hydroxydopamine on brain amines and mounting behavior in male rats, 597, 598, 614
 effect of intraventricular injection on body weight in male rats, 414, 414
 brain levels of serotonin, norepinephrine, and dopamine in male rats, 412, 413, 418
 endocrine organ weights in male rats, 414, 415
 pituitary growth hormone levels in male rats, 417, 417
 plasma and pituitary follicle-stimulating hormone in male rats, 417, 418
 tail length in male rats, 414, 416
 testicular weight in rats, 414, 416, 419
 effect of methysergide on cumulative concentration response curve in isolated strips of rabbit aorta, 459, 460
 effect of *p*-chloroamphetamine on, 260
 effect on brain biochemistry and behavior in rats, 141, 142
 effect on capacity of serotonin-binding protein from myenteric plexus, 89—90, 90
 effect on endogenous norepinephrine, dopamine, serotonin, and 5-hydroxyindoleacetic acid in different parts of brain in cats, 578, 580—581
 effect on monoamine brain concentrations in rabbits, 247, 249
 effects of intracerebral injections on monoamine uptake and content, 320, 321
 effects on the rat central nervous system after intraventricular or intracerebral application and on blood platelets *in vitro*, 595—617
 enhancing release of melatonin and 5-methoxytryptophol, 388
 indolic nitrogen of for serotonin neurotoxic effects, 143
 inhibition of serotonin-binding protein capacity, 88—90, 93
 injection can increase dopamine turnover, 589
 intraventricular infusion in fowl, 248
 irreversible binding to protein, 59, 59, 60, 69
 maximal velocity, 48—49
 mechanism of action, 177
 mechanism of neurotoxicity, 21
 metabolized by monoamine oxidase in rat hypothalamus homogenates, 47
 Michaelis constant, 47—48
 microinjection in rats, 571
 monoamine oxidase-catalyzed conversion of tryptamine, 41, 44
 inhibited, 41, 45
 monoamine oxidase inactivation in brain homogenates, 42, 50
 in vitro, 42—43
 monoamine oxidase inhibited *in vivo*, 43, 51
 not influencing pituitary stores or circulating growth hormone in prepubertal rats, 391
 oxygen requirement for binding, 59
 protein binding after intraventricular injection, 46, 52
 rats pretreated intraventricularly, 483
 reaction with molecular oxygen, 19
 reaction with sulphydryl groups, 68
 reactive nucleophiles, 68, 69
 retarding sexual maturation and massively increasing serum gonadotropins, 399
 selectivity of action on central monoaminergic neurons, 17—19
 synthesis, 1

5,7-Dihydroxytryptamine—(cont'd)
turning, contralateral, to lesioned side
induced in rats by *d*-lysergic acid
diethylamide bitartrate, apomor-
phine hydrochloride, and lisuride
maleate, 605, 608

uptake
inhibition by α -methyltyramine and
serotonin, 62, 64, 71
inhibition by cocaine and desmethyl-
imipramine, 62, 64, 71
temperature-dependent mechanism,
68

uptake by atria, 61, 62, 68—69
temperature-dependent and irrevers-
ible binding, 65, 66, 68—69, 71
with 5,7-dihydroxytryptamine and
norepinephrine, 62, 64, 68—69, 71

vasoconstrictor effect in isolated strips
of rabbit aorta, 458—459

vasoconstrictor effect in rats and rab-
bits, 474

5,6-Dihydroxytryptamine analogs
effect on brain biochemistry and be-
havior in rats, 141, 142
neurotoxicity, 160

5,6-Dihydroxytryptamine and serotonin
axonal swelling and accumulation of
serotonin fluorescence, 213
cf. *p*-chloroamphetamine effects on
brain, 645

degeneration of serotonergic neurons
fluorescent appearances in fowl, 248,
250—251, 252—253
in rats and fowl, 242—243
reduction of brain levels in rabbits,
254

effect on development of neurons, 330

effects on synthesis and metabolism,
315

impairment of serotonin uptake, 306,
306, 324

neuron systems after treatment, 315,
317, 317, 319

neurotoxicity 4, 29, 36, 85, 175, 184—
185

selective degeneration of neurons, 263,
285

selective neurotoxic action in brain
serotonergic nerves, 480, 489

5,6-Dihydroxytryptamine creatinine sul-
fate- $2\text{H}_2\text{O}$ ultraviolet spectra, 29,
30, 33

[1- ^{14}C]-5,6-Dihydroxytryptamine
accumulation and retention in tissue
slices, 308, 310—311, 310, 311

brain regional patterns of radioactivity
after intraventricular injection,
108, 109, 114—117

in rats treated with benzotropine,
110, 110

metabolism in rat brain *in vivo*, 17—18

radioactivity in hypothalamus, pons-
medulla oblongata, and spinal
cord after intraventricular injec-
tion, 5, 6

radioactivity in rat perchloric acid-
homogenized central nervous sys-
tem, 7, 9, 10, 11

radioactivity in rat urine after intra-
ventricular injection, 5, 9, 19

5,7-Dihydroxytryptamine, 107, 118, 178—
179, 198, 254, 289, 297, 328, 343,
385, 388, 390, 400, 456, 476—477,
479, 485, 488, 530—531, 566, 568,
571, 573, 664. *See also* in sub-
heads under other main headings,
e.g. Brain mitochondria—interac-
tion of 5,6-dihydroxytryptamine
and 5,7-dihydroxytryptamine in
rats

α -methylation counteracting impair-
ment of serotonin uptake, 307

and forced extinction with intrabrain
stem injections, 362—363, 365—
366

and hyperactivity in rats, 478

and inhibition of monoamine oxidase,
58

and metabolites of neurotransmitter
compounds, 173

and selective cytotoxicity, 57

and uptake of various substances by
rat brain tissue, 200, 201

appearance of rat brain dorsal raphe
(B7) after intraventricular injec-
tion, 296, 298—299

as tool for morphologic studies of
central indoleamine neurons, 322,
323, 324

better tool than 5,6-dihydroxytrypt-
amine for mapping central sero-
tonin neurons, 346

binding sites in brain, 118

binding sites in lumbar spinal cord, 118

binding to mitochondria, 67

binding to rat hypothalamus homoge-
nates, 38—39, 43—45, 51

biochemical effects when intracister-
nally injected, 199—200

blood-brain barrier for, 331

5,7-Dihydroxytryptamine—(cont'd)
brain content of 5-hydroxyindoleacetic acid, homovanillic acid, and 3-methoxyphenylglycol sulfate in male rats injected in the right medial forebrain bundle after pretreatment with desmethylimipramine, 605, 606, 612
brain content of serotonin, dopamine, and norepinephrine after injection in the right medial forebrain bundle of rats pretreated intraperitoneally with desmethylimipramine or maprotiline, 603, 604, 605, 612
brain lesions, 557—558
breakdown at biologic hydrogen ion concentration and 37°C, 53
cause of considerable degeneration of norepinephrine neurons and dopamine systems, 346
changes in brain monoamines and their metabolites induced in rats pretreated with harmaline or Lu 10-171, 597, 600, 601, 613
changes in systolic blood pressure, pulse rate, and body weight after intracerebroventricular injection in spontaneously hypertensive rats, 472, 473
chemical properties, 29, 33
chosen over 5,6-dihydroxytryptamine because of lower toxicity, 438
chromatography, 60, 61, 68—69
continuous infusion into aortic cannula of an isolated rabbit heart, 465, 465
correlation between decrease in cortical serotonin turnover and the increase in striatal dopamine turnover in rats injected unilaterally into median raphe nucleus or substantia nigra, 526—527, 527
cysteinyl-tyrosyl bridge, 70
discrepancy between effects and those of a raphe lesion, 445
dopamine content after treatment of forebrain in male rats, 426, 427
duration of effects on brain monoamine oxidase content, 161—162, 162, 164—165
effect of 1-phenyl-3-(2-thiazolyl)-2-thiourea, ethanol, and nialamide on the neurodegenerative action, 78, 79, 81
effect of centrally acting drugs on brain monoamine oxidase content, 162—163, 163, 165
effect of intracisternal injection on amines in rat cerebral cortex, 200, 200
effect of *p*-chloroamphetamine on, 260
effect of various doses administered on brain monoamines in newborn rats, 163—164, 164
effect on dopamine uptake, 528
effect on locomotor activity when neonatally injected into rats, 165—166, 166
effect on mounting behavior of male and female rats pretreated with desmethylimipramine, harmaline, or Lu 10-171, 602, 602, 614
effect on norepinephrine output, heart rate, and positive chronotropic effect of exogenous norepinephrine in isolated rabbit hearts, 465, 466, 469
effect on peripheral norepinephrine neurons, 57
effect on proestrous surges of luteinizing hormone and prolactin in female rats, 403, 404
effect on serum levels of luteinizing hormone, prolactin, and growth hormone in rats, 409
effect on tegmentum, 188
effect on tyrosine hydroxylase activity, 528
effect when injected
into median raphe nucleus in rats on serotonin and 5-hydroxyindoleacetic acid levels and serotonin and norepinephrine uptake, 525, 525
into the medial forebrain bundle on the methiothepin-induced increase of monoamine metabolites in male rats, 605, 607, 612
intraventricularly on increase of 5-hydroxyindoleacetic acid and homovanillic acid induced by methiopin in rats, 597, 600
effects of intracerebral injections on monoamine uptake and content, 320, 321
effects of intracerebroventricular injection on systolic blood pressure, pulse rate, and body weight of conscious spontaneously hypertensive rats, 472, 473
effects of intraventricular injection on rat forebrain norepinephrine concentration, 439, 439

5,7-Dihydroxytryptamine—(cont'd)
 effects of intraventricular injection on rat forebrain norepinephrine, dopamine, and serotonin and brain stem serotonin, 439, 440
 effects of monoamine oxidase inhibitors on, 162, 162
 effects on serum values in rats on the afternoon of estrus, 402, 404
 effects on suckling-induced prolactin rise in female rats, 405, 405
 effects on the rat central nervous system after intraventricular or intracerebral application and on blood platelets *in vitro*, 595—617
 efflux from atria, 65, 66, 71
 electroshock seizure threshold in rats, 444, 447
 formation of hydrogen peroxide from oxidative deamination, catalyzed by monoamine oxidase, 74, 75
 given to produce brain lesions in rats, 364—366
 impairment of norepinephrine uptake, 307
 in combination with a catecholamine uptake blocking agent, 497—498
 influence on effect of electrical stimulation of postganglionic sympathetic nerves of an isolated rabbit heart, 465, 467, 469—470
 inhibition of serotonin-binding protein capacity, 88—89, 93
 inhibition of uptake, 84
 injection can increase dopamine turnover, 589
 intracisternal injection in rats, 628
 irreversible binding to protein, 59, 59, 60, 69
 keto-enol tautomeric forms, 29, 32
 maximal velocity, 48—49
 measures of body weight and food and water intake after intracisternal injection in rats, 632, 632
 mechanism of action, 177
 metabolized by monoamine oxidase in rat hypothalamus homogenates, 47
 Michaelis constant, 47
 microinjection in rats, 571
 monoamine analyses
 after anticonvulsant testing in treated rats, 450, 451
 in rats, 444, 445, 447
 monoamine oxidase and, 69
 monoamine oxidase-catalyzed conversion of tryptamine, 41, 46
 inhibited, 41, 47
 monoamine oxidase inactivation in brain homogenates, 43, 50
 in vitro, 42—43
 in vivo, 43, 51
 monoamines in rat central nervous system after given alone or to animals pretreated with uptake inhibitors, 597, 599, 612
 norepinephrine content of forebrain and brain stem in treated male rats, 426, 426
 o-quinone of. *See o-Quinone of 5,7-dihydroxytryptamine*
 oscillatory luteinizing hormone pattern in ovariectomized rats after treatment, 427, 431
 p-quinoneimine of. *See p-Quinoneimine of 5,7-dihydroxytryptamine*
 possible enhancement of toxicity of metabolism, 54—55
 pretreatment of adult rats with desmethylimipramine, 524
 pretreatment with, and locomotor activity, 173—174
 protein binding after intraventricular injection, 46, 52
 rats pretreated intraventricularly with, 483
 reaction product with cysteine and tyrosine residues, 70—71, 70
 reaction with molecular oxygen, 19
 reactive aldehyde, 70, 70
 reducing luteinizing hormone levels in rats treated, 432
 response of rats to maximal electroshock, 443, 444
 restored circoral luteinizing hormone pattern in ovariectomized rats after treatment, 427, 431
 selectivity of section on central monoaminergic neurons, 17—18
 serum luteinizing hormone and prolactin levels in treated proestrous rats, 430, 432
 serum luteinizing hormone, prolactin, and monoamine levels in hypothalamus of treated ovariectomized rats, 427, 428
 serum prolactin, luteinizing hormone, and follicle-stimulating hormone levels
 in ether-stressed treated rats, 426, 430
 in mildly stressed male rats, 425, 425
 sex-related differences in response to, 174
 specificity, 334, 336—337, 528
 subcellular distribution, 67, 67, 71

5,7-Dihydroxytryptamine—(cont'd)
supersensitivity produced by, 260
toxicity to norepinephrine neurons
overcome by pretreatment of animals with protriptyline, 438
tritium overflow in brain slices of treated rats, 334, 335, 336
tyrosyl derivative, 70, 70
uptake
dose-dependent loss of with 6-hydroxydopamine or 5,7-dihydroxytryptamine, 71
inhibition by α -methyltyramine and serotonin, 62, 64
inhibition by cocaine and desmethylimipramine, 62, 64, 71
pretreatment with 6-hydroxydopamine, 5,7-dihydroxytryptamine, or 5,6-dihydroxytryptamine, 62, 64
uptake and accumulation in norepinephrine neurons, 21
uptake by atria, 61, 63, 71
plus 5,6-dihydroxytryptamine and norepinephrine, 62, 64, 68—69, 71
uptake by brain, 176
vasconstrictor effect in
isolated strips of rabbit aorta, 458—459
rats and rabbits, 474
5,7-Dihydroxytryptamine and serotonin, 73
and brain concentration, 171—172
and regeneration within central pathways, 346
cf. *p*-chloroamphetamine effects on brain, 645
content in rat brain after treatment, 426, 429
effect of neonatal administration to rats on *in vitro* serotonin uptake, 331, 332
with 6-hydroxytryptamine and desmethylimipramine on fluorescence histochemical demonstration of nerve terminals, 332, 333
effect of pathway lesions in rat midbrain on
acquisition of one-way avoidance response, 352, 352
forced extinction of one-way avoidance response, 352, 353
retention of one-way avoidance response, 352, 353
effect on central neurons, 3—4, 57
effect on development of neurons, 330
effect when administered to rats on *in vitro* serotonin uptake, 330—331, 331
impairment of serotonin uptake, 306, 324
metabolism and neurotoxicity, 20—21
neurotoxicity, 4—5, 21, 29, 36, 85, 175, 186, 296, 480, 489
reducing brain serotonin and norepinephrine, 166
reducing brain serotonin content after pretreatment with desmethylimipramine, 434
reducing serotonin, 167—168
selective degeneration of serotonergic neurons, 263, 285
specificity in reducing serotonin content, 432—433
5,7-Dihydroxytryptamine creatinine sulfate
changes in ultraviolet absorption with hydrogen ion concentration, 29, 32
ultraviolet spectra, 29, 30, 33
after reaction with oxygen, 33, 33
[¹⁴C]-5,7-Dihydroxytryptamine
accumulation and retention in tissue slices, 308, 310—311, 310, 311
affinity for brain serotonin and norepinephrine uptake sites, 16—17
brain regional patterns of radioactivity after intraventricular injection, 108, 109, 114—117
in rats treated with desmethylimipramine, 111, 113
in rats treated with pargyline, 110—111, 112
in rats treated with 6-hydroxydopamine combined with nialamide, 111, 113
comparison of intraventricular and intracisternal routes of administration, 12—16
effect of injection route on regional retention of radioactivity, 12, 13
increase in fractions from caudal spinal cord, 117—118
radioactivity in hypothalamus, pons-medulla oblongata, and spinal cord after intraventricular injection, 5, 7, 8
radioactivity in rat perchloric acid-homogenized central nervous system, 7, 9, 10, 11
radioactivity in rat urine after intraventricular injection, 5, 9, 19
6,7-Dihydroxytryptamine
biochemical effects when intracisternally injected, 199
impairment of norepinephrine uptake, 307

6,7-Dihydroxytryptamine—(cont'd)
 impairment of serotonin uptake, 306
o-Dihydroxytryptamines and serotonin, 25, 33

3,4-Dimethoxyamphetamine, 126
 as metabolite of *p*-chloramphetamine, 176
 in brain, 120, 124—125
 as psychotoxic agent, 124

5,6-Dimethoxytryptamine
 biochemical and behavioral effects in the rat, 140—141

6,7-Dimethyl-5,6,7,8-tetrahydropterine, 583

N,N-Dimethyltryptamine 487

o,ω-Dinitrostyrenes, 25—26

Dithiothreitol
 antagonizing toxic action of 5,6-dihydroxytryptamine on monoamine oxidase, 53
 preventing oxidation of 5,6-dihydroxytryptamine but not 5,7-dihydroxytryptamine, 54

Dopa, 525
 accumulation, 221
 determination in brain, 223—224
 rat brain concentration after fenfluramine administration, 232—233, 237

L-Dopa, 389—390, 479, 613, 664
 ineffective in producing myoclonic syndrome in rats, 551
 occasional hypersexuality seen in patients during therapy of parkinsonism, 613

Dopa decarboxylase, 583-585

Dopamine, 118, 252, 388—391, 412, 414, 498, 510, 519—520, 530—531, 576, 578, 602, 612—613, 616.
 See also in subheads under other main headings, e.g. 5,7-Dihydroxytryptamine—effect on dopamine uptake
 analyzed in rat forebrain, 439—440
 brain and spinal cord levels after treatment with 5,7-dihydroxytryptamine or *p*-chlorophenylalanine in rats, 498, 499, 503
 effect of 5,7-dihydroxytryptamine-induced lesions of serotonin pathways of midbrain on level in front of the lesion in rats, 355, 356
 within cortex of rats, 354, 354, 356
 in brain, 423, 432, 540, 547
 after intraventricular injection of 5,6-dihydroxytryptamine, 3
 cortex of rats, 365
 of female rats, 621
 of rats, 631
 telencephalon and diencephalon of rats, 349
 in unilaterally lesioned rats, amphetamine thought to induce ipsilateral turning by releasing, 524
 influence of 5,7-dihydroxytryptamine, α -methyl-5,7-dihydroxytryptamine, and desmethylimipramine on forebrain, 14—16, 15
 long-term depletion in brain, 20
 mean concentrations after administration of 5,7-dihydroxytryptamine into rats, 590—591, 592
 measured by radioenzymatic catechol *O*-methyltransferase method, 424
 role in luteinizing hormone release, 388
 uptake by synaptosomes, 92
 Dopamine β -hydroxylase, 182—184, 583—587
 Dopamine denervation hypersensitivity, 406
 Dopamine neurons, 107, 114—116, 342—343, 527, 530, 540
 in rat brain, 336
 regeneration after 5,7-dihydroxytryptamine treatment, 385
 Dopamine receptor agonists, 595, 603, 605, 612—616. See also Apomorphine, *d*-Lysergic acid diethylamide; Ergocornine; Ergometrine; Piribedil
 Dopamine releasers. See *d*-Methamphetamine; Methylphenidate
 Dopaminergic-binding protein, 94
 Drinking, 484—485
 altered by 5-hydroxytryptophan administration in rats, 556
 changes in monkeys and rats, 566, 568
 deficits when 5,6-dihydroxytryptamine microinjected in monkeys and rats, 570—571
 hypodipsia, 484—485. See also *p*-Chlorophenylalanine and serotonin
 hypothalamic actions of serotonin neurotoxins, 573
 in rats, 628—629
 mean daily water intake for rats after serotonin injection and 5,6-dihydroxytryptamine, 566, 567
 regulated in rats, 628

Drugs, centrally acting
effect on actions of 5,7-dihydroxytryptamine in adult rats, 161-163

Drugs, intraventricular vs. intracisternal injections producing different effects, 171

Eating. *See* Feeding

β -Endorphin effect on growth hormone release in rats, 422

met-Enkephalin effect on growth hormone release in rats, 422

Enzymes. *See also* as main headings or in subheads under other main headings: Acetylcholinesterase; Adenyl cyclase; Aldehyde dehydrogenase; Brain—enzymatic activity; Catalase; Catechol *O*-methyltransferase; Choline acetyltransferase; Decarboxylase; Dopa decarboxylase; Dopamine β -hydroxylase; Hydroxyindole *O*-methyltransferase; Hydroxylases; Monoamine oxidase; Oxidase; Peroxidase, horseradish; Phenylalanine hydroxylase; Superoxide dismutase; Tryptophan hydroxylase; Tyrosine hydroxylase

activity in the locus ceruleus after intracisternal injection of 5,6-dihydroxytryptamine, 583, 584

inhibitors. *See* Monoamine oxidase inhibitors; RO4-4602

Ergocornine, 605

Ergometrine, 605

Estriadiol benzoate, 622-624

Estrous cycles in rats, 430, 433

Ethanol as hydroxyl radical scavenger, 82, 84

Ethylene-generating system for measuring flux of hydroxyl radicals, 75

Ethylene production by catalase, superoxide dismutase, and hydroxyl radical scavengers suppressed, 76-77, 76, 80-81

Feeding, 484-485. *See also* Anorexia; Drinking; Hyperphagia
altered by 5-hydroxytryptophan administration in rats, 556
amino acids in rats, 641-642
changes in monkeys and rats, 566-568
deficits when 5,6-dihydroxytryptamine microinjected in monkeys and rats, 570-571

finickiness in rats, 627-628, 630, 634, 642

high-fat diet, 628, 630

hypothalamic actions of serotonin neu-rotoxins, 573

intake after
intraventricular injection of *p*-chlorophenylalanine methyl ester in rats, 590, 591

p-chlorophenylalanine- and sham-injected rats, 593, 593

serotonin and 5,6-dihydroxytryptamine injection in rats, 566, 567

intake in rats, 628-629, 638, 640

obesity, 484, 490

suppression by serotonin system, 594

Fenfluramine, 150, 178, 289-291, 296-297, 300, 302-304, 488-490, 498. *See also* in subheads under other main headings, e.g. 5-Hydroxyindoleacetic acid—brain concentration—after fenfluramine administration in newborn and adult rats

administration, 123

and newborn rats, 239

and tryptophan 5-hydroxylase activity, 126

brains in rats injected later with fluoxetine, 229, 233

can induce anorexia, 478

determination in plasma and brain by gas chromatography, 224

mass spectrometry, 224-225

effect in newborn animals, 172

effect on brain B9 region in rats, 293, 295, 296

hyperthermic effects, 255-256

influence of administration route on brain levels, 120, 120

main site of action, 238

metabolism, 126

metabolite accumulation after brain injection, 120, 121

method to differentiate from norenen-fluramine, 241

neurotoxicity, 125, 127, 259, 480, 482, 484

plasma and brain concentration in rats, 225-226, 227, 228

powerful anorectic agent, 556

subcellular distribution of metabolites after brain injection, 121, 122

suppression of female mating, 621

time course for decrease in serotonin and 5-hydroxyindoleacetic acid in rat brain produced by, 225, 226

Fenfluramine—(cont'd)
used for regulation of body weight in human beings, 485

Fenfluramine and serotonin and reduction of brain serotonin and 5-hydroxyindoleacetic acid, 119 and serotonin-binding protein capacity, 91 effect of acute and chronic injection on brain serotonin content in rats, 296, 298 effect on brain serotonin content when fenfluramine neonatally administered in rats, 163—164, 164 effect on content in rat brain regions, 292, 295 effect on serotonergic terminal processes, 222 possible serotonin deficiency, 1 relation of concentration in brain to serotonin depletion, 222 serotonin releasing, 621

p-Fluoroamphetamine, 150, 154, 289—291

Fluoxetine, 172, 289—290, 476, 515, 519, 649. *See also* in subheads under other main headings, e.g. *p*-Chloroamphetamine—interaction with fluoxetine in mice ability to reverse action of fenfluramine, 238 and brain uptake and metabolism of amphetamines, 121 and protein synthesis, 105—106 and serotonin-binding protein, 95 as inhibitor of serotonin-binding protein capacity, 92 blocking of anorectic effects of fenfluramine, 241 effects on *p*-chloroamphetamine, 158—159 effects on serum prolactin and brain and hypothalamic serotonin and norepinephrine concentrations in female rats, 406, 407 high dosage with serotonin producing myoclonus, 207 inducing analgesia, 487 inhibition of mixed-function oxidase activity, 215 metabolism in brain, 124 potentiating action of 5-hydroxytryptophan 389, 392 selectivity in rat brain, 229, 233 significantly blocking all aspects of the *p*-chloroamphetamine-induced myoclonic syndrome in rats, 518

significantly decreasing serotonin reuptake, 503 stimulant effects of *p*-chloroamphetamine blocked in pretreated animals, 482 termination of norfenfluramine serotonin-reducing action, 236 termination of serotonin-lowering action of fenfluramine, 226—227, 229 unavailable to protect serotonin fibers from 5,6-dihydroxytryptamine, 613

Follicle-stimulating hormone, 387—389, 412, 419—420, 434 determined by radioimmunoassay, 424 inhibitory effect of serotonin on release, 433

Food. *See* Feeding

Gastrointestinal system autopsies in rats, 635—636 motility in rats, 640 pathology in rats, 631, 640

Glutathione antagonized toxic action of 5,6-dihydroxytryptamine on monoamine oxidase, 53 prevention of oxidation of 5,6-dihydroxytryptamine but not 5,7-dihydroxytryptamine, 54

Glutathione, reduced effect on brain serotonin, 121, 123

Gonadotropin release elevated by progesterone, 624

Gramine synthesis of indole derivatives via, 27, 27

Growth hormone, 390—391, 399—400, 412, 419—420 in rats, 630, 638, 641 plasma levels reduced by stress in rats, 422 role of serotonin in regulating in primates, 391

Guanosine triphosphate as inhibitor of serotonin-binding protein capacity, 91

Habituation to novel stimuli by rats, 486—487

Halogenated amphetamines. *See also* *p*-Bromoamphetamine; *p*-Chloroamphetamine; β , β -Difluoro-4-chloroamphetamine; Fenfluramine; *p*-Fluoroamphetamine effect blocked by fluoxetine, 292

Halogenated amphetamines—(cont'd)
 effect of chronic treatment, 292, 296
 effect on brain serotonin, 291
 neurotoxicity, 289—300

Haloperidol, 515, 518—519
 blocking response to amphetamine and apomorphine re contralateral rotation in rats, 526

Harmaline, 596, 602, 613

Heart rate
 increase induced by
 bolus injections of 5,7-dihydroxy-tryptamine, 468, 468
 tryptamine derivatives and some other amines on right atrial strips of guinea pigs, 462, 463
 tryptamine derivatives on right atrial strips of guinea pigs, 461—462, 461

isolated hearts of rabbits, 462, 465
positive chronotropic effect of 5,6-dihydroxytryptamine and 5,7-dihydroxytryptamine, 461—462
spontaneously beating right atria of guinea pigs, 461

Hippocampus
 depletion of serotonin by *p*-chloroamphetamine, 196—197
 loss of the serotonin innervating, 453
 perfusion with serotonin increased seizure activity in rats, 437

Hippurates and enzymatic synthesis in rat brain homogenates, 122, 123

Histamine, 462

Homovanillic acid, 118, 173, 596—597, 605, 612—613, 615—616

Hormones. *See also* as main headings or in subheads under other main headings: Adrenocorticotrophic hormone; Estrogen; Follicle-stimulating hormone; Gonadotropins; Growth hormone; Luteinizing hormone; Melanocyte-stimulating hormone; Progesterone; Prolactin; Thyroid-releasing hormone; Thyroid-stimulating hormone
used as terminal neuroendocrine measures, 638, 639, 641

5-Hydroxy-7-chlorotryptamine, 175

5-Hydroxy-6-methoxyindoleacetic acid, 17

4-Hydroxy-5-methoxytryptamine
 rapid autoxidation preventing application as selective neurotoxic agent, 29

4-Hydroxy-5-methoxytryptamine hydrochloride ultraviolet spectra, 29, 30, 33

5-Hydroxy-6-methoxytryptamine, 18
 and alteration of dopaminergic neurotransmission, 146
 biochemical and behavioral effects in rats, 140

3-Hydroxybenzylhydrazine hydrochloride, 223, 225, 232—235, 237

6-Hydroxydopamine, 53, 76—78, 107, 114—117, 254—255, 289, 297, 328, 339, 342, 362, 406, 436, 478, 530, 566, 568, 570, 594, 631, 649, 664. *See also* in subheads under other main headings, e.g. 5,6-Dihydroxytryptamine—effect alone and in combination with 5-hydroxytryptophan or 6-hydroxydopamine on brain amines and mounting behavior in male rats
1,4-*p*-quinone derivative of, 68
and neuroblastoma cells, 68
and regeneration in catecholamine-containing neurons, 370
autoxidation, 57
autoxidative and enzymatic formation from dopamine, 135
cytotoxicity, 57
degeneration of central catecholaminergic fibers by intraventricular and intracisternal injection, 19
effect of reducing agents on, 68
effect of polysomal profiles, 102, 103
effect on protein synthesis, 98—99, 99, 100, 101—103, 101
for lesioning central catecholamine neurons, 505
for lesioning rats, 605, 609, 614
formation of 2,5-dicysteinyl derivative, 68
formation of hydrogen peroxide from spontaneous reaction with oxygen, 74, 75
inhibition of uptake, 84
introduction, 1
lesions, 526—527
long-lasting depletion of norepinephrine in peripheral organs, 36
mechanism of action, 80
neurotoxicity, 160, 184—185
paraquinone of, 57
paraquinone reaction with free sulfhydryl group, 68
quinoidal products, 80—82
shown after intracisternal injection, 342
uptake by atria
 5,7-dihydroxytryptamine, 5,6-dihydroxytryptamine, and norepinephrine, 62, 64, 68—69, 71

5-Hydroxyindole, 390

Hydroxyindole derivatives and serotonin-binding protein, 95

5,6-Hydroxyindoleacetaldehyde, 18

5-Hydroxyindoleacetic acid, 199, 208, 211, 213, 217, 239, 525, 530—531, 533, 576, 578—579, 596—597, 600, 605, 612—613, 616, 621. *See also* *p*-Chloroamphetamine—*influence on brain concentration of serotonin and 5-hydroxyindoleacetic acid*

brain concentration, 152

after fenfluramine administration in newborn and adult rats, 231, 236

after norfenfluramine administration in rats, 229, 234

after *p*-chloroamphetamine intraperitoneally injected in rats, 515, 517

after treatment with fluoxetine in rats, 227, 228, 229

determination, 222—223

effect of 5,6-dimethoxytryptamine on, 140—141

formation from tryptophan in different central nervous system regions of rats, 315, 318

in brain of rats, 519—520, 631, 636, 638

in central nervous system, 4

increase caused by 5,6-dihydroxytryptamine and 3-(β -aminoethyl)-5,6-dihydroxybenzo[*b*]thiophene, 139

increase or decrease caused by 5-hydroxy-6-methoxytryptamine, 140

permanence of recovery in brain induced by fluoxetine in rats, 227, 231

probencid-induced accumulation in cerebrospinal fluid and brain, 300, 304

reduced in brain by *p*-chloroamphetamine in rats, 645

spectrofluorometric assay from brain, 400

substantially blocking hyperphagia and obesity following medial hypothalamic lesion in rats, 628

[³H]-5-Hydroxyindoleacetic acid

metabolism from [³H]-tryptophan, 373, 374—375, 376

Hydroxyl radicals

effect of scavenging on the neurodegenerative action of 6-hydroxydopamine and 6-aminodopamine, 77, 78, 80—81

from superoxide and hydrogen peroxide, 75, 76—77, 80

role of 6-hydroxydopamine in neurotoxicity, 74

scavengers. *See* Ethanol; 1-Phenyl-3-(2-thiazolyl)-2-thiourea

Hydroxylases

brain and spinal cord activities of tryptophan, tyrosine, and dopamine β -hydroxylases, 184, 184

effect of 5,6-dihydroxytryptamine on brain and spinal cord activities of tyrosine and dopamine β -hydroxylases, 185, 185

Hydroxymethoxyindoleacetaldehyde synthesis, 27

2-[β -(4-Hydroxyphenyl)ethylamino-methyl]tetralone, 457—458

antagonism of methysergide and toward the contractile response to vasoconstrictor amines in aorta of rabbits 360, 460

cf. methysergide and on cumulative concentration-response curve of 5,6-dihydroxytryptamine in aorta of rabbits, 460, 461

6-Hydroxytryptamine

as inhibitor of serotonin-binding protein capacity, 86, 88, 93

neurotoxicity on catecholamine cell bodies, 300

5-Hydroxytryptophan, 254—256, 260, 284, 366, 389—390, 392—394, 437, 444, 481, 483, 485, 487, 525, 590, 602, 613, 615—616, 621, 627, 664. *See also* in subheads under other main headings, e.g. *p*-Chlorophenylalanine—mounting behavior in male, female, castrated, and ovariectomized rats alone or in combination with 5-hydroxytryptophan or haloperidol

able to block preovulatory luteinizing hormone discharge in intact rats, 423

administered intraperitoneally to rats pretreated with intracranial injections of 5,7-dihydroxytryptamine, 510, 519

administration intraperitoneally elevating brain serotonin, 388

and brain serotonin, 484

and increase in circulating growth hormone level, 391

and reduction of tryptophan 5-hydroxylase, 119

blocking of ovulation, 399

5-Hydroxytryptophan—(cont'd)
brain concentration after fenfluramine administration in rats, 232-233, 237
causing release of melanocyte-stimulating hormone after administration in frogs, 394
determination in brain, 223-224
effect on prolactin release in rats pretreated with
5,7-dihydroxytryptamine, 408, 408
p-chloroamphetamine, 408-409, 408
effects on serum prolactin, brain and hypothalamic serotonin, and brain and hypothalamic norepinephrine concentrations in female rats, 406, 407
in brain serotonin biosynthesis, 483
increasing release of corticosteroids after total interruption of neural afferents to hypothalamus, 393
inducing prolactin rise in both p-chloroamphetamine- and 5,7-dihydroxytryptamine-treated animals, 410
injected rats, earlier injected with desmethylimipramine and intracranial 5,7-dihydroxytryptamine, 510-511, 512
restoring cyclicity of luteinizing hormone, 389
supersensitivity to, 239

5-Hydroxytryptophan-induced neurologic syndrome
antiserotonin agents, 203
behavior after administration of desmethylimipramine plus 5,7-dihydroxytryptamine, 203, 205
denervation supersensitivity, 205
myoclonus, 204-207
myoclonus after intracisternal injection of 5,7-dihydroxytryptamine, 201-203, 202
myoclonus effect of drug treatment in 5,7-dihydroxytryptamine- plus desmethylimipramine-lesioned rats, 204, 205
pharmacologic studies, 203
postsynaptic serotonin receptor mechanisms, 205
presynaptic mechanisms, 205

6-Hydroxytryptophan, 285

Hyperphagia. *See also* p-Chlorophenylalanine; 5-Hydroxyindoleacetic acid
5-hydroxytryptophan reversed p-chlorophenylalanine-induced in rats, 590, 591
and obesity, 485
central injection of 5,7-dihydroxytryptamine to desmethylimipramine-pretreated adult female rats did not induce, 638
failure of 5,7-dihydroxytryptamine to produce, 590
in rats, 484, 642
induced by systemic injection of gold thioglucose in mice, 627

Hypertension. *See also* Deoxycorticosterone acetate-saline hypertension in rats
regulation by central serotonergic neurons in rats and rabbits, 471
regulation in rats and rabbits, 474

Hyperthermia, 251-252, 254-256, 558.
See also d-Amphetamine; Apomorphine; Chlorpromazine and prevention of lethal hyperthermia; Fenfluramine; Pimozide; Sleeping and waking
and pretreatment effect of p-chlorophenylalanine or 5,6-dihydroxytryptamine in rabbits, 245-247
induced by
5-hydroxytryptophan plus phenylethylhydrazine in rabbits, 246, 248
apomorphine in rabbits, 246, 246, 255-256
bacterial pyrogen in rabbits, 246, 247
d-amphetamine in rabbits, 245-246, 245, 255-256
fenfluramine and serotonin in control and 5,6-dihydroxytryptamine-treated fowl, 251, 251
fenfluramine in rabbits, 247, 250
injection of 5,7-dihydroxytryptamine in rats, 665
injection of serotonin in cats, 242

Hypodipsia. *See* p-Chlorophenylalanine and serotonin; Drinking

Hypothalamohypophyseal portal capillaries, 387

Hypothalamus, 393-395
action of 5,6-dihydroxytryptamine on in monkeys and rats, 568, 570-572
dopamine levels, 429
fall in serotonin level, 392
lesion in rats, 572
mesencephalic norepinephrine fibers play key role in stimulating preovulatory luteinizing hormone surge, 423

Hypothalamus—(cont'd)
 monoaminergic innervation, 423
 norepinephrine levels, 429, 434
 serotonin cell bodies, 436
 serotonin content after 5,7-dihydroxy-
 tryptamine administration, 429
 synaptosomes in rats, 128

Hypothermia. *See also* Apomorphine
 fatal in monkeys, 563—564
 induced by injection of norepinephrine
 in cats, 242

IIndole derivatives
 inhibition of serotonin-binding protein, 86

Indoleamines, 129—132, 470, 472
 histofluorescence, 244

Indolectomy, chemical, 387—395

5,6-*o*-Indolquinone, 36

Iprindole administration, 124

Iprindole and brain uptake and metabo-
 lism of amphetamines, 121

Iproniazid, 470
 uptake by atria of 5,7-dihydroxytrypt-
 amine, 5,6-dihydroxytryptamine,
 and norepinephrine, 62, 64

Isoleucine, 642

Isoprenaline, 462

Kainic acid, 530

Lleucine, 642

Lineweaver-Burk representations, 40—41,
 41, 43, 44, 46, 47, 48

Lisuride maleate, 596, 605
 given intraperitoneally and tested for
 inducing contralateral turning in
 rats, 605, 608, 614—616

Locomotor activity, 480—482
 effects of serotonin neurotoxic drugs
 on, 481—482
 hyperactivity vs. hypoactivity, 481
 hyperactivity, 482
 hypoactivity, 482
 in rats, 664

Locus ceruleus
 and unilateral rotational behavior when
 lesioned, 589
 in brain of cats, 582—587

Lordosis mediation by estrogen in female
 rats, 623—624

Lu 10-171, 596, 602, 613
 preventing both serotonin depletion and
 the occurrence of mounting be-
 havior in rats, 614

preventing destruction of serotonergic
 system, 56

Luteinizing hormone, 362—363, 387—
 389, 400, 423, 432—434

change of rhythm after ovariectomy
 plus 5,7-dihydroxytryptamine, 436

determined by radioimmunoassay, 424

inhibitory effects of serotonin infusion
 into cerebrospinal fluid, 399

surges induced by estrogen adminis-
 tration blocked by *p*-chlorophenyl-
 alanine injection in ovariectomized
 rats, 399

d-Lysergic acid diethylamide, 203, 204,
 207, 260, 349, 363, 487—488, 498,
 596, 605, 614—616, 664
 as inhibitor of serotonin-binding pro-
 tein capacity, 91
 binding *in vitro* in brain of rats, 337,
 338, 342—343
 blocked myoclonic syndrome in rats,
 511

d-Lysergic acid diethylamide-induced be-
 havioral syndrome in rats, 406

[³H]-*d*-Lysergic acid diethylamide
 binding in rat cerebral cortex, 351,
 358—360, 358, 359, 360, 361, 362
 after serotonin denervation of fore-
 brain, 364—366

Maprotiline, 596, 603, 612—613

Mating behavior. *See* Sexual behavior

Melanocyte-stimulating hormone, 394

Melatonin
 in rats, 631, 638
 inhibitory influence on pituitary go-
 nadotropin secretion, 388

Metaraminol, 597

d-Methamphetamine, 302, 605, 615

Methergoline, 515, 518—519
 as blocker of serotonin receptors, 392

Methimazole structure, 77, 77, 80—81

Methiopin, 389, 515, 518—519
 as blocker of cerebral serotonin, dopa-
 mine, and norepinephrine recep-
 tors, 597, 605, 612

5-Methoxy-*N,N*-dimethyltryptamine, 254,
 498
 producing myoclonic syndrome in rats,
 511

5-Methoxy-6-hydroxyindoleacetic acid, 17

3-Methoxy-4-hydroxyphenylethlenegly-
 col, 173

3-Methoxy-4-hydroxyphenylethlenegly-
 col sulfate, 582, 597, 605, 612—
 613, 616

5-Methoxy-6-hydroxytryptamine, 17
 biochemical and behavioral effects in rats, 140

6-Methoxy-5-hydroxytryptamine, 17

5-Methoxytryptamine, 538

5-Methoxytryptophol inhibitory influence on pituitary gonadotropin secretion, 388

α -Methyl-5,6-dihydroxytryptamine, 69

α -Methyl-5,7-dihydroxytryptamine, 116
 and cytotoxicity, 58
 as serotonin neurotoxin, 4-5
 cytotoxicity, lack of effect with, 69
 intraventricular cf. intracisternal routes of administration, 12-16, 14, 15
 molar neurotoxicity, 20-21
 toxic effects on norepinephrine- and serotonin-containing brain axons, 11

N-Methyl-5,6-dihydroxytryptamine impairment of norepinephrine uptake, 307

N-Methyl-5,7-dihydroxytryptamine impairment of norepinephrine uptake, 307

α -Methyl-5-hydroxytryptamine
 as serotonergic false neurotransmitter, 194
 measurement by chromatography, 191, 191
 use to deplete serotonin, 190

α -Methyl-5-hydroxytryptamine phosphate time course of changes in brain nuclei after injection, 194, 195

α -Methyl-5-hydroxytryptophan, 194, 196

α -Methyl-p-tyrosine, 436, 515, 518-519

3-Methylcholanthrene induction of hepatic oxidase activity, 215

Methylphenidate, 605

Methylscopolamine, 515, 518

6-Methyltetrahydro- β -carboline and changes in central serotonergic neurons, 284

6-Methyltetrahydropterin as cofactor in assay of tryptophan and tyrosine hydroxylases, 183

Methysergide, 203, 204, 207, 284, 390, 406, 409, 458-459, 462, 498, 504-505, 515, 518-519, 539
 as inhibitor of serotonin-binding protein capacity, 91
 blockade of serotonin receptors, 623
 blocked myoclonic syndrome in rats, 511
 effects on serum values on the afternoon of estrus in rats, 403, 405

inhibition of estrous rise of serum prolactin, 403

pretreatment with neither enhances nor antagonizes 5,7-dihydroxytryptamine-induced hypothermia in rats, 489

putative serotonin receptor antagonist, 485

Monoamine oxidase, 11-12, 17-21, 470-471, 585. *See also* in subheads under other main headings, e.g. 5,7-Dihydroxytryptamine—metabolized by monoamine oxidase in rat hypothalamus homogenates and clearance of 5,7-dihydroxytryptamine from the brain, 116 conversion of 5,6-dihydroxytryptamine, 40, 41, 54-55 conversion of 5,7-dihydroxytryptamine, 40, 42, 54-55 conversion of serotonin *in vitro*, 40, 43 determination using [1^4C]-5,6-dihydroxytryptamine and [1^4C]-5,7-dihydroxytryptamine as substrates, 37 effect of intracisternal injection of 5,6-dihydroxytryptamine in locus ceruleus of cats, 583, 585 effect of *p*-chloroamphetamine on, 260 inactivation by 5,6-dihydroxytryptamine or 5,7-dihydroxytryptamine, 53 inactivation *in vitro* and *in vivo*, 38 Michaelis constants and maximal velocities for conversion of 5,6-dihydroxytryptamine, 5,7-dihydroxytryptamine, and serotonin in rat hypothalamus, 40, 40 time course conversion of 5,6-dihydroxytryptamine in rat hypothalamus, 39, 40

Monoamine oxidase A, 48-49, 54

Monoamine oxidase B, 49

Monoamine oxidase inhibitors, 3-4, 19, 21, 74, 78, 81-82, 118, 254-256, 260, 307, 324, 347, 437-438, 481, 483, 486, 497, 520, 595, 600, 612-613, 664. *See also* Harmaline; 5-Hydroxytryptophan; Nialamide; Pargyline; Tranylcypromine affecting cytotoxicity of 5,6-dihydroxytryptamine and 5,7-dihydroxytryptamine differently, 56 and neurotoxicity, 160

Monoamine oxidase inhibitors—(cont'd)
and uptake of 5,7-dihydroxytryptamine, 171-172
kinetics of 5,6-dihydroxytryptamine and 5,7-dihydroxytryptamine, 41—42
protection against action of 5,7-dihydroxytryptamine, 167

Monoamines, brain, 636, 637. *See also* in subheads under other main headings, e.g. 5,7-Dihydroxytryptamine—changes in brain monoamines and their metabolites induced in rats pretreated with harmaline or Lu 10-171 and their main metabolites, 616 catecholamines. *See* Dopamine; Norepinephrine indoleamines. *See* 5-Hydroxyindoleacetic acid; Serotonin

Morphine, 462, 488
effect on growth hormone release in rats, 422

Morphine analgesia, effects of 5,6-dihydroxytryptamine, 541
5,7-dihydroxytryptamine, 541—542
6-hydroxydopamine, 541
fluoxetine, 541
in rats, 348
p-chlorophenylalanine, 541
selective electrolytic raphe lesions, 540—541
zimelidine, 541

Mounting behavior. *See also* *p*-Chlorophenylalanine; Lu 10-171
after 5,6-dihydroxytryptamine or 5,7-dihydroxytryptamine in rats, 602, 616
after *p*-chlorophenylalanine in rats, 603, 613—614
classified as sexual behavior or not, 665
in rats, 596
serotonin neurons shown to originate in, 394

Myoclonus
and cerebellar function, 260—261
drugs interfering with dopaminergic, norepinephrinergic, and cholinergic neurotransmission did not block syndrome in rats, 511
effect of serotonin antagonists produced by 5-hydroxytryptophan after 5,7-dihydroxytryptamine administration in rats, 511, 514
induced by *p*-chloroamphetamine, 518—520

record induced by 5-hydroxytryptophan in rats, 510, 513
syndrome related specifically to central indoleamine neurons, 511

Nasoanal length in rats, 630, 636, 638
Neuroblastoma cells. *See* 6-Hydroxydopamine—and neuroblastoma cells
Neuroendocrine regulation and role of serotonin, 387, 394—395
Neurohumoral amine metabolic pathways, 182, 183

Neurons. *See* Catecholamine neurons; Dopamine neurons; Norepinephrine neurons; Serotonin neurons

Neurotoxic indoleamines. *See also* 5,6-Diacetoxypyramine
cardiovascular effects, 457—474
degenerative effects on central monoamine neurons, 305—324
effects of various doses on brain and spinal cord serotonin and brain and spinal cord catecholamine content, 312—313, 312, 314
effects on monoamine levels, 312—313
effects on serotonin and norepinephrine uptake, 313—314
in vitro, 307, 307
fluorescence morphology, 315—317, 319
local intracerebral injections, 320—322
morphologic studies, 322—324
uptake site affinity and inhibition *in vitro*, 307—308, 309, 313

Neurotoxins. *See* 5,6-Diacetoxypyramine; 5,6-Dihydroxytryptamine; 5,7-Dihydroxytryptamine; *o*-Dihydroxytryptamine; 6-Hydroxydopamine; α -Methyl-5,7-dihydroxytryptamine; Neurotoxic indoleamines; Serotonin-like neurotoxins

Nialamide, 114, 117
as potentiating agent, 80
decreasing lordosis response frequency in female rats, 485
inhibiting conversion of 5,6-dihydroxytryptamine and 5,7-dihydroxytryptamine by monoamine oxidase, 47, 54

Nicotinic drugs and nicotinic receptors, 468

Nigrostriatal pathway, 524
model for interaction with other tracts, 530

Nigrostriatal pathway—(cont'd)
modulation by striatal interneurons,
530
motor efferents, 530

o-Nitrotoluene, 25

Nociception
analgesia, 488
hyperalgesia, 487—488

Norepinephrine, 390, 393, 412, 418, 467,
477, 481, 490, 519—520, 576, 578,
582, 595, 602, 612—613, 624, 627,
665. *See also* in subheads under
other main headings, e.g. Des-
methylimipramine — blocking
brain norepinephrine transport
sites

5,7-dihydroxytryptamine effect on brain
and spinal cord concentration in
rats, 200

analyzed in forebrain of rats, 439—440

and specificity of 5,7-dihydroxytrypt-
amine, 334, 336

appearing to be caused by an activation
of presynaptic serotonin receptors on sympathetic nerve ter-
minals, 462, 465

as neurotransmitter, 134

brain and spinal cord levels after
treatment with 5,7-dihydroxytrypt-
amine or *p*-chlorophenylalanine in
rats, 498, 499, 503

catabolism, 21

concentration after administration of
5,7-dihydroxytryptamine in rats,
590—591, 592

concentration-response curve, 460

depletion by reserpine, 3

depletion in the heart, 135

effect of 5,6-dimethoxytryptamine on,
140

effect of 5,7-dihydroxytryptamine-in-
duced lesions of serotonin path-
ways of midbrain on level
in front of the lesion in rats, 355,
356

within cortex in rats, 354, 354, 356

effects of various drugs
and of calcium ion omission on out-
put from isolated hearts and on
the positive chronotropic effect
evoked by 5,7-dihydroxytrypt-
amine bolus injection in rabbits,
468, 469

on output from isolated hearts of
rabbits, 468, 468

in brain, 402, 432—433, 540—541, 547
after intraventricular injection of

5,6-dihydroxytryptamine, 3—4,
146

cortex of rats, 365

hypothalamus, 406

long-term depletion, 20

of female rats, 621

of rats, 631, 638

telencephalon and diencephalon of
rats, 349

turnover in rats, 252

influence of 5,7-dihydroxytryptamine
on output and on increase in heart
rate evoked by electrical stimu-
lation, 469—470, 470

on removal of exogenous, by isolated
hearts of rabbits, 469, 470

plus α -methyl-5,7-dihydroxytrypt-
amine and desmethylimipramine
on central nervous system, 14—
16, 15

measured by radioenzymatic catechol
O-methyltransferase method, 424

role in luteinizing hormone release,
388

substrate for monoamine oxidase, 48

uptake by atria in mice, 74—75

Norepinephrine neurons, 107, 114—116,
337, 339—340, 342—343

lesions by 6-hydroxydopamine and re-
generation of, 347

pathways in rats, 605, 612—613

pathways unaffected in rats, 603

regeneration after 5,7-dihydroxytrypt-
amine or 5,6-dihydroxytryptamine
treatment, 379, 383

regeneration after 5,7-dihydroxytrypt-
amine treatment, 385

Norfenfluramine, 120, 125, 150. *See also*
in subheads under other main
headings, e.g. 5-Hydroxyindoleacetic
acid—brain concentration—
after norfenfluramine administra-
tion in rats

as major metabolite of fenfluramine,
236

depletion of brain serotonin, 5-hy-
droxyindoleacetic acid, and trypto-
phan hydroxylase in rats, 150, 151

determination in plasma and brain by
gas chromatography and gas
chromatography-mass spectrome-
try, 224—225

mediator of long-term effect of fen-
fluramine, 236

method to differentiate from fenflur-
amine, 241

Norfenfluramine—(cont'd)
 plasma and brain concentration in rats, 225—226, 227, 228
 relation of brain concentration to depletion of serotonin, 222

Ontogenesis of serotonin neurons. *See* Serotonin neuron development
 Osmophilia of serotonin organelles, 609, 609, 610
 Ovariectomy not affecting mounting behavior in female rats, 603
 Ovulation blocking by 5-hydroxytryptophan. *See* 5-Hydroxytryptophan—blocking of ovulation
 Oxygen consumption. *See also* Antimycin A and oxygen consumption
 cyanide effect in brain mitochondria of rats, 79, 79, 81
 dopamine, serotonin, and boiled mitochondrial preparation, 79, 79, 81
 in brain mitochondria of rats, 75
 in brain mitochondria stimulated by 5,6-dihydroxytryptamine and 5,7-dihydroxytryptamine in rats, 79, 79, 81
 Oxygen reduction to form superoxide radical and ionized peroxide, 75, 75, 80

Pain sensitivity, effects of 5-hydroxytryptophan, 539—540
 5,6-dihydroxytryptamine, 539
 5,7-dihydroxytryptamine, 539—540
 and raphe lesions, 664—665
 electrolytic lesions in medial forebrain bundle, 539—540
 fluoxetine, 540
p-chloroamphetamine, 540
p-chlorophenylalanine, 539—541
 quipazine, 540
 tryptophan, 540
 Pancreas protection against alloxan by thiourea, 80
 Paraquinone of 6-hydroxydopamine. *See* 6-Hydroxydopamine
 Pargyline, 4, 17, 20, 203, 204, 502
 decreasing lordosis response frequency in female rats, 485
 effect on actions of 5,7-dihydroxytryptamine on newborn brain in rats, 165, 165
 effect on retention of rat brain radioactivity, 108, 110—111, 114, 116

Parkinsonism, therapy for. *See* L-Dopa
 Pentobarbital effect on growth hormone release in rats, 422
 Pentylenetetrazol inducing convulsions in mice, 437
 Pentylenetetrazol response after treatment with 5,7-dihydroxytryptamine or a raphe nuclei lesions in rats, 442, 443
 Perchloric acid, 5, 7, 9, 11—12, 20, 29, 38—39, 52, 53—54, 108, 110—111, 115—116
 Peroxidase, horseradish, 537
 Phenethylamine derivatives, autoxidizable. *See* 6-Hydroxydopamine
 Phenobarbital, 438
 and β,β -difluoro-*p*-chloroamphetamine, 153
 and half-life of *p*-chloroamphetamine, 221
 effect of 5,7-dihydroxytryptamine or a raphe lesion on anticonvulsant action, 448—450, 452
 effect on maximal electroshock-induced hindleg extension in rats, 449, 450
 induction of hepatic oxidase activity, 215
 Phenothiazines reducing receptor availability of neurotransmitters, 389
 Phenoxybenzamine, 515, 518
 Phentolamine, 458
 1-Phenyl-3-(2-thiazolyl)-2-thiourea
 as copper chelator, 84
 as hydroxyl radical scavenger, 82
 as protective agent, 80
 structure, 77, 77, 80—81
 Phenylalanine, 546, 642
 Phenylalanine hydroxylase, 540, 546
 Phenylethylamine compound effect on protein synthesis, 96, 99, 100, 101
 3-Phenylpiperidines, chlorinated, 153
 Phenytoin, 438
 effect of 5,7-dihydroxytryptamine or a raphe lesion on anticonvulsant action, 448—450, 452
 effect on maximal electroshock-induced hindleg extension
 after a raphe nuclei lesion in rats, 450, 450
 in rats, 449, 449, 450
 Pimozide, 515, 518
 counteraction of hyperthermic effect of *d*-amphetamine, 252
 Pindolol, 467
 Piperocaine, 623—624

Piperonyl butoxide
effect on reduction of serotonin and tryptophan hydroxylase by *p*-chloroamphetamine, 208, 209
inhibition of hepatic oxidase activity, 215

Piribedil, 605

Pituitary-adrenal axis suppression by intraventricular injection of indoles, 392

Pituitary, anterior, regulation of secretion, 387

Platelets, blood. *See* Blood platelets

Postural syndrome and *p*-chloroamphetamine-induced abnormalities, tremor, and myoclonus in rats, 511, 514

Probenecid, 17

Progesterone location of implants in female rats, 624, 624

Progesterone uptake by all brain regions in rats and guinea pigs, 623

Prolactin, 362—363, 389—390, 394, 400, 434
in rat plasma, 436
in rats, 630, 638, 641
serum estrogen-induced surges blocked by *p*-chlorophenylalanine or methysergide, 399
serum values on the day of vaginal estrus in rats, 402, 403

stimulation of release after intracerebroventricular serotonin injection, after administration of 5-hydroxytryptophan and treatment with serotonin agonists, 399

stress-induced release governed primarily by the norepinephrine system, 433

Propranolol, 462, 515, 518

Prostaglandins, 665

Protein synthesis inhibition by neurotoxins, 96—104

Protriptyline, 438, 595
as norepinephrine uptake blocker, 346
plus 5,7-dihydroxytryptamine as a means of selective lesioning serotonergic neurons, 439, 452

pretreatment with, 543
preventing the effects of 5,7-dihydroxytryptamine on norepinephrine neurons, 439

Quinine sulfate
acceptance of varying solutions instead of tap water by rats, 634, 635
in drinking water for rats, 630

Quinoid structures, 18, 29, 54
of 6-hydroxydopamine, 36

1,4-*p*-Quinone derivative of 6-hydroxydopamine. *See* 6-Hydroxydopamine—1,4-*p*-quinone derivative of

o-Quinone
of 5,7-dihydroxytryptamine, 21
sulphydryl group reduction, 103

p-Quinone
sulphydryl group reduction, 103

p-Quinoneimine of 5,7-dihydroxytryptamine, 19—21
neurotoxicity, 55

Quinoneimines from 5,6-dihydroxytryptamine or 5,7-dihydroxytryptamine, 53

Quinones
from 5,6-dihydroxytryptamine or 5,7-dihydroxytryptamine, 53—54
neurotoxic effects, 175

Quipazine, 207, 487
producing myoclonic syndrome in rats, 511
stimulation of serotonin receptors
stimulating prolactin release, 389—390

Raphe nuclei
dorsal raphe nucleus, 482
in midbrain, 484—485
in rats, 488—490

lesions. *See also* Acetazolamide; Acetylcholine; Activity level; Avoidance behavior; Behavior, rotational; Brain; 5,7-Dihydroxytryptamine; Pain sensitivity; effects of; Pentylenetetrazol; Phenyltoin; Receptor supersensitivity; Spatial reversal learning
producing behavioral and electrophysiologic signs of insomnia in cats, 483

locomotor activity, 481

median or dorsal, 489—490

nucleus raphe dorsalis or nucleus raphe magnus, 487

Rearing activity
behavior of rats, 652, 652, 654, 655, 656, 657

Receptor supersensitivity
absence after median raphe nucleus lesions, 527
due to serotonin or dopamine neurons in rat brain, 526

Ungerstedt's model, 526—527

Rectal temperature
effect of 5-hydroxytryptophan in rats pretreated with desmethylimipramine and 5,7-dihydroxytryptamine, 511, 513

Reserpine, 302, 437, 462, 467, 578. *See also* in subheads under other main headings, e.g. Norepinephrine—depletion by reserpine
amine depletion with, 392
and serotonin-binding protein, 95
as inhibitor of serotonin-binding protein capacity, 86
brain injected later with fluoxetine in rats, 229, 233
reduction of thyroid-stimulating hormone with, 394
uptake by atria
5,7-dihydroxytryptamine, 5,6-dihydroxytryptamine, and norepinephrine, 62, 64, 71

Reticulocyte ribosomes, 97

Ribonucleic acid, globin messenger, 97—98

RO4-4602, 203, 204
correlation between the decrease in cortical 5-hydroxytryptophan and the decrease in striatal dopamine after injection of rats, 528, 528
preventing conversion of 5-hydroxytryptophan to serotonin, 392
to measure the turnover of dopamine and serotonin in rats, 525

Rotational behavior. *See* Behavior, rotational

Rotenone and oxygen consumption, 81

Salicylates and brain serotonin concentration, 92

Schizophreniform symptoms, fenfluramine-induced, 490

Seizure susceptibility changes, 456
after intracerebral treatment with 5,7-dihydroxytryptamine, 437—453
effect of 5,7-dihydroxytryptamine, 438—445, 447—448
effect of a raphe lesion, 438—445, 446, 447—448
electroshock seizures by corneal stimulation in rats, 442
forebrain norepinephrine and dopamine concentrations unaltered in 5,7-dihydroxytryptamine-treated rats, 452
induced by pentylenetetrazol by intra-

peritoneal injection in rats, 441—442, 445, 452
role of serotonin, 453

Serotonergic elements, 242
receptor supersensitivity, 243
selective destruction, 263

Serotonergic motor syndromes, 510—520

Serotonergic nerve terminals, supersensitivity after destruction of. *See* Supersensitivity after destruction of serotonergic nerve terminals

Serotonergic raphe inputs to the nigrostriatal pathway diagrammatic model, 529, 529

Serotonin, 254—256, 422, 437—440, 442, 444—445, 447—448, 450, 452—453, 472, 497, 504—505, 530—531, 556, 568, 613, 616—617, 627. *See also* other main headings beginning "Seroton—" or with the word "serotonin" (e.g. 5,7-Dihydroxytryptamine and serotonin); also subheads throughout the subject index may refer to serotonin and should be sought by referring to related concept, as they are too numerous to list here (e.g. Brain—serotonin content; Hydroxyindole derivatives—and serotonin-binding protein)

abnormal motor response complex induced by *p*-chloroamphetamine, 209, 211

alterations in postnatal development of serotonin neurons after administration at birth, 339, 341

analyzed in forebrain, brain stem, and spinal cord of rats, 439

and mediation of hyperthermic response to *d*-amphetamine and apomorphine in rabbits, 252

as neurotransmitter, 134, 483

binding sites in lumbar spinal cord, 118

brain and spinal cord levels after *p*-chlorophenylalanine and 5,7-dihydroxytryptamine administration, 511, 514, 514

brain and spinal cord levels after treatment with 5,7-dihydroxytryptamine or *p*-chlorophenylalanine in rats, 498, 499, 503

brain concentration, 152, 171
after fenfluramine administration in rats, 231, 235
after intraperitoneal injection of *p*-chloroamphetamine in rats, 515, 517

Serotonin—(cont'd)
brain concentration—(cont'd)
after norfenfluramine administration
in rats, 229, 234
after treatment with fluoxetine in
rats, 227, 228, 229
in forebrain and midbrain after fen-
fluramine administration in rats,
231, 237
in rats, 519
measured, 87—88
permanence of recovery induced by
fluoxetine in rats, 227, 230
spectrofluorometric assay, 400
brain concentration depletion
after injection of fenfluramine, 222
after injection of *p*-chloroamphet-
amine or *p*-chloro-*N*-methylam-
phetamine in rats, 150—151, 151
after intracisternal injection of 5,7-
dihydroxytryptamine, 4
and recovery in rat brain regions
after single intraventricular injection
of 5,6-dihydroxytryptamine,
370, 371, 372
by *p*-chloroamphetamine in rats, 645
in whole brain by *p*-chlorophenylala-
nine and reversed by 5-hydroxy-
tryptophan in rats, 590, 592
long-term, 20
related to route of administration
used, 171
causing release of melanocyte-stimula-
ting hormone after administra-
tion in frogs, 394
chronic receptor blockade, 498
competition of unlabeled vs. tritium-
labeled *in vitro* in brain of rats,
337, 339
competition vs. *d*-lysergic acid diethyl-
amide for [³H]-*d*-lysergic acid di-
ethylamide *in vitro* in brain of
rats, 337, 340
depletion, 119
effect of 5,7-dihydroxytryptamine-in-
duced lesions of serotonin path-
ways of midbrain on level
in front of the lesion in rats, 355,
356
within cortex in rats, 364, 354, 356
endogenous in bulbospinal system given
injection of 5,6-dihydroxytrypt-
amine intraventricularly in rats,
372, 372
failure of depletion to prevent induced
prolactin rise in females treated
with 5,7-dihydroxytryptamine, 478
formation from tryptophan in different
central nervous system regions in
rats, 315, 318
history of isolation and characteriza-
tion, 1
importance of interval between injec-
tion of fenfluramine and fluoxetine
on recovery in brain of rats, 227,
232
in brain, 402, 411, 418—420, 432—434
activating the secretion of adrenocor-
ticotropic hormone, prolactin,
and growth hormone, 411
after injection of 5,6-dihydroxytryp-
amine, 3—5
binding *in vitro* in rats, 337, 338
cortex in rats, 365
cortical uptake after fenfluramine
administration in rats, 231, 235
depletion having anorexigenic effect,
418—419
hypothalamus, 406
in rats, 631, 636, 638, 640—642
inhibits secretion of gonadotropins,
411
recovery produced by fluoxetine in
rats treated with norfenfluramine,
229, 230
reduced with *p*-chlorophenylalanine
plus 5,6-dihydroxytryptamine, 436
telencephalon and diencephalon in
rats, 349
time course of changes in nuclei
after injection of α -methyl-5-hy-
droxytryptamine, 194, 195
time course of changes in nuclei after
injection of *p*-chloroamphetamine,
192, 193
tryptophan-induced elevation, 392
uptake in rats, 334, 335
whole brain, 406
influence of 5,7-dihydroxytryptamine,
 α -methyl-5,7-dihydroxytryptamine,
and desmethylimipramine on cen-
tral nervous system, 13—14, 14
inhibition of surgery-induced adrenal
steroid secretion with intraventric-
ular doses in dogs, 392
intraventricular injection shown to in-
hibit gonadotropin release and to
stimulate prolactin release in male
rats, 423
long-lasting effect of fenfluramine,
234—235
maximal velocity, 48—49

Serotonin—(cont'd)
mean concentrations after administration of 5,7-dihydroxytryptamine into rats, 590—591, 592
measured by radioenzymatic hydroxyindole *O*-methyltransferase method, 424
measurement by chromatography, 191, 191
metabolic effects, 394
Michaelis constant, 48
microinjection into hypothalamus at room temperature raises body temperature in monkeys, 488—489
monoamine oxidase-catalyzed conversion of tryptamine, 41, 48
inhibited, 41, 49
nervous system regional differences, 213—214
reduction of cerebrospinal serotonin accompanied by enhancement of sexual activity in male rats, 595
release, 561
role in mechanism of sleep in cats, 576
storage and/or transport, 86—87
synthesis rate, 234
toxic inhibitory tone on gonadotropin release, 388
uptake, 133
by synaptosomes, 92
Serotonin analogs, 129—132
Serotonin-binding protein
5,6-dihydroxytryptamine and 5,7-dihydroxytryptamine as inhibitors of, 85
binding of newly synthesized serotonin, 92, 93
characteristics of capacity, 87
ferrous ion-enhancing capacity, 86
inhibition of serotonin binding by neurotoxins, 88—89, 88
location in synaptosomal cytoplasm and cytosol of brain and peripheral nervous tissue, 86
role of sulphydryl group, 86
Serotonin cell group (B1-B9) anatomy, 532—533, 533, 535, 536—537, 537—538, 544
afferent connections, 538—539
efferent projections from
dorsal raphe to amygdala, 537
dorsal raphe to caudate-putamen, 537
median raphe to individual hypothalamic nuclei, 537
median raphe to septum-hippocampus, 537
Serotonin denervation hypersensitivity, 406
Serotonin depletion methods
differences in neurochemical effects, 532
importance in determining behavioral effects, 532
Serotonin inhibitors. *See* Lisuride maleate; Lu 10-171; Methysergide
Serotonin-like neurotoxins, 129—132
Serotonin neuron development, 329, 338—343, 346—350, 366
axonal sprouting in rats, 376
effects of neonatal 5,7-dihydroxytryptamine treatment in rats, 330—332, 334
growth regulation, 342
intracisternal 5,7-dihydroxytryptamine injection, 341—342
not associated with collateral sprouting of nerves not damaged by 5,7-dihydroxytryptamine, 342
route of neurotoxin administration, 328—329
serotonin receptors, 337, 342
Serotonin neuron ontogenesis. *See* Serotonin neuron development
Serotonin neurons, 107, 114—116, 573, 576, 582, 659—660
affecting behavior including sleep, feeding, temperature control, and pain sensitivity, 510
effect of 5,6-dihydroxytryptamine on, 346
effect of *p*-chloroamphetamine on in rats, 645, 649
evaluation of degeneration, 350—351
false neurotransmitter as tool for study of, 190
hyperresponsivity in rats after lesions, 363—364
in hypothalamus, 410
in rat brain, 642
in rats, 602, 605, 609
negative reinforcement, 363
regeneration after 5,7-dihydroxytryptamine or 5,6-dihydroxytryptamine treatment, 379, 383
regeneration in brain after 5,6-dihydroxytryptamine-induced axotomy in rats, 370—383
5,7-dihydroxytryptamine-induced axotomy in rats, 370
supersensitivity disappearing, as shown by reduced responsiveness to 5-methoxydimethyltryptamine and to tryptophan, 347

Serotonin neurons—(cont'd)

- terminals as primary site of action of fenfluramine, 238

Serotonin neurotoxins, 394—395, 409.

- See also* 5,6-Diacetoxytryptamine; 5,6-Dihydroxytryptamine; 5,7-Dihydroxytryptamine; α -Dihydroxytryptamine; 6-Hydroxydopamine; α -Methyl-5,7-dihydroxytryptamine; Neurotoxic indoleamines; Serotonin-like neurotoxins

as tools to study thyroid function, 394

Serotonin receptors, 457, 664

- newly synthesized serotonin, 86
- supersensitivity, 593

Serotonin-secreting neurons, central, 457

Serotonin system, ascending and progressive, 623—624

[³H]Serotonin

- accumulation and retention in tissue slices, 308, 310—311, 310, 311
- binding in brain cortex after serotonin denervation of forebrain in rats, 364—366
- binding in brain cortex of rats, 351, 358—360, 358, 359, 360, 361, 362
- metabolism from [³H]tryptophan, 373, 374—375, 376
- uptake in cortex and hypothalamus after 5,7-dihydroxytryptamine-induced lesions in rats, 356
- uptake in medulla oblongata and spinal cord after 5,6-dihydroxytryptamine treatment in rats, 372, 373
- uptake of total tritium and unchanged [³H]serotonin by brain slices and spinal cord in rats, 370, 371, 372

Sexual behavior. *See also* p-Chloroamphetamine; L-Dopa; Fenfluramine; Mounting behavior

- dependent on ovarian hormones estrogen and progesterone appearing mediated by a serotonergic system, 624
- effect of intracranial hormone administration in female rats, 623, 623
- facilitated by norepinephrine in female rats, 622
- increased after injection of p-chlorophenylalanine in rats, 485—486
- suppressed by serotonin in female rats, 622

Sleeping and waking, 481—484. *See also* p-Chlorophenylalanine; 5,6-Dihydroxytryptamine—as tool for studying sleep mechanisms in cats;

Serotonin—role in mechanism of sleep in cats

- amount of paradoxical sleep after injection of 5,6-dihydroxytryptamine in cats, 578, 579
- amount of stage-2 sleep after injection of 5,6-dihydroxytryptamine in cats, 578, 579
- and hyperthermia in serotonin-infused fowl, 247—248
- and lesions of serotonin pathways with 5,7-dihydroxytryptamine in rats, 349, 365
- arousal, 480, 487
- brain serotonin neurons may play important role in mediating, 480
- rapid eye movement, 483—484
- sedation and depression, 481—482
- slow-wave sleep, 484

Spatial reversal learning effects of midbrain raphe lesions, 545

Spinal cord

- decrease in serotonin level in rats, 503 in rats, 377

Spleen

- norepinephrine level after single dose of 5,6-dihydroxytryptamine or 3-(β -aminoethyl)-5,6-dihydroxybenzo[b]thiophene in rats, 136, 137
- serotonin level after single dose of 5,6-dihydroxytryptamine or 3-(β -aminoethyl)-5,6-dihydroxybenzo[b]thiophene in rats, 136, 137

Subcommissural organ

- after injection of 5,6-dihydroxytryptamine in rats, 267, 268, 279, 280—281, 283
- after intraventricular injection of 5,7-dihydroxytryptamine in rats, 272—273, 275, 276, 277
- and serotonergic synapses, 262—264
- apical process in contact with cerebrospinal fluid after intraventricular injection of 5,7-dihydroxytryptamine in rats, 273, 275

autoradiography, 265

definition and location, 262

detection of somatostatin, luteinizing hormone-releasing factor, thyrotropin-releasing factor, and arginine vasotocin in, 283

electron microscopic observations in rats, 265, 269, 270—271, 273

fluorescence histochemistry, 264

fluorescence micrograph of sagittal section from rats, 266, 266

Subcommissural organ—(cont'd)
 histochemical demonstration of nucleoproteins, glycoproteins, and neurosecretory proteins, 265
 increased extracellular space in hypendyma after injection of 5,6-dihydroxytryptamine in rats, 275, 278
 indoleaminergic innervation confirmed, 284—285
 inhibitory effects of serotonin on protein synthesis, 284
 innervation, 282—283
 of rats as model for neuron-target cell interaction, 282—284
 perinuclear region of cells after intraventricular injection of 5,6-dihydroxytryptamine in rats, 273, 274
 protein and glycoprotein synthesis inhibited by serotonergic input, 264
 secretory function, 279—280, 282—283
 serotonergic terminals in the ependymal cells, 385
 serotonin terminals, 282—284
 varicose fluorescent fibers after intraventricular injection of 6-hydroxytryptamine in rats, 267, 268

Subsensitivity after destruction of serotonergic nerve terminals affected by various doses of fenfluramine in injected rats, 501—502, 502

Sucrose
 acceptance of varying solutions instead of tap water by rats, 634, 634
 in drinking water for rats, 630

Sulphydryl groups, 54, 56. *See also* 5,6-Dihydroxytryptamine—reaction with sulphydryl groups; Serotonin-binding protein
 in peptides and proteins, 18

Superoxide dismutase
 inhibition of tryptamine conversion not antagonized, 41

Superoxides
 sites of action from neurotoxins, 84

Supersensitivity after destruction of serotonergic nerve terminals
 5-methoxy-*N,N*-dimethyltryptamine, 497—498
 5,7-dihydroxytryptamine, 498, 500—502, 504—506
 adenyl cyclase activity, 506
 administration of L-tryptophan (after monoamine oxidase inhibition) and L-hydroxytryptophan both producing the syndrome, 497, 504—505

effect of various doses of 5-methoxy-*N,N*-dimethyltryptamine in injected rats, 500—501, 501, 504—505
 effect of various doses of *d*-lysergic acid diethylamide in injected rats, 500—501, 501, 504—505
 effect of various doses of L-5-hydroxytryptophan in injected rats, 500, 500, 503, 503
 effect of various doses of L-tryptophan in rats, 501, 502
 fenfluramine, 497, 504—505
 p-chloroamphetamine, 497
 presynaptic, 504
 serotonin, 497
 Sympathetic nerves of the heart, 457
 decrease in norepinephrine content, 471
 degeneration of the terminals, 471
 in rabbits, 462
 norepinephrine uptake, 469
 serotonin causing norepinephrine release from, 468

Synaptosomal accumulation of serotonin in various brain regions in rats, 647—648

Temperature, body. *See also* p-Chlorophenylalanine; Hyperthermia; Hypothermia; Rectal temperature
 average deviation in response to exposure to cold or warm air in rats, 559, 561
 behavioral thermoregulation in monkeys, 564—566
 deviation from a baseline after injection of 5,6-dihydroxytryptamine in monkeys, 562, 563, 565, 565
 injection of saline and 5,6-dihydroxytryptamine in rats, 558, 560
 intrahypothalamic injection of serotonin in monkeys, 558, 559
 risk of exposure to cold and warm air after serotonin and saline injection and after 5,6-dihydroxytryptamine injection into anterior hypothalamus in rats, 561, 562
 hypothalamic actions of serotonin neurotoxins, 573
 maximum rise induced by serotonin injected into hypothalamus before and after 5,6-dihydroxytryptamine injections at the same site in rats, 558, 560
 of monkeys after injection of 5,6-dihydroxytryptamine, 564, 564
 regulation, 488—489

Temperature, body—(cont'd)
thermoregulatory mechanism
after hypothalamic injection with
5,6-dihydroxytryptamine, 559, 561
deficits in monkeys and rats, 571—
572
in hypothalamus, 556—557

Testosterone, 486

Thiourea
as protective agent, 80—81
structure, 77, 77

Thyroid C cells
uptake of 6-hydroxydopamine, 56

Thyroid-releasing hormone, 389

Thyroid-stimulating hormone, 393—394

Tibial length, right, in rats, 631, 636, 638

Transmitter turnover
correlations with rotational behavior,
526
dopamine turnover, 526
serotonin turnover, 526

Tranylcypromine, 510, 519

Trazodone as inhibitor of serotonin-binding protein capacity, 91

m-Trifluoromethylbenzoylglycine
recovery from rat brain as fenfluramine
metabolite, 120, 122, 125—126

Triton® X-100
and oxygen consumption, 81

Tryptamine, 387, 538, 540, 546, 664
and excess concentration of 5,6-dihydroxytryptamine, 5,7-dihydroxytryptamine, or serotonin to inhibit conversion, 49, 54
in brain, 481
noncompetitive inhibition by 5,6-dihydroxytryptamine or 5,7-dihydroxytryptamine, 53

Tryptamine derivatives
acute toxicity, 458
in isolated strips of rabbit aorta, 459,
459, 461
numbering system, 128, 129

Tryptamines
synthesis, 25, 27

Tryptamines, hydroxylated
effect on serotonin, norepinephrine, and
dopamine uptake into hypothalamic homogenates, 128—129, 130,
131
effect on serotonin uptake into hypothalamic homogenates, 128—129,
129

Tryptophan, 199, 203—205, 254, 389,
391, 483, 519, 532, 576, 578, 642,
664
as precursor for serotonin, 510
essential amino acid for serotonin bio-synthesis, 481
in central nervous system, 4
in diet, 487
loading to increase neuronal serotonin levels, 394
pretreatment with neither enhances nor antagonizes 5,7-dihydroxytryptamine-induced hypothermia in rats, 489

Tryptophan hydroxylase, 153—154, 158—
159, 182—184, 204, 259, 297, 437,
532—533, 537—538, 540, 546,
586, 621
and *p*-chloroamphetamine, 208, 211,
213—215, 217
in rat brain, 649
inactivated by *p*-chlorophenylalanine,
519
measurement by high-pressure liquid chromatography, 190
reduced in brain by *p*-chloroamphetamine in rats, 645
time course of changes in brain nuclei after injection of *p*-chloroamphetamine, 192, 193

Tryptophan-induced neurologic syndrome
myoclonus, 206—207

Tryptophan-poor diets, 539—540

Tubulin relation to serotonin-binding protein, 90—91

Turning behavior. *See* Behavior, rotational

Tyrosine, 583, 642
in brain of cats, 578

Tyrosine hydroxylase, 182—184, 221,
255, 478, 540, 546, 589, 621
effect of intracisternally injected 5,6-dihydroxytryptamine
in locus ceruleus of cats, 583—584,
585
on activity in the locus and frontal cortex in cats, 582—583, 583, 584

increase in activity in the locus ceruleus after bilateral injection of 5,6-dihydroxytryptamine in cats, 585—586, 586

Urethane anesthetizing of rats, 458

Valine, 642
injections, 487

Vinblastine
as inhibitor of serotonin-binding protein capacity, 86
effect on capacity of serotonin-binding protein in brain, 90, 91

Water intake. *See* Drinking
Weight, body. *See also* *p*-Chloroamphetamine; 5,6-Dihydroxytryptamine; Fenfluramine
after exposure to a high-fat diet instead of pellet chow in rats, 634, 635
average loss or gain in rats injected intraventricularly with 5,6-dihydroxytryptamine, 6-hydroxydopamine, or artificial cerebrospinal fluid and some given 5,7-dihydroxytryptamine similarly, 568, 570
changes in monkeys and rats, 566, 568
ethanol preference test obtained for 5,6-dihydroxytryptamine- and 6-hydroxydopamine-injected rats, 571, 572
gain accompanying overeating in rats, 571

gain in rats, 642
in rats, 627, 638, 640—642
loss or gain in rats after single injection of 5,6-dihydroxytryptamine, 5,7-dihydroxytryptamine, 6-hydroxydopamine, or cerebrospinal fluid in brain ventricle, 568, 569
obesity in rats, 627
regulation in rats, 628, 640, 642

Zimelidine, 352, 352, 353, 354—356, 355, 362, 645—646, 648—649, 651—660. *See also* in subheads under other main headings, e.g. Morphine analgesia, effects of—zimelidine
as potent serotonin uptake-blocking agent





Author Index

(Italicized page numbers refer to comments in discussions; boldface page numbers indicate abstracts.)

Ainsworth, E. J., 325-342
Allen, T., *199*
Allison, A. C., *324*, 367-370, 393, 427-428
Alving, C. R., *122-123*, 233, 257, 365, 369
Atchison, M. L., 395-410

Bach, D., *385*
Bangham, A. D., *2-7*, 82-83, 100, 163, 182, 248, 266-267, 341-342, 367, 368, 424, 425
Barratt, D. G. **441**
Basu, M. K., *198*
Bauraing, R., 226-234
Bennett, L. G., 8-28
Bergelson, L. D., **438**
Bharucha, J., 325-342
Bittman, R., **441**
Blackwell, B., 8-28
Blok, M. C., *85-100*
Blumenthal, R., *183*, 280, 385, **433**
Boulanger, Y., 8-28
Butler, K. W., 8-28

Carballo, P. P., 200-214
Caride, V. J., **435**
Carr, V. M., 200-214
Cerny, E. A., **438-439**
Chapman, D., 67-84
Chester, D., *162*
Clejan, S., **441**
Cleland, L. G., **410**
Cohen, B., *99*

Dave, C., *371-386*, 394, **436-437**
Day, E. P., **437**
Deamer, D. W., *250-258*, **440**
de Duve, C., *226-234*, 423, 424
de Gier, J., *63*, 85-100
Deprez-de Campeneere, D., *226-234*
Deroo, P. W., **441**
Derzko, Z., **437**
Desnick, R. J., *232-233*, 366-367, **432**
Dingle, J. T., **435-436**
Dombroso, F. A., *366*
Dray, S., **433**

Elsborth, *198-199*
Englehardt, *122*
Finkelstein, M., 235-249
Fisher, J. A., 200-201
Garnick, M. B., *233*
Giacomoni, D., **433**
Gould, R. M., *162*, 225
Grant, C. W. M., **441**
Gregoriadis, G., *343-370*, 384-386
Guilmette, R. A., **438-439**

Hanson, W. R., 325-342
Hargreaves, W. R., **440-441**
Haynes, D., *66*, 234, **440**
Haywood, A. M., 275-280
Heiss, A., *64*
Henkart, P., **433**
Henney, C. S., **434**
Hill, M. W., *48-49*, 64, 101-110,
Ho, J. T., **437**
Hoffman, R. M., **438**
Hoffstein, S., 235-249, **435**
Hsia, J. C., *139-148*
Huang, C., *29-49*
Huang, L., *182*, 224, 280, **439**
Hunt, C. A., *342*, 386, 410, *431-432*

Ihler, G. M., *367*
Jacobson, K., **437**
Jaroslav, B. N., 325-342
Jewkes, R. F., *281-307*
Jeyasingh, K., *281-307*
Jonah, M. M., **435**
Jones, N. C., *215-225*
Joyce, A., 8-28
Juliano, R. L., *411-425*
Kalman, T., *257*, **393**
Kang, C. H., **440**
Kantor, H., *162*
Kataoka, T., *387-394*
Kelly, R. B., **439-440**

Kimelberg, H., 248-249, 395-410
 Kinsky, S. C., 111-123, 137, 138, 147,
 369, 394
 Knight, C. G., 435-436
 Kobayashi, T., 387-394
 Korchak, H., 235-249
 Kunze, R. K., 437

Lajtha, A., 182, 183
 Lampert, M. A., 65
 Landsberger, F., 183, 273, 436
 Laughlin, R. G., 233, 258
 Lavelle, L., 433
 Layton, D., 83
 Lettman, 163
 Lewis, J. T., 124-138
 Lowe, J. S., 435-436
 Lyles, D. S., 436

MacDonald, R. C., 65-66, 200-214,
 248, 258, 273, 274, 370
 MacDonald, R. I., 200-214
 Macek, C. M., 435
 Magee, W. E., 308-323
 Margolis, L. B., 438
 Mason, J. T., 29-49
 Mayhew, E., 371-386, 436-437
 McConnell, H., 6-7, 26-28, 64, 100,
 122, 124-138, 147, 160
 McCullough, N., 411-425
 McLaughlin, S., 63, 64
 Metcalfe, J. C., 65
 Mihich, E., 365-366, 394, 409-410, 428-
 429
 Members, C., 85-100
 Murphree, S. A., 438

Osborn, M. J., 160, 161, 163, 164, 182,
 215-225
 Osborne, M. P., 281-307
 Oster, K., 83, 162, 437-438
 Ostro, M. J., 433
 Ozato, K., 434

Pagano, R. E., 185-199, 280, 370
 Pangborn, W., 50-66
 Papahadjopoulos, D., 1, 50-66, 99, 121-
 122, 147, 148, 160-161, 164-184, 198,
 225, 247-248, 259-267, 268-274, 369-
 370, 371-386, 394, 426-427, 436-437
 Patel, H. M., 281-307
 Peel, W. E., 67-84
 Peria, 306

Phillips, N. C., 435-436
 Portis, A., 50-66
 Poste, G., 164-184, 199, 232-234, 248,
 280, 365
 Pownall, H. J., 257
 Preisler, H., 429-431

Quinn, P. J., 67-84

Rader, R., 123
 Rahman, Y. E., 325-342, 439
 Richardson, V. J., 281-307
 Ritchie, A. K., 439
 Ritter, C., 434-435
 Roerdink, F. H., 306, 410, 433-434
 Rogers, J. D., 441
 Rosenthal, A. F., 441
 Ross, D. J., 437-438
 Rustum, Y. M., 371-386, 436-437
 Rutman, R. J., 434-435
 Ryman, B. E., 281-307

Sandra, A., 185-199
 Sartorelli, A. C., 438
 Scherphof, G. L., 433-434
 Schindler, M., 215-225
 Schreier, S., 8-28
 Shafer, D., 49
 Sharnick, S., 437-438
 Sharom, F. J., 441
 Sharow, S. O., 433
 Shaw, I. H., 435-436
 Smith, I. C. P., 8-28, 48, 49
 Smolen, J., 235-249
 Stamp, D., 411-425
 Stockton, G. W., 8-28
 Strong, P. N., 83, 439-440
 Sun, S.-T., 437
 Szoka, F. C., Jr., 437

Taber, R., 268-274
 Takeichi, M., 185-199
 Tan, C. T., 139-148
 Tattersall, M. H. N., 281-307
 Thomas, D. P. P., 435-436
 Thompson, T. E., 49, 100, 441
 Tom, B. H., 435
 Tracy, T., 394
 Tritton, T. R., 438
 Trouet, A., 226-234
 Tulloch, A. P., 8-28
 Turcotte, J., 385
 Turner, E. H., 435-436
 Tyrrell, D. A., 281-307

Vail, W. J., 259-267

Valder, L., 234, 387

van Deenen, L. L. M., 85-100

van der Neut-Kok, E. C. M., 85-100

van Dijck, P. W. M., 85-100

Verkley, A. J., 85-100

Vogl, S., 385, 394

Waite, M., 198, 233

Webb, W., 137-138

Weinstein, J. N., 120, 147, 197-198, 225,
273-274, 306, 423-425, 433

Weissmann, G., 120, 121, 136, 137, 224-
225, 235-249, 307, 323, 324, 368-369

White, A., 161

Wilson, T., 268-274, 279-280


Wisse, E., 433-434

Yatvin, M. B., 83-84

Zaret, B. L., 435

Zeigler, H. K., 434

Zilversmit, D. B., 149-163



Subject Index

Acanthamoeba *castellanii*, endocytosis in, 167, 238-239
Acholeplasma laidlawii:
 ¹³C nmr of, 11, 15
 cholesterol effects on, 24, 96
 deuterium of, 22-24
 gel-state viability of, 86
 liquid-gel transitions in, 24
 quadrupole splittings in, 24
Actinomycin D:
 in antibody-forming cell production, 334-335
 antitumor effectiveness of, 325
 DNA synthesis inhibition by, 332-333
 effects of, in female mice, 331-332
 immunosuppressive effects of, 337
 hematologic uptake, 327
 intestinal epithelial cells and, 332
 liposomal entrapped, 326, 350, 416-419
 cytotoxicity of, 252, 328-339
 lymphotoxic effects, 336-337
 target specificity role of, 308-309, 320-321
 toxicity of, free and entrapped, 328-336
 toxic side effects of, 325
 uptake and tissue distribution of, 326-329
Acyl chains:
 Ca ion effects on, 52, 58-59
 of egg PC, 30
 fatty, *see* Fatty acyl chains
 Mg ion effects on, 58
Adriamycin, 228-229, 233, 238, 413
Adsorption:
 cell microvilli in, 187-188
 cell surface proteins in, 192, 406; *see also* Exchange proteins
 fusion distinguished from, 171, 182; *see also* Fusion
 of gastrointestinal, nonabsorbable substances, 296, 298
 immunoglobulin in, 126-129, 237-238
 in liposome-cell membrane interactions, 166, 169; *see also* Liposome-cell interactions
 by mammalian cell surfaces, 187, 189
 metastability and, 197, 198
 phospholipid release in, 192
 proteolytic enzymes in, 189-190
 techniques in establishing, 189-199
 of vesicle components, 173, 176, 178
 of viruses, by liposomes, 276-277

Agglutination, 200, 201, 205, 212
Aging, phospholipid oxidation and, 83
Alcohol(s):
 partition coefficients of, 104-105
 synaptic membrane polarization effects, 106-108
Amphiphilic substances:
 characterization of, 3-4, 412
 liposomal entrapment of, 414-419
Amyloglucoside, 282-283
Amyloglucosidase, 346
Anesthetics, general, *see also* Local anesthetics
 cation permeation and, 101, 102
 gas solubility and, 101-102
 Gibbs free-energy hypothesis of, 102, 109
 liposome as working model for, 101, 109
 Meyer-Overton rule of, 102
 organic solvent permeation and, 101
 partition coefficient of (K), 103-104
Anhydrous solute molecule, 35-36
Antibodies:
 antinitroxide specific, 124-129
 complement depletion by, 124-127
 in complement fixation, 126
 diagnostic, liposomes in production of, 115
 in entrapped antigen response, 353
 entrapment and synthesis of, by act D, 337, 338
 immunoglobulin (Ig) and, 127-129, 317, 318
 liposomes and, 115, 140-141; *see also* Immune response; Liposomes
 in monocyte lysis, 129
 specificity of, in lymphocyte activation, 317-321
 viral resistance to, via encapsulation, 269
Anticancer chemotherapy, *see* Antitumor chemotherapy
Antigens:
 haptens and, *see* Haptens
 lateral distribution of, 124
 lipid, in liposomal immunity, 111
 lipid linked, as sensitizer, 139-140
 liposome-entrapped, 299-300, 353
 liposomes and, in antibody response, 338
 in lysis measurement, 142, 147
 tumor specificity of, 429

Antitumor chemotherapy:
actinomycin D in, 325-342
adriamycin in, 228-229, 413
daunomycin as, 338, 349, 412, 414
drug carrier liposomes in, 281-307,
328-338, 349-359, 387-389, 391
392, 402-403
drug types in, 412-416
encapsulation of drugs in, 325-339,
402-406, 412-419
human considerations in, 359-361, 366,
426-432
immunosuppressive variables in, 338
in vivo drug administration in, 426-429
in vivo inhibitory factors in, 387
liposomal enhancement in, 387-389,
392
requirements of, in general, 343
respiration systems therapy in, 418-
419
side effects in, 325
single massive versus sustained release
drug administration in, 429-430
S-phase specific drugs in, 420-423; *see*
also DNA synthesis inhibition
toxicity of drugs in, 325, 328-338,
402-403
vinblastine in, 337, 412, 414

Antiviral resistance, 311-314

Aqueous phase liposomes (APL), 326-
329

Apparent fusion index (AFI), 205

Arabinofuranosylcytosine (ara-C), *see*
Cytosine arabinoside (ara-C)

Arabinosylcytosine (ara-C), *see* Cytosine
arabinoside (ara-C)

Arabinosyl-5-fluorocytosine, 2,2'-anhydro
(AAFC), 381

Arabinosyl-5-fluorouracil, 1- β -D, 381

Artificial membrane systems, 2-8; *see*
also Bilayer lipid membranes;
Model membrane systems

Arzobenzenearsonic acid (ABA) com-
pounds, 114-115

Asparaginase, liposomal carriers and,
350-352

Aspergillus niger amylglicosidase, en-
trapment of, 345

Asymmetric membranes:
in biomembranes, 157-158
exchange protein approach to, 156-157
nmr spectroscopy of, 157
in microsomes, 162

Asymmetric vesicles:
in liposome-cell membrane interaction,
194-196, 199
preparation of, 194-195

Aureobasidium pullulans, membrane
properties of, 11-15

Bacteria:
membrane structure of, 215
phospholipid transfer in, 215-219

BCG (Bacillus Calmette-Guérin), 430-
431

Behenoyl-ara-C, potential chemothera-
peutic utility of, 391, 393

Bilayer lipid membranes, *see* Lipid bi-
layer membranes

Binding:
of bivalent metallic ions, 51, 57
of calcium ion, 55, 57, 63-65
in carrier liposomes, *see* Encapsulation
cell-surface proteins in, 192-194
of Fc stems and monocytes, 132-133,
137

ligand-induced capping and, 173, 174
in liposome-cell membrane interaction,
see Adsorption; Fusion; Liposome-
cell membrane interaction

of local anesthetics and lipids, 20

of magnesium ions, 50-57

of viruses and liposomes, 275-277

Biological membranes:
calcium ion activity in, 50-56, 175-
176, 395

fluidity in, *see* Biological membrane
fluidity

fusion in, 50-56

growth temperature and permeability
of, 87

immunologic approaches to, with lipo-
somes, 111-122

lipid bilayer resemblances of, 85

liquid-gel transition in, 27

local anesthetics and permeability of,
19

phase transitions in, and cell functions,
75-76

phase transition temperature in, 50,
53-56, 68, 85-87

phospholipid translocation mechanisms
in, 156-157, 163

polypeptide roles in, 67-75

Biological membrane fluidity:
adaptation of, by organisms, 82-83
bond saturation and, 84

cholesterol effects on, 79-80

factors changing, 76

hydrogenation of, 76-80

phase change temperature and, 86

polypeptide-lipid contiguity in, 83

Biological Transport, Symposium on Biophysics and Physiology of (1965), 5

Biomembranes, *see* Biological membranes

Birefringence, 2

Bivalent cations, *see also* Calcium ions; Magnesium ions
binding ratios of, 57
effects on phospholipids, 50-60

Blebs, 129-130, 205

Blood-brain barrier, 284

Bone marrow cells:
actinomycin D toxicity to, 329, 336
actinomycin D uptake by, 326-329
Technetium-liposome uptake by, 289

Bordetella pertussis, 353

Boundary layer effect, 72

Bound water, 38-40

Brain tissue, toxicity of phospholipids in, 284-285

C aeruloplasmin, 347

Calcium ions:
acid phospholipids and, 51-53
binding of, 55, 57, 63-65
in exocytosis, 61
fusion induction by, 50-56, 61, 65, 175-176, 178, 182, 395
isothermal phase transition and, 52-53
in large unilamellar PS vesicles, 260, 265
in lateral phase separation, 178, 217
in liposome-cell membrane interactions, 176, 178, 182, 216-219
in permeability, of lipid bilayers, 90-92
in phase separations, 51-52, 56, 90-92
in secretion, 61
structural changes in liposomes due to, 58-59, 89-90

Cancer chemotherapy, *see* Antitumor chemotherapy

Candida utilis, 11

Capping, of vesicle-derived ligands, 173, 174

Carbon-13:
in enriched acetate method, 11-16
fatty acid labeling with, 12-15
lipid labeling with, 11-15
mobility values of, 12-15
in nuclear magnetic resonance (nmr), 8-9, 11-16
relaxation time of, 10-11

Carbon-14, tissue uptake of, 396-402, 405

Carboxylfluorescein, 129, 130, 147

Carcinomas, carrier liposomes in treatment of, 281-307, 349-354; *see also* Antitumor therapy

Cardiolipin, 3, 150, 393

Catalytic hydrogenation, 76-80

Cations, liposome permeation by, in anesthesia, 101-102; *see also* Bivalent cations; Monovalent cations; and specific kinds by name

Cell(s), biological
agglutination of, 200, 201
antibody responses to, 114, 115
bacterial, *see* Bacteria; *Salmonella*
endocytosis by, *see* Endocytosis
erythrocytes as, *see* Erythrocytes
fusion within, *see* Cell fusion
fusion with liposomes, *see* Fusion
lipid vesicle uptake and incorporation by, *see* Liposome-cell membrane interaction
malignant, 79-80
proliferation regulation of, 431

Cell fusion, 200-214

Cell-mediated immunity, 114

Cell membranes, *see* Biological membranes

Cell phase specificity, of encapsulated drugs, 420-421, 423

Cell surface proteins, 192-194; *see also* Exchange proteins

Cephaein, *see* Phosphatidylethanolamine

Cerebrosides, 3

Chalones, 431

Chemical labeling agents, in liposome-cell membrane exchanges, 157-158

Channels, transmembrane, 68

Chemotherapy, *see* Antitumor chemotherapy

Cholesterol:
in asymmetric vesicle uptake, 195
in catalytic hydrogenation, 77-79
fatty acid chain effects of, 18-19
in DPPC phase transition, 72
erythrocyte membrane and, 97
gauche conformation effects of, 68-69, 94
in exchange reactions, 170
immunogenic effectiveness of, 392
in malignant cell control, 79-80
permeability effects of, 94-96
in phase-change enthalpy, 74, 94
phospholipid immune responses and, 118-119
phospholipid mobility and, 93-94
preferential affinities for, among phospholipids, 96-97, 100

Cholesterol—Continued
random arrays of, in lipid chains, 73–74
in *Salmonella* membranes, 221
tissue uptake and clearance of, 396–402, 405, 406
in virus-liposome fusion, 277
in volume-trapping efficiency, 253, 254

Circulatory system, carrier liposomes and, 416–417

Closed membrane theory, 2–3

Clostridium perfringens neuramindase, 345

Cochlear cylindrical structures, 52, 53, 90, 91, 260, 265, 26^g

Colony stimulating factor, 431

Complement:
cascade of, 128
depletion of, 124–129
—antioxidant antibody in, 124–127
—haptens lateral mobility in, 126
fixation of, 126–127
immunoglobulins and, 126
recognition component activation, 127
in target membrane activation, 128–129

Conformational changes, in membrane lipid molecules, 9–10

Corynebacterium parvum, 431

Cytolysis, extracellular, 134

Cytosine arabinoside (ara-C) (Arabinosylcytosine):
in carrier liposomes, 371–382, 387–389
—enhanced effects in SM/SA/Chol carrier, 389–391
cell phase specificity of, 389–390, 391
cytotoxicity of, 376–380
enzymatic degradation of, 376–377, 389
in DNA synthesis inhibition, 375, 412, 420–421
liposome entrapment and leakage, 414, 416–419
therapeutic effects, free versus encapsulated, 389–391
time-sustained release of, 385–386, 390–391
tissue uptake of, 375–378

Cytosine triphosphate arabinoside (ara-CTP);
in carrier liposomes, 371–382
cytotoxicity of, 378–381
DNA synthesis inhibition by, 375–376
encapsulation of, 373, 376, 278

Cytotoxicity:
in antitumoral chemotherapy, 325, 328–338, 402–403; *see also specific drugs by name*

carrier liposome characteristics and, 350–353, 360, 376–378, 382, 402–403
in CNS, of liposomes, 284–285
enhancement of, by encapsulation, 328–338, 353–354, 376–378, 380–381, 385, 426
ionic charges on liposomes and, 285, 376, 378, 381, 392

Daunomycin, 338, 349, 412, 414
Daunorubicin, 228–229
DNA complex with, 228–229
DEAE-dextran, 311, 314
Deoxyribonucleic acid (DNA), *see also DNA actinomycin D and, 332–333*
cytosine arabinoside (ara-C) and, 371–386, 412, 420–421
cytosine triphosphate (CTP) and, 371–386
as drug-molecule carrier, 228, 233–234, 328, 349
as lysosomotropic-agent carrier, 228–229
synthesis inhibition of, 332–333, 371–376, 379, 381, 421
Deuterium, in membrane properties analysis, 8–28

Diacytosis, 230

Diffusion coefficient, 34–35

Dimyristoyl phosphatidylcholine (DMPC), 88; *see also Phosphatidylcholine*

Dinitrophenyl phosphatidylethanolamine (DNP-PE), and derivatives, 112–119, 142; *see also Phosphatidylethanolamine*

Dioleoyl phosphatidylcholine (DOPC), in liposome immunity response, 118; *see also Phosphatidylcholine*

Dipalmitoyl lecithin, *see Dipalmitoyl phosphatidylcholine (DPPC)*

Dipalmitoyl phosphatidylcholine (DPPC):
C-13 mobility of lipids in, 12, 14
deuterium nmr studies of, 16
liposomes of, preparation, 252
as partition coefficient model, 103–106
in phase separation, mixed membranes, 56
phase transition enthalpy in, 70–72
potassium ion leak and, 88
volume trapping efficiency of, 253–255

Dipalmitoyl phosphatidylglycerol (DPPG):
in calcium-ion-induced fusion, 55
in mixed lipid-water transition, 72–73

Dipalmitoyl phospholipids, sonication and transition temperature in, 169

Distearoyl phosphatidylcholine (DSPC):
immunity response of, 118
in phase separation, mixed membrane, 56
x-ray differentiation spacing of, 57

Divalent cations, *see also* Calcium ions;
Magnesium ions
binding specificity of, 51
in lipid incorporation by cells, 216
lipid vesicle changes due to, 90-91
phase transition temperature shifts and, 90

DNA, *see* Deoxyribonucleic acid (DNA)

DNA-adriamycin complex, 228, 229, 234

DNA-gaunorubicin complex, 228, 229

Drug administration:
animal studies of, 429-430
of antitumor drugs, 412-416; *see also*
Antitumor chemotherapy
carrier liposome characteristics and
role in, 259, 344-345, 355-359,
376-378, 431-432
developments in, 344-346, 357-359,
365, 426-431
in vivo problems of, 239-245, 426-439
sustained versus intermittent release in,
371, 380-381, 385-386, 390-391,
429-430

EDTA, *see* Ethylenediaminetetraacetic acid

Egg lecithin, *see* Egg phosphatidylcholine

Egg phosphatidylcholine, 29-49, *see also*
Phosphalipid vesicles
acyl chain composition of, 30
beef sphingomyelin vesicles compared
with, 117-118
cholesterol effects on, 17-19
deuterium nmr of, 16-19
endocytosis of, 167, 168, 187
fluorescence depolarization in, 109
homogeneity computation for, 33-34
hydration computations for, 40-42
immunogenic responses with, 117-118
intrinsic viscosity calculation for, 35
isolation of, 29-30
lipid molecule packing geometry of,
29, 43-46
partial specific volume calculation for,
35-36
plasma membrane fusion with, 167-
168

preparation of, 29-30, 185
procaine binding with, 20
sedimentation coefficient of, 32
trapped volume calculations for, 37
volume trapping efficiency of, 253-254

Electron paramagnetic resonance (epr),
see Electron spin resonance (esr)

Electron spin resonance (esr):
applications of, 8, 10, 139
of fatty-acyl chain conformations, 10
of polypeptide-lipid systems transition,
69-73
in spin-membrane immunoassay
(SMIA) applications, 139-146

Encapsulation, liposomal:
of actinomycin D, *see* Actinomycin D
of antitumor drugs, *see* Antitumor
chemotherapy
of cytosine arabinoside (ara-C), *see*
Cytosine arabinoside (ara-C)
of cytosine triphosphate (CTP), 380,
385
in drug administration, *see* Drug ad-
ministration
drug effectiveness and, *see* Cytotoxicity
of enzymes, 236-237, 345-347
in enzymes, 236-237, 345-347
in enzyme replacement therapy, 282-
283, 347-349
in vivo effectiveness of, 265, 402-406
liposomal aspects of, *see* Liposomes
of macromolecules, 259-267
mechanisms of, 414-415
metabolic breakdown and, 397-401
of poliovirus, 268-269
of polyribonucleotides, 308-324
potentials for, by vesicle size and type,
259
release from, *see* Sustained release
sonicated release of, 415

Tissue uptake and, *see* Tissue uptake
viral infection capability and, 269-271
volume and, *see* Vesicle-trapped vol-
ume
of water, *see* Water, encapsulated

Endocytosis:
characterization of, 346, 395
in egg PC vesicles, 167-168, 187
fluidity of membrane and, 167
fusion as distinguished from, 427
immunoglobulins and, 237-240
inhibition of, 167-169
of liposomes by cells, 164-167, 173,
176-178, 230; *see also* Liposome-
cell membrane interaction

Endocytosis—Continued
of lysosomotropic carriers, 226–227, 230
of negatively charged vesicles, 238, 412
as sustained release mechanism, 386
temperature dependence in, 170

Enthalpy, in phase change, 70–71, 74

Entrapment:
of drugs by liposomes, *see* Encapsulation
of liposomes by cells, *see* Fusion; Liposome-cell membrane interaction
by organs and tissues, *see* Tissue uptake

Enzyme(s):
in adsorbed phospholipid release, 189–193
encapsulation of, 236–237, 345–347
as liposome markers, 141
replacement of, *see* Enzyme replacement therapy
in targeting liposomes, 235–249

Enzyme replacement therapy (ERT):
drug carrier liposomes in, 235–236, 346–349
in glycogen storage disease (Pompe's), 282–283, 298

Erythrocyte(s):
agglutination of, 201, 205, 212
ballooning of, 205–214
ghosts of, *see* Erythrocyte ghosts
substances effecting liposomal fusion with, 202–209

Erythrocyte ghosts:
as drug-carrier liposomes, 367
liposome fusion with, 202, 209

Erythropoietin, 431

Escherichia coli, 87

Esr, *see* Electron spin resonance

Ether-injection liposome production, 250–258

Ethylene diaminetetraacetic acid (EDTA):
in cell fusion enhancement, 212
in phospholipid preparation, 252, 260, 263
in virus-liposome fusion, 276

Exchange protein(s), phospholipid:
adsorption and fusion in, 160–161
beef brain, 150, 158
beef heart, 149–150, 158
beef liver, 149–150
in biological membrane transfer, 157
characterization of, 149–150
in erythrocytes, 163

ion leakage and, 162
kinetic studies of, 161
lipid membrane asymmetry of, 152–153

in liposome-cell membrane interaction, 192–195

microsomal membranes and, 153–156, 162

net exchange and, 149

nonspecificity of, 150–154

properties of, by sources, 150

radiolabeling of, 192
rat liver, 149, 150, 158

Exocytosis, 60–61, 230–231; *see also* Liposome-cell membrane interaction

Fatty acids:
carbon-13 labeling of, 12, 13, 15
cholesterol and, 18–19
oxidation of, and aging, 83
synthesis of, 11, 12, 15

Fatty acyl chains:
in amphiphilic drug entrapment, 415
carbon-13 mobility values in, 12–14
cholesterol effects on, 18–19
conformational changes in, 9–10
schematic of, 9
segmental changes in, 10

Fatty-acyl residues, catalytic hydrogenation of, 76–80

Fc receptors:
immunoglobulin (IgG)-coated liposome uptake by, 237–240
in monocyte-immunoglobulin (IgG) molecule binding, 132–133, 137

Ferritin, 263

Fluorescence:
in fluorescein loaded vesicles, 130–131, 168
in liposome-cell membrane interactions, 167, 202, 204
in liposome-t-cell adsorption, 189

Fluorescence depolarization, 108–109

Fluorodeoxyuridine (FUDR), 413, 419, 421

Fluorogenic substrates, as liposome markers, 141

F protein, in viral-liposome fusion, 278

Freeze-fracture, of liposomes, 253, 260–263

Frictional coefficient, for phospholipid bilayers, 39

Fusion:
among cells, *see* Cell fusion

Fusion—Continued
among lipid bilayers, *see* Lipid bilayer fusion
between liposomes and cell membranes
see Liposome-cell membrane interaction

Fusogenic agent(s):
cell-shape effects of, 204
characterization of, 200–201
EDTA as, 212, 276
gramicidin A as, *see* Gramicidin A
in liposome-cell membrane interaction, 200–209
in vesicle-cell lipid uptake, 239

Gangliosides:
in enzyme replacement therapy, 235, 284
in liposome uptake, 406
as viral receptors, in liposomes, 275–277

Gauche conformations, 18–19, 68–69

Gaucher's disease, carrier liposome treatment in, 347, 348, 356, 365

Gel-liquid crystalline transition, *see* Phase transitions

Gibbs free-energy hypothesis, of anesthesia, 102

Glucose:
degradation to acetate, 11, 12
as liposome marker, 141

Glucocerebrosides, carrier liposome administration of, 347, 366, 367, 432

Glycogenosis, type II (Pompe's disease), carrier liposomes in treatment of, 282–283, 298

Glycolysis, 168

Glycophorin, 72, 420

Glycoproteins, as viral receptors, 275, 276

Golgi system, 231

Gramicidin (G):
cell fusion effects of, 204–205, 209, 212
in lipid molecule transitions, 68–69, 72
in transmembrane channel formation, 68

Halobacterium cutirubrum, 15

Haptens:
antigens and, 113, *see also* Antigens
in complement depletion, 128, 129, 135
in complement fixation, 126, 127
in immune responses, 124, 126
immunoglobulins and, 126–127, 129
lateral mobility of, 124–128, 135, 137

Hapten II, 129

Hemagglutination, 276

Heterogeneity parameter, 33, 34

Hexosaminidase A, 284

HN proteins, 279

Human clinical administration, of carrier liposomes, 359–361, 365, 426–431

Hydrodynamic analysis, of phospholipid bilayers, *see* Egg phosphatidylcholine; Lipid bilayer vesicles

Hydrogenation, catalytic, 76–80

Hypersensitivity reactions, 353

IgM, *see* Macroglobulin

Immune response, liposomal:
bilayer fluidity and, 119
cell-membrane mediated, 114
characteristics of, 140–141, 381
cholesterol in, 118–119, 392
enhancement of, 115–116, 353
fatty-acid composition and, 113–116, 121

haptens and, *see* Haptens
in vivo versus *in vitro* approaches in, 121–122
lateral distribution of antigens/haptens in, 124–128, 135, 137

phase separation in, 121

phase transition temperature and, 117–118

phospholipids in, 112–119, 353, 392–394, 427

research consideration in, 111, 116, 120–121, 429

spin-membrane immunoassay (SMIA) in, 139–148

Immune RNA (IRNA):
liposomes containing, preparation of, 308–309
in lymphocyte activation, 318

Immunoassay techniques, 139–146

Immunoglobulin (IgG):
in complement fixation, 126–129
in endocytosis stimulation, 237–238
in liposome uptake facilitation, 237–240, 317–318, 357
in lymphocyte activation, 317–318
in monocyte-mediated erythrocyte lysis, 132–134
as targeting antibodies, 317, 318

Interconversion rate, of liquid-gel transition, 27

Influenza virus, 276

Intensity ratios, 68–69

Insulin therapy:
liposomes as carriers in, 292–298, 354
by oral administration, 292–298

Interferon, 309, 312-317
Intrinsic viscosity, 35, 40-41
Ionic charges, *see* Surface charges
Isotopic labeling:
 of actinomycin D, 326-328
 in IgG-coated liposome uptake, 240-244
 of cytosine arabinoside, 375
 in liposome-cell membrane interactions, 164-165, 182-183, 202
 in lymphocyte activation, 318
 in lysosomotropic uptake, 230
 of methotrexate, free and encapsulated, 396-400
 multiple detection of, 141-144
 in phospholipid molecule exchange, 150
 in specific tissue uptake studies, 299
 spin labels as, 139-144
 in tissue distribution studies, 326-328
 of thyroid-stimulating hormone (TSH), 299
 of tumor-therapy carrier liposomes, 286
 in tumor-tissue localization, 298, 352

Kupffer cells, liposome uptake by, 230, 232, 240, 345

Large unilamellar vesicles (LUVs):
 cochleated cylinders in, 260
 encapsulated volume and efficiency of, 264
 poliovirus encapsulation by, 268-274
 preparation of, 259-260, 374
 properties of, 260-265
 terminology for, 367, 368
 tissue uptake of, 375
 toxicity with, 376

Lateral mobility:
 complement and, 126-128, 135, 137
 constants for, of spin-labeled phospholipids 126

Lateral phase separation, 178, 212

Leakage:
 from carrier liposomes, 176, 228-229, 349, 402-406, 414
 cholesterol and, 402-404
 of cytotoxic drugs, 349
 of lysosomotropic drugs, 228, 229
 secondary carrier role in, 349
 tissue distribution problem and, 350
 as tumor-therapy strategem, 290
 of vesicle into cytoplasm, 176

Lecithin, *see* Phosphatidylcholine (PC)
egg, *see* Egg phosphatidylcholine

Leukocytes:
 actinomycin D effects on, 328-329, 331
 liposome uptake by, 240-244, 284

Lipid(s), *see also* Lipid bilayer(s); Liposomes; Phospholipids

 crystallization of, and protein aggregation, 75

 fluidity of, 67; *see also* Membrane fluidity

 incorporation into intact cells, 215-217
 in liposome immunity enhancement, 116, 123

 liquid-gel molecular transitions of, *see* Phase transition(s)

 membranes, *see* Lipid bilayer(s)

 molecular conformations of, 9-19

 polypeptides and, *see* Polypeptide-lipid systems

Lipid bilayer fusion, *see also* Cell fusion; Liposome-cell membrane interaction

 calcium ion induction of, 50-56, 61, 65, 175-178, 182, 260-267

 domain size and, 64-65

 ionic surface charges and, 61

 magnesium ion induction of, 50, 53-56, 61

 of mixed phospholipids

Lipid bilayer ratio (X), 40-44

Lipid bilayer packing geometry, *see* Packing geometry, lipid molecule

Lipid bilayer vesicles, *see also* Liposomes

 asymmetry of, 29, 44-46

 barrier functions of, 85-93

 biological membranes and, 2-4, 85; *see also* Model membrane systems

 bound water of, 38-39

 characteristics of, 9-16

 cholesterol effects on, 73-74, 77-79, 94-96

 of egg PC, *see* Egg phosphatidylcholine

 electrostatic charges on, *see* Surface ionic charges

 encapsulated volume of, 264

 geometric packing of, *see* Packing geometry, lipid molecule

 gramicidin A spanning of, 68

 head-group area calculations, 46-47

 heterogeneity parameter (p) of, 33-34

 hydration of, calculations, 38-40

 hydrodynamic analysis of, 29-49

 intrinsic viscosity analysis, 35, 40

 ionotropic phase transitions in, 50

 large, *see* Large unilamellar vesicles (LUV)

Lipid bilayer vesicles—Continued
liquid-gel transitions in, *see* Phase transition(s)
local anesthetics and, *see* Local anesthetics
model membrane characteristics of, *see* Model membrane systems
molecular number, calculations, 38, 41
molecular volume in, 44–46
multilamellar, *see* Multilamellar vesicles (MLV)
nitroxide spin-label sensitized, 124
outer to inner layer ratio, 40
permeability in, *see* Permeability, lipid bilayer
phase separation, in mixed, 56–57
—lateral, 178, 212
phase transitions in, *see* Phase transition(s); Phase transition temperature
preparation of, *see* Liposome preparation
sedimentation coefficient, 32
shape of, calculation, 38
small, *see* Small unilamellar vesicles
surface charges on, *see* Surface charges
thermotropic phase transitions of, 50; *see also* Phase transitions
thickness of, 44–47
transport process in, 32
trapped water in, 36–37
water in, 36–41

Lipid bilayer fusion, *see also* Liposome-cell membrane interaction
calcium ion induction of, 50–56, 61, 65, 175–176, 178, 182, 260–267
domain size and, 64–65
magnesium ion induction of, 50, 53–56, 61
of mixed phospholipids, 56–57, 60, 160–161
surface charge asymmetry and, 61

Lipid bilayer ratio (X), 40–44

Lipid molecule packing geometry:
asymmetries of monolayers in, 43–47
of egg phosphatidylcholine vesicles, 29, 43–46
of lipid bilayer vesicles, 43–46
in polypeptide-lipid systems, 73

Lipid molecules, *see* Phospholipids

Lipid-water dispersion systems:
phase transition enthalpy in, 70–73
polypeptide concentrations and, 72–73

Liposome(s), *see also* Lipid bilayer vesicles; Phospholipids
actinomycin D encapsulation in, 325–339
aerosolized, 418
anesthetics and, 101, 109; *see also* Local anesthetics
animal experiment model of, 426–431
antibodies and, 115, 140–141
antigens and, *see* Antigens
in antitumor chemotherapy, *see* Antitumor chemotherapy
aqueous phase (APL), 326–339
as biodegradable, in lysosomes, 231, 233
blood-brain barrier problem, 284
calcium ion effects on, *see* Calcium ions
catabolic degradation of, 314–317
cell membrane interactions with, *see* Liposome-cell membrane interactions
characterization and properties of, 1, 5, 140, 343–346, 367–369, 387
cholesterol effects on, *see* Cholesterol in circulatory system administration, 416–417
cytotoxic effects of, *see* Cytotoxicity
development in concepts and uses of, 2–7, 29, 50, 85, 111, 281, 343–349, 426–431
in diagnostic antibody production, 115
DNA role in, *see* Deoxyribonucleic acid (DNA)
in drug administration, 259, 281, 344–346, 355–357, 376–378, 404–405, 431–432; *see also* specific drugs by name
efficiency and size of, 357
empty, 402
encapsulation of drug agents by, 259, 325–329, 402–406, 412–419; *see also* Antitumor chemotherapy; Encapsulation, and specific substances by name
endocytosis of, *see* Endocytosis
entrapment of, by tissues and organs, *see* Tissue uptake
as enzyme carriers, 235–245
in enzyme replacement therapy, 235–236, 346–349
erythrocytes as, 367
functional-environmental potentials, 355–357
fusion of aggregates of, *see* Lipid bilayer fusion
fusion with cells, *see* Liposome-cell membrane fusion

Liposome(s)—Continued
as host cells, in viral interactions, 278–280
human clinical applications of, 350–361, 365, 426–431; *see also* Antitumor chemotherapy
immune response of, *see* Immune response
immunoglobulins and, 237–245, 317–318, 357
immunologic potentials of, 111–119, 123, 353–354, 432
insulin therapy via, 292–298, 354
in interferon synthesis, 313–314
in vivo administration of, 239–245, 406–412, 426–429
ionic charges on, *see* Surface charges
large, *see* Large unilamellar vesicles (LUV)
leakages from, *see* Leakages
lipid phase (LPL), 326–339
in lymph node localization, 290–292
lymphocyte activation via, 317–319
lysosomal uptake and degradation of, 230–231, 233
in lysosome storage disease, 346–349
as lysosomotropic carriers, 226–230
as macromolecule carriers, *in vivo*, 265
methotrexate (MTX) containing, 395–410; *see also* Methotrexate
in model membrane systems, *see* Model membrane systems
monocytes and, 129–133
multilamellar, *see* Multilamellar vesicles (MLV)
nomenclature for, 367–369
phase separations in, *see* Lipid bilayer vesicles
phospholipid molecule exchange in, 150–156, 160–163
phospholipids in, *see* Phospholipids, and specific types by name
in polioviral transmission, 269–275
polyribonucleotides encapsulated in, 308–324; *see also* Polyribonucleotides
preparation of, *see* Liposome preparation
proteolysis inhibition by, 292–299
purity criteria problem, 370
release of encapsulated materials from, 176–177, 419–424
in respiratory distress therapy, 418–425
second carrier developments in, 349
size and sizing of, 253–255, 257–259, 286, 352, 368, 397, 399, 400, 412
sonication of, *see* Sonication
surface charges on, *see* Surface charges
sustained release of drugs from, *see* Sustained time release
targeting of, *see* Targeting
terminology for, 367–368
therapeutic applications for, 281–282, 298–302, 306–307, 343–370, 426–431; *see also* Antitumor therapy
tissue-specific localization with, 284, 299–300, 306–307, 349–350, 353; *see also* Tissue uptake
toxicity of, *see* Cytotoxicity
tumor-cell uptake monitoring of, 286–290
type specificity of, 250
uptake of, by organs and tissues, *see* Tissue uptake
vesicle characteristics and entrapped drug availability, 431–432
viral receptors in, 275–277
volume trapping by, 36–38, 253–254, 257
viruses and, *see* Viruses
Liposome-cell membrane interactions, 218
adhesion in, 187–194
adsorption in, 166, 169, 171, 175, 182, 276
agglutination in, 201
apparent fusion index (AFI) of, 205
asymmetrical vesicles in, 194–196
binding in, 166n, 173, 275–277
calcium ion induction of, 61, 65, 175–182, 216–219
capping in, 173–174
cell-line genetic factors in, 248
cell plasma role in, 165–166, 171–172, 178–179, 395
cell proliferation and, 198
cell type differences and, 182–183
chemical factors effecting, 195, 200–204, 216–217, 238–239
cholesterol in, 195, 277, 405
egg phosphatidylcholine and, 167–168
electronmicroscopic evidence of, 171, 172
endocytosis and, 164–170, 176–178, 230
erythrocytes and, 201–214
exchange proteins in, 192–195
exocytosis and, 61, 230–231
freeze-fracture evidence of, 172
glycoproteins in, 420
hydrophobic protein transfer in, 174
interferon induction by poly(I):poly(C) in, 312–313
in vivo mechanisms of, 405–406
lipid degradation and, 198

Liposome-cell membrane interactions—
 Continued
 lipid-membrane component exchanges in, 166, 170, 238
 lysophosphatidylcholine in, 175–176, 201, 238–239, 248
 mammalian cells in, 185–199
 methods of study of, 164–165, 200
 mechanisms indicated for, 165–166, 200–201, 218, 395, 405–406
 metabolic inhibitor effects in, 186–187
 net transfer in, 149, 195, 218
 phase transition temperature and, 168–170, 187–192
 polyribonucleotide (poly[I]:poly[C]) in, 313
 reciprocal component transfer in, 166n, 170
 release of encapsulated materials in, 165, 173, 176–177, 216–217
 in *Salmonella*, 215–225
 surface ionic charges in, 167–168, 175, 238–239, 249, 312
 targeting as, *see* Targeting
 temperature and uptake in, 238–239
 tissue uptake as, *see* Tissue uptake
 transfer as, 218
 vesicle properties and, 178
 by viral infection, 275–278

Liposome preparation:
 actinomycin D containing, 326
 asymmetric vesicles, 194–195
 cytosine arabinoside (ara-C) entrapped, 373–374, 388
 cytosine triphosphate arabinoside (ara-CTP) entrapped, 373–374
 egg phosphatidylcholine, 29–30, 185
 by ether injection, 250–258
 ionic strength and, 258
 multilamellar, 373
 methotrexate (MTX) containing, 397–399
 negatively charged, 373–374
 multilamellar-IRNA, 308
 positively charged, 373–374
 spherical, 265
 SUV-*Salmonella*, 215
 ultrasonically irradiated, 30
 unilamellar, 250–256
 viral infected, 276

Lipopolysaccharides, 111
 translocation of, in *Salmonella*, 221–222, 225
 in vesicle transfer activity, 217

Liquid crystalline-gel transitions, *see* Phase transitions

Local anesthetics:
 capping inhibition by, 174
 concentration and lipid interactions in, 27–28
 egg PC interactions with, 20, 21
 membrane permeability and, 19
 phospholipid membrane binding to, 20–22

Lymph node localization, 290–292

Lymphocytes:
 actinomycin D effects on, 336–337
 antibody-phospholipid formations and, 116
 LUV-cell absorption in, 187, 189
 liposome content interaction sites for, 423
 tumor-cell toxicity activation and, 317–320

Lysolecithin, *see* Lysophosphatidylcholine (LPC)

Lysophosphatidylcholine (LPC), in liposome-induced cell fusion, 175–176, 201, 238–239, 248

Lysosomal storage disorder, 346–349

Lysosomes:
 carrier liposome uptake and, 345–346
 endocytic vacuoles and, 177
 enzymatic genetic disorders and, 235
 in lipid vesicle uptake, 165, 176–177
 in lysosomotropic carriers, 226–227, 234

Lysosomotropic carriers:
 active agents carried by, 226–229
 characteristics of, 226–227
 endocytosis of, 226, 227, 230
 extracellular release of, 228, 234
 ionic charges in, 232–233
 liposomes as, 226–234
 target accessibility in, 229–230

Lysozymes, 236, 240, 244

Macroglobulin (IgM), in complement activation, 128–129, 428

Macromolecules, encapsulation of, 259–267

Macrophages:
 in actinomycin D-liposome uptake, 338
 liposome uptake by, 240

Magnesium ion(s):
 in binding with PS, 57–59
 in membrane fusion, 50–51
 in phase transition temperature changes, 50–53, 90
 in phospholipid vesicle fusion, 53–56
 in vesicle lipid incorporation by cells, 216

Markers, isotopic, *see* Isotopic labeling
 Mammalian cells, phospholipid interactions with, 185-199
 Melphalen, 349
 Membrane(s):
 asymmetry of, *see* Asymmetric membranes
 biological, *see* Biological membranes
 fluidity of, 167, 175, 238
 fusion of, *see* Cell fusion; Lipid bilayer fusion; Liposome-cell membrane interaction
 immunoassay of, 139-148
 microsomal, 153-156
 mitochondrial, 175
 surface charges on, *see* Surface ionic charges
 Metabolic inhibition, 186-187, 427
 Methotrexate (MTX):
 in carrier liposomes, 349
 clearance, of free and entrapped, 396-401
 metabolism of,
 -compared with cytosine arabinoside, 406
 -species variance in, 409
 plasma level maintenance of, 404-405
 surface ionic charges and entrapment of, 396
 therapeutic effectiveness of, 401-410
 toxicity of, 402-403
 tumor cell response to, 402-404, 427
Micrococcus freudenreichii, 15-16
 Micropinocytosis, 169
 Microsomal phospholipids, 153-156
 Mithramycin, 238
 Mitochondrial membranes, 75
 MLV, *see* Multilamellar vesicles
 Mobility, molecular, 11-14, 28
 Model membrane systems:
 biological membrane convergencies with, 5, 9-16, 67, 85, 185
 historical development in, 2-5
 in immunology, 111-112, 124-138
 lipid bilayers as, 29, 60, 85, 124
 liposomes as, 3, 200, 281
 of lipid phase transitions, 8, 50
 local anesthetics in, 19
 therapeutic dimensions for, 343-346
 Molecular number, 38, 41
 Molecular phase transitions, *see* Phase transition(s)
 Molecular segmental order:
 cholesterol and, 17-19
 in egg phosphatidylcholine, 16-17
 local anesthetics and, 19
 mobility and, 12, 28
 water exclusion by, 28
 Monocytes, 129-133
 Monolayers, 43-47
 Monovalent cations, 88
 M protein, 279, 280
 Multilamellar vesicles (MLV):
 drug delivery by, 259, 377
 encapsulated volume and efficiency of, 264
 fusion with plasma membrane, 165, 171, 237
 polyribonucleotide entrapment in, 308-310
 preparation of, 373
 tissue uptake of, 310, 375, 412-413
Mycobacterium bovis (BCG), 430-431
Mycobacterium tuberculosis, 353

Negative charges, *see* Surface ionic charges
 Negative stain, in sizing liposomes, 253-255
 Net transfer, in liposome-cell membrane interactions, 149, 195, 218
 Neuramindase, 345-347
 Nomenclature, for liposomes, 367-369
 Nuclear magnetic resonance (nmr), 8-24, 40-43, 157
 Nucleic acid, liposome encapsulation of, 308-324; *see also* Polyribonucleotide
 Neutrophilic granulocytosis, 337

Olefins, 76-77
 Oleic acid, 11
 Order parameter, *see* Molecular segmental order
 Osmotic shrinkage, 94
 Osmotic stress, 214
 Oxidation, and aging, 83

Packing geometry, lipid molecule:
 asymmetry of, 46; *see also* Asymmetric membranes
 of bilayer vesicles, 29, 43-47
 of biological membranes, 157-158
 characterization of, 29, 46
 of egg phosphatidylcholine vesicles, 29, 43-46
 in polypeptide-lipid systems, 73
 of proteins, 73-74
 quantitative analysis of, 43-45
 random arrays, 73-74

Palmitic acid, 22-23
Paramagnetic resonance spectra (pmr), 124
Paramyxovirus, 275-277
Parenchymal cells, carrier liposome uptake by, 345, 434
Partial specific volume, 35-36, 44
Partition coefficients (K), calculation of, 103-105
PC, *see* Phosphatidylcholine
PE, *see* Phosphatidylethanolamine
Permeability, lipid bilayer:
 alkane chain length and, 88
 ion size and, 88
 monovalent cations and, 87, 88, 90
 temperature and, 86-88, 92
 of water-contained, 86-87, 94, 100
Phagocytosis:
 conditions affecting, 238-239
 enzyme uptake in, 237-238
 of erythrocytes, 130
Phagolysosomes, 230
Phagosomes, 230-231
pH:
 in cell fusion, 209-212
 in local anesthetic-lipid interactions, 20, 21
Phase transitions, liquid-gel:
 in *Acholeplasma laidlawii*, 24
 bilayer barrier functions and, 85-89, 93
 in biological membranes, 50, 75-76
 bivalent cation effects on, 50-59
 cholesterol and, 77-78, 94
 enthalpy of, 70-72, 74
 ionic charges in, 51-53
 membrane fusion and, 60-61
 in mitochondrial membranes, 75
 permeability and, 86-88, 92
 in polypeptide-lipid systems, 69-72
 temperature in, *see* Phase transition temperature
Phase transition temperature (T_c):
 in biological membranes, 50-51, 85-86
 bivalent metalic ions and, 51-53, 56, 90
 bond saturation and, 84
 carrier liposomes and, 354, 381
 cell growth temperature and, 87
 in channel formation, 68
 lipid bilayer properties and, 86-87
 in liposome-cell membrane interaction, 168-170, 189-192
 in liposome immunity response, 118
 in membrane fusion, 60-61
 monovalent cation permeability and, 88
 negative ion charge neutralization and, 51
 in partition coefficient calculations, 103, 104
 protein aggregation and, 75
 water permeability and, 86, 100
Phosphatidylcholine (PC), *see also* Phospholipids
 asymmetric vesicles, preparation of, 194-195
 egg PC, *see* Egg phosphatidylcholine
 in cell fusion, 201
 in cholesterol affinity series, 96-97, 100
 local anesthesia interactions with, 20, 21
 phase transition temperature and fusion in, 53, 168-169
 in phospholipid exchange protein studies, 149-158
 vesicle transfer inactivity of, 217
 in viral-liposome fusion, 277
Phosphatidylethanolamine (PE):
 in cholesterol affinity series, 97
 dinitrophenyl (DNP) derivatives in immune reactions, 111-119
 N-substituted derivatives, of, in immune reactions, 114-119
 in phospholipid exchange protein studies, 149-158
 in virus-liposome fusion, 277
Phosphatidylinositol (PI), 149-158
Phosphatidylserine (PS):
 binding of, with Ca^+ and Mg^+ ions, 57, 63-64
 calcium ion effects on, 52-54, 58, 59
 exchange protein transfer in, 150
 isothermal phase transitions in, 53-55
 local anesthesia interactions with, 20, 21
 magnesium ion effects on, 57-64
 membrane thickness changes in, 59
 phase transitions in, 53-55, 59
Phosphatidylstearylamine liposomes, 201, 209-212
Phospholipases, in biomembrane transfer and asymmetry, 157-158
Phospholipid(s), *see also* Lipids; Lipid bilayer vesicles; Liposomes
 in antibody response enhancement, 338
 in blood-clotting, 4
 cell membrane transfer of, 218-223
 cell release of adsorbed, 189-194
 cholesterol and, *see* Cholesterol
 as drug carriers, 345, 354-361
 egg PC as, *see* Egg phosphatidylcholine
 exchange of, vesicle to cell, 149, 150, 170; *see also* Phospholipid exchange protein

Phospholipid(s)—Continued
immunogenic effectiveness of, 117–118, 392–394
local anesthesia and, 19–22, 101–104
microsomal, 153–153, 156
as model systems, *see* Model membrane systems
in partition coefficient measurement, 103–104
in respiratory distress therapy, 418
therapeutic applications of, *see* Antitumor chemotherapy
toxicity of, *see* Cytotoxicity
in viral membrane-liposome fusion, 277

Phospholipid exchange proteins, *see* Exchange proteins, phospholipid

Picornaviruses, 268–274

Plaque-forming cells (PFC), 116

Plasmalogens, 3, 83

Polar drugs, encapsulation of, 412–415

Polioviruses, 269–274

Poly(I):poly(C), *see* Polyribonucleotides

Polyamino acids, 406

Polypeptides, *see also* Proteins
coordination number of, 73
lipids and, *see* Polypeptide-lipid systems
liposome-encapsulation of, 264–265
in mixed, lipid-water systems, 72–73

Polypeptide-lipid systems, 68–75
biological membrane implications of, 73–75
component arrangements in, 70
phase transitions in, 69–72
random arrays in, 73

Polyribonucleotides (poly[I]:poly[C]):
in antiviral resistance, 331–312
carrier liposome entrapment by, 308–311
cytotoxicity of, 313
in interferon synthesis, 312–314
in lymphocyte activation, 317–318
protection of, from catabolic degradation, 314–317

Polyvinylpyrrolidone, 354

Pompe's disease, *see* Glycogen storage disease

Positively charged liposomes, *see* Surface ionic charges

Potassium ions:
cholesterol effects on, 94–96
permeation by, 88, 90, 94–96, 101, 102
valinomycin and, 3, 94–96

Procaine, 19–21; *see also* Local anesthesia

Proteins, *see also* Polypeptides
in adsorption and targeting, 406

aggregation of, 75
in biological membranes, 67–68, 75
boundary layer effects with, 72
cardiolipin and, 150
exchange, *see* Exchange proteins, phospholipid
lipid bilayer spanning by, 67–68
in lipid bilayer systems, *see* Polypeptide-lipid systems
in paramyxovirus membrane, 275
random arrays of, 73–74
in viral-liposome fusion, 278–279, 280

Q uadrupole splittings, in phospholipid membranes, 20–28

Radioactive labeling, *see* Isotopic labeling
Random arrays, 73–74; *see also* Packing geometry
Reciprocal component transfer, 166n, 170
Red cell ghosts, *see* Erythrocyte ghosts
Relaxation time, 10–11
Respiration, endocytosis and, 168
Respiratory distress syndrome (RDS), 418
Respiratory system, liposomal therapy for, 418–425
Reticuloendothelial system:
actinomycin D uptake by, 326–331
–toxicity effect of, 335–339
carrier liposome uptake by, 284, 288–289, 291, 315–317, 345, 349, 357, 428
drug administration via, 430
MTX uptake by, 399–400, 405

Ribonucleic acid (RNA):
immune, 308, 318
messenger, 433
polioviral, 270–273
viral, encapsulation of, 368
–in liposome fusion, 277–278

Salmonella, 215, 225
lipid vesicle incorporation by, 215, 216–219
membrane composition differences in, 224
translocation of lipids, intracellular, 219

Second carrier, liposomal, 349

Sedimentation coefficient, 32, 36

Segmental order, *see* Molecular segmental order

Sendai virus, 276-278
Sensitizer, 139-140
Shrinkage velocity, 86
Simha coefficient, 40
Sindbis virus, 276
Small unilamellar vesicles (SUV):
 cell fusion induction by, 175
 drug carrier potentials of, 259
 in cytosine arabinoside (ara-C) delivery, 374
 in cytosine triphosphate arabinoside (ara-CTP) delivery, 376, 377
 encapsulated volume of, 264
 stability of, 257-258, 370
 sonicated, 368
 surface ionic charges on, 175, 414;
 see also Surface ionic charges
 tissue uptake of, 375, 381, 412, 413
Sonication:
 carrier liposome uptake and, 397-404,
 410
 in cell fusion, 209, 250, 410
 in clearance of MTX, 397, 399, 400
 release from encapsulation by, 415
 standardization for, 370
 therapeutic efficiency and, 399-402
Spectrin-actin complex, 90, 99, 100
Sphingomyelin:
 antienzymatic stability of, 391
 beef, 117-118
 in cholesterol affinity series, 97
 exchangeability of, 154
Spin-membrane immunoassay (SMIA),
 139-148
Spin labels, *see* Isotopic labeling
Spin-lattice relaxation time, 10
Spin-spin relaxation time, 10
Spleen, *see* Reticuloendothelial system
Statolon, 314
Stearic acid, 20, 21
Stearylamine (SA):
 in agglutination, 201
 in cell fusion, 201, 212
Streptomyces hydrogenans, 87
Surface ionic charges:
 in antigen enhancement, 353, 366
 asymmetry of, in membrane fusion, 61
 in cell-to-cell fusion, 175
 clearance rate and, 412
 in cytosine triphosphate-arabinoside (ara-CTP) entrapment, 374, 375
 cytotoxicity and, 285, 376, 378, 381, 392
 in DNA synthesis inhibition, 375-377
 in drug encapsulation, 265, 310-311,
 315-317, 392, 396, 413-414
 in drug uptake, 349-350, 406, 412
 in endocytosis, 238, 412
 in enzyme-bearing liposomes, 237, 285
 in ganglioside receptors, 276
 in leukopenia, 243-244
 in liposome-cell membrane interaction,
 60, 167-168, 175, 238-239, 249,
 312
 in lymph node localization, 290-291
 in lymphocyte activation, 320
 methotrexate entrapment and, 396
 in polyribonucleic acid entrapment,
 310-311, 315-317
 in spleen-enhanced liposome uptake,
 291
 in subcellular localization, 232-233
 in SUV sustained release, 414
 in toxicity, *see* Cytotoxicity
 in viral resistance by cells, 331
Surfactant replacement, by liposomes,
 418-419
Sustained time release:
 of cytosine arabinoside (ara-C), 371,
 385-386, 390-391
 encapsulation and, 386
 endocytosis and, 386
 intermittent versus, 380-383, 390-391,
 409, 429-430
 liposome carriers for, 371, 380-381,
 385-386, 390-391, 429-430
 massive dosage versus, 429-430
 of methotrexate, 409
 by positive SUVs, 414
SUV, *see* Small unilamellar vesicles
Symposium on Biophysics and Physiology of Biological Transport (1965), 5

Targeting:
 actinomycin D in, 320-321
 cell proliferation and, 431
 characterization of, 419-420
 of drug carrier liposomes, 284, 317-
 321, 349-350, 354-355, 406, 420;
 see also Tissue uptake
 of enzymes, 235-245
 in vivo problems of, 284, 406-407,
 426, 429
 in liposome-cell membrane interaction,
 420
 protein adsorption in, 406
Tay Sachs disease, 235-245, 284
T-cell, *see* Lymphocytes
Temperature:
 in lipid vesicle phase transition, *see*
 Phase transition temperature

Temperature—Continued
in paramyxovirus-liposome fusion, 280
in vesicle-cell lipid uptake, 238–239

Tetracaine (TTC), 19–21

Therapy, *see* Antitumor therapy; Respiratory system

Thermotropic phase transition, 50, 53;
see also Phase transition temperature

Thyroid stimulating hormone (TSH), 299

Tilorone, 314

Time-spaced release, *see* Sustained time release

Tissue uptake:
of actinomycin D, 326–329
of cholesterol, 396–402, 405, 406
criteria for distribution in, 350
of cytosine arabinoside, 375–378
of drug carrier liposomes, 284, 317–321, 349–350, 354–357, 399–406, 416–417; *see also* specific drugs by name
of large unilamellar vesicles, 375
by liposome size, 375, 412, 413
by liver, 284, 288–289, 299, 315–317
metabolic inhibitor effects on, 186
of methotrexate, 399–407
of multilamellar vesicles, 410
by organ systems, 412–413
of small unilamellar vesicles, 375, 412–413
by specific tissues, 299–300, 306–307, 317–321, 353–357, 419–420
by spleen, 284, 288–289, 299, 315–317
surface ionic charge and, 349–350, 412
targeting of, 406; *see also* Targeting tumors and, *see* Tumors

Transfer:
definition of, 218; *see also* Liposome-cell membrane interaction
exchange as, 149, 160–161; *see also* Exchange protein, phospholipid
of membrane proteins, 225
net, 149, 195, 218
of phospholipids, between cell membranes, 219–223
of saccharides, 221, 222

Translocation, *see* Transfer

Transport process, hydrodynamic, 32

Trapped volume, *see* Volume trapping

Tritium, *see* Isotopic labeling

Trypsin, in phospholipid release, 189–193

Tubocurarine, 354

Tumors:
antigen specificity for, 429

chemotherapy for, *see* Antitumor chemotherapy
drug carrier liposome uptake by, 352, 266
localization of, 286–290
lymphocyte activation against, 317–320
methotrexate and, 402–404, 427
radioactivity uptake by, 285–390, 352

Ultracentrifugation, 32–36

Ultrasonic irradiation, 30

Unilamellar lipid vesicles, *see* Large unilamellar vesicles; Lipids; Small unilamellar vesicles

Valinomycin, K⁺ ion leakage and, 94–96

Vesicles, lipid, *see* Lipids; Lipid bilayer vesicles; Liposomes

Vesicle hydration water, 38

Vesicle molecular number, 38, 41

Vesicle-trapped volume, 36–40; *see also* Volume trapping efficiency

Vinblastine, 337, 412, 414

Viral receptors, 275–277

Viral RNA:
encapsulation of, 270–271, 368
in liposome fusion, 277–278

Virosomes, 300, 353

Virus(es), *see also* Paramyxovirus; Poliovirus, and other specific types by name

endocytosis of, 177

liposome interactions with, 300

resistance to, 311–314

Viscosity, intrinsic vesicle, 35, 40, 41

Volume-trapping efficiency, of liposomes
alcohol injection method, 257
aqueous concentration and, 266–267
calcium-induced, sonicated, 264
ether injection made, 252–256
handshaken (Babraham method), 257
by size and type, 259, 264

Water, phospholipid
bound, in liposomes, 38–40
of hydrated, calculation of, 39–41
permeability of, *see* Water permeability
trapped, 36–37

Water permeability, phospholipid
cholesterol effects on, 94
phase transition temperature and, 86–87, 100

White blood cells (WBC), *see* Leukocytes





Index of Contributors

(Italicized page numbers refer to comments made in discussion.)

Allen, N., 70-96, 95-96

Bachrach, S., 374, 393, 438

Bateman, J. L., 390-391

Bennett, D. B., 110-120, 141-142

Beresford, H. R., 339-348, 345-348, 392-393, 433-434, 436, 437, 438, 439, 440

Boshes, B., 11-18, 225-226, 328, 347

Braunstein, P., 143-167, 168-183, 211, 214, 263, 265-271, 280

Brun, A., 184-214

Brush, J., 398-416

Burkholder, J., 70-96

Capron, A. M., 45-61, 347, 349-362, 359-362, 373, 390, 391-392

Caronna, J., 95, 264

Carse, J. P., 322-328, 327, 328

Chaloner, J., 281-292

Comiscioni, J., 70-96

Cranford, R. E., 440-441

Fein, J., 97-104, 108, 208, 418-419

Frappier, J., 345

Gayet, H., 241-251

George, A. E., 168-183

Glass, 96

Goldensohn, E. S., 137-142, 140, 141, 209

Goldman, M. H., 141, 263, 438

Goodman, J., 211-214, 259-261, 280

Grenvik, A., 96, 141, 226, 227, 346, 437

Harden, A., 281-292

Hardy, P. M., 393

Hass, W. K., 105-109, 108, 109, 214

Hauerwas, S., 329-338, 337-338

Hawkins, R. A., 105-109

Henry, C., 337

Hinterbuchner, L. P., 140

Horan, D. J., 363-375, 373-375, 393

Hughes, J. R., 121-136, 140-141, 279

Ingvar, D., 96, 108, 109, 184-214, 208-209, 210, 211, 214, 224, 304

Johansson, L., 184-214

Kalkines, G., 425-431

Keene, B., 347, 376-393, 391, 392, 393

Kleiman, M. A., 425-431

Knill-Jones, R. P., 293-306

Korein, J., 1-5, 6-10, 19-38, 95, 96, 142, 143-167, 168-183, 256-259, 265-271, 320-321, 439-440

Kricheff, I. I., 143-167, 168-183

Leaffer, T., 318, 359, 360

Levy, D. E., 293-306, 304-305

Lieberman, A., 143-167

Milhaud, A., 241-251, 263-264, 434-436

Molinari, G. F., 62-69, 96, 210, 279, 280, 305

Moraczewski, A. S., 318, 327

Nathanson, M., 209-210

Nesbakken, R., 319, 320, 348, 439

O'Brien, J., 281-292

Ouaknine, G. E., 252-264

Pampiglione, G., 141, 210-211, 280, 281-292, 291, 305

Pearson, J., 108-109, 214, 265-271, 279-280

Pinto, R. S., 168-183, 208

Plum, F., 224-225, 226-227, 261-262, 263, 280, 291-292, 293-306, 305-306

Posner, J. B., 215-227, 226

Van Till, A., 96, 346, 361, 373, 374, 439

Veatch, R. M., 307-321, 318-320, 327-328, 337, 338, 419-420, 422-423

Veith, F. J., 417-441, 434, 436, 438, 439, 440

Vernon, S., 347, 392

Riboulot, M., 241-251

Roelofs, R., 39-44

Samuelsson, S. M., 184-214

Satran, R., 108

Suter, C. R., 142, 262, 291, 398-416, 437, 439

Walker, A. E., 228-240, 263, 264, 272-280, 305

Woolsey, R. M., 361

Youngstein, K., 391

Tendler, M. D., 394-397, 420-422

Zimmet, J., 436-437

Subject Index

Abdominal reflexes as criteria in brain death, 71, 84, 85
Akinese mutism, 203, 219–221, 225
Alaska, 1974 statute in, 429
Alpha coma, 219, 408, 409,
EEG of, 131
Altered consciousness, anatomy of, 221
American Bar Association, statute proposed by, 354, 365–367, 430–431
Angiography
carotid and vertebral, 253
and changes in status of CBF, 208
in demonstrating CBF, 211, 231
in diagnosing brain death, 31, 231, 238
gamma imaging technique, 211–214
See also Intracranial angiography
Ankle reflexes as criteria of brain death, 71, 85, 86
Anoxia
in cats, 231
EEG in, 284, 286–287, 289
effect on brain, 97–98
Apallic syndrome, 21, 219, 302
case material on, 186–198
CBF in, 184, 202, 204–205
corneal reflex in, 201
definition of, 9, 184–185, 202–203
EEG in, 184, 202–203, 205
eye movement in, 304
pathogenesis, 203–204
pupillary reflex in, 201
spinal reflexes in, 201
term discussed, 225
Apnea
correlations with ECS, 114, 116
defined, 9, 113
diagnosis in comatose patients, 216–217
in disconnecting tests, 241–250
and patients with brain waves, 117–119
quantification of, 241
Apneic oxygenation, technique of, 217
Arkansas, 1977 right-to-die law in, 52
Artfact
in CT scans, 403
muscle, in EEG, 406–408
Arteriovenous oxygen difference (AVDO₂)
in cerebral metabolism, 228–229
in determining brain death, 238
Artificial respiration, effect on brain, 275
Astrocytes, in defectively perfused brains, 270

Atropine test, 253–255
Audio-ocular reflex
as criteria in brain death, 71, 74, 75, 83, 85, 91
with cardiac arrest, 88
in normal subjects, 87
Auditory blink reflex, *see* Audio-ocular reflex
Autolysis, with absent bolus, 267
AVDO₂, *see* Arteriovenous oxygen difference
Barbitrare intoxication
AVDO₂ in, 230
brain death and, 141
in disconnecting test, 241
ECS and, 122–123
Biblical law, brain death and, 394–395
Biceps reflexes as brain death criteria, 71, 85
Black's Law Dictionary, definition of death in, 345, 425–426
Blood flow, cerebral, *see* Cerebral blood flow
Bodily integration, and definition of death, 310–312, 314, 315
Body, Christian view of, 332
Body fluids, and definition of death, 310, 314, 315
Bolus technique, 162, 211, 253
advantages and limitations, 238
angiography and, 169, 178
clear head bolus in, 149, 150, 152–153
in evaluating cerebral circulation, 143–163, 231
in infants and children, 163
“intermediate” head bolus, 153–164, 161–162, 168
return of flow in, 280
“small” head bolus in, 155–156, 162, 168
technique for, 145–148
Brain
as control system, 24–25
diencephalon, 273

Brain—(cont'd)
weight of, 279-280
See also, Cerebellum; Cortex; Critical system

Brain autopsy in brain death, 253

Brain death
apallic syndrome vs., 202-203
Biblical law and, 394-395
Christian attitudes towards concept, 422-423
concept of, 20, 39-43
deep coma as mimicking, 116-117
defined, 7, 21, 110
irreversibility and, 26-28
maintenance of patient with, 208-209
neuropathology of, 29, 272-279
philosophical basis for, 419-420
protocols for decision-making in, 34
religious concepts of, 330-331
social ramifications of concept, 33-34
as symbol, 336, 337
term discussed, 28, 307-308
See also Cerebral death; Criteria for brain death; Diagnosing brain death; Respirator brain

Brain energetics, cerebral death and, 97-104

Brain function, defined, 21

Brain perfusion, ethics and, 396

Brain scanning, 253

Brain stem
in defectively perfused brains, 270
electrical activity in, 235
in respirator brain, 273

Brain-stem auditory evoked responses, 127-128

Brain-stem death
with cortical life, 129
defined, 7-8, 21

Brain-stem function
absence of, 215-216
in comatose patients, 216
motor activity and, 217-218

Brain-stem injury, simulation of brain death by, 116-117

Brain weight, 279-280

Bulbar reflexes in presumptive brain death, 79, 82

Burst suppression, in EEG, 410

California Natural Death Act of 1976, 52, 54-58, 376
chronology of, 388-390
criticisms of, 380-381
disobedience to, 391-392

living will and, 380, 390-391
opposition to, 379
physicians' attitudes to, 382-383
purpose of, 379
rights of terminally ill under, 382
California, 1974 statute in, 51, 354, 430

Caloric response, *see* Vestibular reflex

Caloric test on brain-dead patients, 253

Capron-Kass model statute, 51, 349, 354, 361, 429-430

Carbon monoxide poisoning, EEG in, 131

Cardiac alterations in brain death, 252-256

Cardiac arrest
apallic syndrome after, 210
cerebral ischemia secondary to, 88-89
EEG in, 282-290
effect on brain, 281
hypoxia from, 116
vegetative state and, 296

Cardiac death, ECS and, 116

Cardiovascular collapse, as criteria for brain death, 64

Carotid angiography, 253

Case law, on brain death, 426-428
See also Statutory definitions of death

Catatonia, defined, 220

Cathepsin, in postmortem autolysis, 276

Central nervous system as control system, 25

Cephalic reflexes
with cardiac arrest, 88
in CS study, 117-118
defined, 10, 113
and ECS, 73-74, 93, 114-116
frequency in normal persons, 87
in presumptive brain death, 71, 74-76, 90-93
with primary brain-stem lesions, 89
in respirator brain, 275-276
See also specific reflexes

Cerebellum
in brain death, 273, 283
in defectively perfused brains, 270

Cerebral anoxia
in apallic syndrome, 201
survival after, 184-207

Cerebral blood flow
angiography in demonstrating, 168-169, 231
in apallic syndrome, 184, 202, 204-205
bolus technique and, 143-163, 214, 231
cerebral circulatory deficit in, 180
in cerebral metabolism, 230-231
changes in status of, 208
in comatose patients, 158-160
computerized tomography and, 237

Cerebral blood flow—(cont'd)
direct demonstration of, 231–232
echoencephalography in determining, 232–233
EEG and, 129–130
in establishing CMRO₂, 229
experimental studies of, 98–104
indirect demonstration of, 232–235
inhalation techniques and, 232
intracranial pressure and, 236
measurements of, 97, 105
pathology of brain death and, 279
postmortem autolysis and, 277
PvO₂ and, 229–230
regional blood flow and, 106
in sleep, 219
tests for, 31, 143–144, 253

Cerebral circulatory deficit, 180

Cerebral death
brain death vs., 95–96, 180, 356, 364–365, 367
brain energetics and, 97–104
concept of, 265, 267
defined, 7, 10, 21
legal issues in, 370–371
metabolic criteria of, 228–230
proposed statute on, 355–356
techniques for confirmation of, 228–238
term discussed, 200–201, 308
See also Brain death; Cognitive death; Neocortical death; Respirator brain

Cerebral evoked response, equipment for, in ICUs, 400

Cerebral metabolic rate of oxygen consumption (CMRO₂), 161, 228–229, 238

Cerebral metabolism
AVDO₂ in, 228–229
cerebral blood flow in, 230–231
CMRO₂ in, 228–229
lactic acid in, 228–230
PvO₂ in, 229–230

Cerebral O₂ consumption, 253

Cerebral oxidative metabolism, 105–107

Cerebral temperature, in diagnosing brain death, 237

Cerebral unresponsivity
defined, 113
ECS and, 114, 116, 130

Cerebrospinal fluid, lactic acid content of, 230

Cerebrum, role of, 265, 267

Children, diagnosing brain death in, 163, 181–182

Christianity
"attitude towards death, 323, 329–337
brain death concept and, 422–423

Chronic vegetative states, *see* Persistent vegetative state

Cognitive behavior, defined, 21

Cognitive death
law and, 339–341
proposed statute on, 335–356
"whole brain" approach vs., 356
See also Cerebral death

Collaborative Study on Cerebral Survival, 419
criteria for brain death in, 65
methods of, 71–72
results of, 72–94

Coma
alpha-frequency coma, 408, 409
vs. apallic syndrome, 203
apnea and, 216–217
deep, 116–117, 158–159
defined, 294
differential diagnosis of, 215–218, 222–223
as diminished state of consciousness, 219–220
EEGs of patients in, 408–411
evaluation of patients with long-standing, 412
irreversible, 9
nontraumatic, 296, 302
oculovestibular responses in, 216–217
patients with brain waves in, 117–119
"pseudocoma," 220–221
pupillary fixation in, 216
term discussed, 209
theta-frequency coma, 408
unresponsive, 8
See also Coma dépassé; Coma vigile; Deep coma; Nontraumatic coma; Reversible coma

Coma dépassé, 7, 29, 70, 234

Coma vigile, 184, 203

Common law
anatomical gift act and, 48–49
definitions of death in, 48, 349, 350, 363

Commonwealth v. Golston, 351

Computerized tomography, 237, 263, 277, 400–403

Concept, defined, 6, 19–20

Consciousness
classification of states of, 218–223
irreversible loss of, 314, 315

Constructs, defined, 6, 19–20

Consultants, problems related to, 412–413

Control systems, in living systems, 24-25
Corneal reflex
in apallic syndrome, 201
with cardiac arrest, 88
as criteria in brain death, 71, 73-75,
79, 82-87
in presumed brain death, 80, 81, 92, 93
in vegetative state, 298-300, 305
Cortex, in respirator brain, 273-274
Cortical life, with brain-stem death, 129
Cost containment, 369, 374-375
Cough reflex, as criteria for brain death,
71, 74, 75, 80, 85
with cardiac arrest, 88
in potential survivors, 93
Criteria, defined, 6, 19-20
Criteria for brain death, 20, 26, 138-139,
215-216, 412, 415
cardiovascular collapse, 64
current, 32
development of, 28-31
See also Electroencephalography; Harvard criteria
Critical system, defined, 26-27
CSF in diagnosing brain death, 238
CT scan, *see* Computerized tomography

D

Death

brain-stem, 7-8, 21, 129
Christian attitudes towards, 329-336
concepts of, 20, 39-40, 308-313
conceptual and technical questions in,
313-314
criteria of, *see* Criteria of death
determination of moment of, 329-330
dual criteria of, 27-28
Eastern attitude towards, 322-323
as event, 22
historical evolution of attitudes to, 11-
17
irreversible loss of consciousness as,
312-315
loss of bodily integration as, 310-312,
314, 315
loss of capacity for social interaction
as, 312-314
loss of the soul as, 309-310
moral attitude towards, 322-327
"natural," 335-336
policy questions on, 315-317
as process, 22
statutory definitions of, *see* Statutory
definitions of death
systemic, 21
terminology of, 20-22

Western attitude towards, 322-324
See also Brain death; Definition of
death; Legal death
Deceased, rights of, 41
Declaration of Sydney, 30-31
Deep coma
CBF in, 158-159
as mimicking brain death, 116-117
Definition of death
in Biblical law, 395
in *Black's Law Dictionary*, 345, 425-
426
cerebral vs. brain death, 364-365
classical, 23, 27
common law, 349
double vs. single standard, 354
ethical issues in, 395-396
legal, *see* Legal definition of death;
Statutory definitions of death
statutory, *see* Statutory definitions of
death
Delta waves in EEG, 408, 410, 411
Depth recording of brain electrical ac-
tivity, 234-235
Diagnosing brain death, 413
disconnecting tests in, 241-250
etiologic basis for, 32
pitfalls in, 216-223
Diencephalon in brain death, 273
Diminished consciousness, states of, 219
Disconnecting tests, 241-250, 263
Discrimination indices, 83-87
Doll's-eye response, *see* Oculocephalic re-
flex
Drug intoxication
AVDO₂ in, 230
deep coma and, 116
in disconnecting test, 241
ECS and, 122-123
EEG in, 218
as mimicking brain death, 32-33, 116-
117
as pitfall in diagnosis of brain death,
143, 216-218
recovery from ECS and, 115-116
in survivors of presumptive brain
death, 76-83
See also Barbiturate intoxication
Dying, care of, 334-335
See also Terminally ill patients
Dynamic flow sequence, in bolus tech-
nique, 162

Echoencephalography, 232-233, 253
Electrocardiogram (EKG), 122, 252-254

Electrocerebral silence (ECS), 228, 408
apnea and, 114, 116
cardiac death and, 116
cephalic reflexes and, 73, 93, 114–116
clinical signs and, 128–129
definition, 110–112
drug intoxication and, 115–116, 122–126
evoked potentials and, 127–128
hypothermia and, 123–124, 211
spinal reflexes and, 73–74, 115
visual responses (VER) and, 127

Electrocorticography, 112

Electroencephalography, 112, 228, 262, 289
in akinetic mutism, 203
in apallic syndrome, 184, 202–203, 205
blood pressure and, 233
in brain death, 31, 110–119, 132, 253, 419
in cardiac arrest, 282–290
in coma dépassé, 29
depth recording of, 234–235
in diminished states of consciousness, 219–220
evoked potentials in, 235
ipsilateral changes in, 131
isoelectric, 144
in locked-in syndrome, 221
misleading signs in, 130–131
muscle artefact in, 406–408
pitfalls in interpretation, 218, 281, 288
prognostic value, 131–132, 284–285, 287–290
reader concurrence, 112–113
in respirator brain, 275–276
steady potentials in, 235–236
technical difficulties with, 121–122
use in ICUs, 400, 403–410
versus other criteria, 137–139
See also Electrocerebral silence

Electromyogram (EMG), 122

Electronystagmography test, 253

Electro-oculogram (EOG), 122

Electroretinogram (ERG), 122

Entropy in open systems, 23–25

Epicurean attitude towards death, 324

Ethical issues
in apallic syndrome, 206, 210
in brain death, 41–43
cerebral vs. brain death, 364–365, 367–368, 371
in human experimentation, 318–319
redefinition of death and, 337–338
technology and, 325–328

Euthanasia, 340
arguments against, 372
California Natural Death Act and, 380–382
cerebral death and, 365
as homicide, 368–369
physician's role in, 369, 373–374
statutory definitions of death and, 354
termination of treatment and, 369–370

Evoked cortical potentials, 235
ECS and, 127–128

Extracranial circulation in bolus technique, 157–159

Eye movements
in apallic syndrome, 304
in vegetative state, 295, 297, 301–302, 304–305
See also Spontaneous eye movements

F

Funeral customs, history of, 11–13

Gag reflex, *see* Pharyngeal reflex

Gamma imaging technique, 211–214, 253, 259

Georgia, 1975 statute in, 51, 354, 430

Glucose metabolism in brain, 106, 108

Grave-robbing statutes, 46

H

Harvard criteria, 30, 41–42, 63, 66–67, 70, 308
cerebral death and, 364–365
common law conflict with, 48–49
irreversible coma and, 311, 314
legal issues and, 361–362
validity of, 418–419

Head trauma
cerebral oxidative metabolism and, 105–107
study of, in ICUs, 401

"Heart" as metaphor, 331

Herniation
in brain, 267, 270
effect on EEG, 130

Homicide
euthanasia as, 368–369
termination of treatment as, 340–342, 345–346

Hospitals, terminally ill in, 327

Human experimentation
ethical issues in, 41–42, 318–319
legal guidelines in, 359–361

Hypercapnic acidosis, in disconnecting tests, 245
Hypersomnia, 219-220, 222
Hyperventilation, in disconnecting tests, 241
Hypotension, in presumptive brain death, 76
Hypothermia, 72-73
 ECS with, 123-124, 211
 spontaneous, apnea and, 241

Idaho, 1977 statute in, 51, 354, 430
Induced movements
 correlation with ECS, 74, 115
 as criteria in brain death, 71-72, 75, 84-86, 92
 in survivors, 80
Infants, diagnosing brain death in, 163, 181-182
Information
 definition of, 24
 in open systems, 24-26
Informed consent, patients', 378
Inhalation techniques, in demonstrating CBF, 232
Intensive care units, 33
 baseline studies by, 401
 equipment in, 400
 neurophysiology laboratories in, 398
 personnel in, 400
Intra-arterial isotope perfusion in demonstrating CBF, 232
Intracerebral techniques of demonstrating CBF, 232
Intracranial angiography
 cerebral infarction and, 169
 circulation in posterior fossa, 174, 178, 180-181
 extravasation in, 174, 178-179, 181
 intracranial hemorrhage and, 169
 transtentorial hippocampal herniation, 174
 See also Angiography
Intracranial blood flow, 157, 169, 172-175, 180-181
 brain destruction and, 418
 See also Cerebral blood flow
Intracranial pressure in diagnosing brain death, 236, 238, 253, 261
Intrathecal injection of radioiodinated serum albumin, 253
Intrathecal spinal injection of RISA, to determine brain death, 236
Iowa, 1974 statute in, 430

Irreversible coma
 brain death vs., 28, 222
 defined, 9, 21
 in Harvard criteria, 311, 314
See also Apallic syndrome; Irreversible noncognitive state; Neocortical death; Persistent vegetative state

Irreversible noncognitive state, 21

Ischemia

 EEG in, 284, 286-287, 289
 resistance to, 130

Isoelectric EEG

 in comatose patients, 217
 conditions producing, 234

See also Electrocerebral silence

Isotope angiography, 231, 238, 259-262

Japanese criteria of brain death, 64, 66-67

Jaw jerk

 with cardiac arrest, 88
 as criteria of brain death, 71, 73-75, 79-82, 85, 91

 in normal subjects, 87

Jewish law, accord of brain death concept with, 420-422

See also Biblical law

Kansas, 1970 statute in, 344, 354, 428-429

Knee reflexes as criteria in brain death, 71, 84-86

Lactic acid

 in cerebral metabolism, 228-231
 as content of cerebrospinal fluid, 230

 in postmortem autolysis, 277

Legal definition of death, 48-52

 effect on administration of justice, 350

 interests of society in, 49

 judicial role in framing, 351

 legislative role in framing, 352

 medical expertise and, 49, 350-351

 uncertainty about, 350

Legal fictions, 349

Legislation

 on organ transplantation, 45-49, 423-425

 on termination of treatment, 52-58, 342

See also Statutory definitions of death

Life
definition of, 22-23
potential for, 23
sacredness of, 331-334
See also Living systems

Light reflex, *see* Pupillary reflex

Living systems
control systems of, 24-25
irreversible states of, 26-28
as open systems, 23-24
See also Open systems

"Living will" laws, 343
California Natural Death Act and, 380, 390-391

Locked-in syndrome, 203, 220-221
differential diagnosis of, 225-226

Mari case, 52

Maryland, 1972 statute in, 349, 429

Medical research and attitudes towards death, 324-325

Medical technology, needs of terminally ill and, 377

Medicine, cultic qualities of, 325-326

Meprobamate intoxication, ECS and, 122

Mercy killing, euthanasia distinguished from, 381-382
See also Euthanasia

Metabolic changes in brain death, 252, 255

Metabolism, cerebral, *see* Cerebral metabolism

Michigan, 1975 statute in, 430

Midbrain reticular formation lesions, 106

Montana, 1977 statute in, 430

Moral issues, *see* Ethical issues

Motor abnormalities in coma, 219-220

Motor activity
in comatose patients, 217
drug intoxication and, 218
in presumptive brain death, 74-76
in vegetative state, 294, 295, 298-299, 300, 302

Movements, correlation with ECS, 115
See also Induced movements; Spontaneous movements

Muscle tone
with cardiac arrest, 88
as criteria in brain death, 71, 78, 85-86, 92

Myoclonic jerks, in EEG, 410

“Natural death”, 335-336

Negentropy, 25

Neocortical death
Christian view of, 333-334
defined, 8
as irreversible coma, 21
term debated, 200-201
See also Cerebral death

Nervous system, plasticity in, 107

Neurologic recovery, from coma, 294-296

Neurons, in patients with absent bolus, 267

Neurophysiology laboratories, in ICUs, 398, 399

Neuroscience progress sheets, in ICUs, 401

New Hampshire, 1977 right-to-die law, 52

New Mexico, 1973 statute in, 52, 429

New York City Health & Hospitals v. Sulsona, 50

New York State Anatomical Gifts Act, 428

NINDS Collaborative Study, 63

Noncognitive states
brain death vs., 28
defined, 8-9

Nontraumatic coma, 296, 302

North Carolina, 1977 statute in, 52, 357

Nurses in ICUs, 400

Ocular reflexes in presumptive brain death, 79, 82

Oculocephalic reflex
cardiac arrest with, 88
as criteria in brain death, 71, 74, 75, 83-87

depth of unconsciousness and, 209
in presumed brain death, 91-93
in vegetative state, 298

Oculovestibular response
in comatose patients, 216-217
as criteria for brain death, 215-216
depth of unconsciousness and, 209
in vegetative state, 298

Oklahoma, 1975 statute, 51, 430-431

Open systems
defined, 21-22
information in, 24-26
See also Living systems

Ophthalmic artery blood flow in determining CBF, 233-234

Organ transplantation, 30-31
 anencephalic donors, 141-142
 apallic syndrome and, 210
 ethical issues in, 41-42, 396-397
 "extraordinary care" and, 33
 hypotension and, 64
 legal barriers to, 45-50
 problems of supply, 47
 role of ICUs in, 411-412
 statutes on, 45-49, 423-425
See also Uniform Anatomical Gift Act
 Orthodox Jewish law, *see* Jewish law
 Oregon, 1975 statute in, 51, 429
 Oxidative metabolism
 of brain, 97-98
 experimental study, 98-103
 Oxygen uptake in disconnecting tests, 246

P ancuronium bromide in determining ECS, 408
 Parental decisions in termination of treatment, 344-345
 Pathology of brain death, 272-279
 Patient consent, experimentation and, 360
 Patients' rights, 41
 termination of treatment and, 53-56, 328, 341, 378-379, 382
People v. Flores, 351
People v. Lyons, 370-371, 427
 Perioral facial reflex, *see* Snout reflex
 Persistent vegetative state
 defined, 8-9, 219-222
 neocortical death and, 8, 21, 27, 160
 proposed statute on, 355-356
 term discussed, 224-225
See also Quinlan case
 Pharyngeal reflex
 cardiac arrest with, 88
 as criteria for brain death, 71, 74, 75, 80, 83, 85
 in survivors, 80, 93
 Physicians
 California Natural Death Act and, 382-383, 391-393
 euthanasia, 369, 373-374
 needs of terminally ill and, 377
 social attitudes towards, 323-326
 statutory definition of death and, 424-425
 termination of treatment and, 341-342, 344, 345
Pius XII, proclamation of, 28-29
 Plantar responses as criteria in brain death, 71, 84, 85, 91-92

Posterior fossa
 circulation in, 174, 178, 180-181
 EEG and lesions in, 130
 exclusion of, in bolus technique, 145
 in respirator brain, 276-277
 Postmortem autolysis, biochemical changes in, 276-277
 Primary diagnoses, correlation with EEG, 113, 114
 Privacy, right to, 378
 "Prolongation of Life, The" (Pius XII), 28-29
 Protestant thought, accord of brain death concept with, 423
 "Pseudocoma," 220-222
 "Pseudo-isoelectric" EEG, 122-123
 Psychological problems, related to coma, 413
 Pulmonary insufficiency, disconnecting test with, 263
 Pupillary fixation, in comatose patients, 216-217
 Pupillary reflex
 in apallic syndrome, 201
 in cardiac arrest, 88
 in coma, 219-220
 as criteria in brain death, 71, 74, 75, 82-87
 in presumed brain death, 91-93
 Pupil size
 with cardiac arrest, 88, 93
 in presumed brain death, 90-91, 93, 215
 PVO₂, in determining brain death, 238
 PVS, apallic syndrome and, 9

Quinlan case, 52, 320-321, 334-341, 425
 termination of treatment and, 346-347

Radial reflexes as criteria of brain death, 71, 85
 Radioactive tracers
 in evaluating cerebral circulation, 143-163
¹³³Xe isotope technique, 185, 203, 205
See also Bolus technique
 Radioisotopic bolus technique, 31, 130
 medical ethics and, 395
See also Bolus technique
Reginia v. Potter, 351
 Regional brain glucose metabolism, 106

Religious attitudes
history of, towards death, 11-14
toward identification of person with
brain death, 42-43

REM sleep, 218-219

Research, *see* Human experimentation

Respiration
in coma, 219
in survivors, 77, 78, 80
See also Spontaneous respiration

Respirator brain, 9, 87, 89, 275-278

Respiratory pattern in vegetative state, 298

Resuscitation
after cardiac arrest, 281, 284-290
quality of survival after, 283, 287-288
stages after, 287-289

Reticular formation lesions, 105-107

Reye's syndrome, 410

Rheoencephalography, 234, 238

RISA, spinal injection of, to determine
brain death, 236

Roman Catholic ethics, accord of brain
death concept with, 422-423

Rostral reorganization, 107, 108

Rostral reticular formation lesions, 106

Scavenger cells, in patients with defec-
tively perfused brains, 270

Seizures, treatment of, 410-411

Simultaneous bilateral reticular formation
lesions, 106

Skeletal muscle tone, in vegetative state, 295, 299

Sleep, 218-219
Slow-wave sleep, 218-219
"Small" bolus, 214

Smith v. Smith, 426

Snout reflex
cardiac arrest with, 88
as criteria of brain death, 71, 73-75,
79-80, 82-83, 85, 91
in normal subjects, 87

Social interaction, loss of capacity for
as definition of death, 312, 314

Soul, loss of, as definition of death, 309-
310

Spinal cord
with absence of bolus, 267
in respirator brain, 272-273

Spinal reflexes, 10, 85, 86, 418-419
in apallic syndrome, 201
defined, 10
as discrimination indices, 74-76, 84, 91,
218
ECS and, 73-74, 115

in locked-in syndrome, 225-227
in survivors, 81-83

Spindle activity, in EEG, 408, 410, 411

Spontaneous eye movements, in vegetative
state, 295, 298

Spontaneous hypothermia, apnea and, 241

Spontaneous movement
with cardiac arrest, 88
as criteria in brain death, 71-72, 75,
84-87, 92
with ECS, 74, 115

Spontaneous respiration
in biblical sources, 421
in comatose patients, 217
in presumptive brain death, 83, 84,
215-216
testing for, 413

State v. Brown, 426

Statutory "conscience clause," 356-357

Statutory definitions of death, 50-52, 363
American Bar Association (1975), 51,
356, 365-366
California (1974), 354
Capron-Kass model statute (1972), 51,
349, 354, 361
degree of specificity in, 352
euthanasia and, 354
Georgia (1976), 51, 354
Idaho (1977), 354
Kansas (1970), 50, 51, 349, 353, 354
Maryland (1972), 349
medical opposition to, 350, 353
North Carolina (1977), 357
Oklahoma, 51
Oregon (1975), 51
scientific basis for, 353
uniformity in, 352-353, 357
See also Case law

Steady potentials, in diagnosing brain
death, 235-236

Stroke, ICUs and, 401, 403, 404

Subcortical activity, ECS and, 126-127

Succinylcholine, 406-408

Suicide
euthanasia as, 369
rejection of treatment and, 370

Suppression burst pattern, in EEG, 123

Survival, quality of, 287-289

Survivors, of presumptive brain death,
76-83

Swallow reflex
as criteria of brain death, 71, 74, 75,
84, 85
in survivors of presumptive brain death,
80, 81, 93

Swedish criteria of brain death, 64, 66-67

Systemic death, defined, 6, 21

Technetium pertechnate, in bolus technique, 145
Technetium sulfur colloid, in bolus technique, 145
Technology, moral issues and, 325-328
Tendon reflexes
 in presumed brain death, 91
 in vegetative state, 295, 299
Tennessee, 1976 statute in, 431
Terminally ill patients
 medical technology and, 377
 preparation of health professionals and, 377
 and specialization of medicine, 377
 See also Dying
Termination of treatment
 changes in physician's role, 341-342
 distinguished from euthanasia, 369-370
 legislation and, 52-58, 342, 344-348
 nonlegislative options, 343-344
 patient's choice of, 328
 Quinlan case and, 339-340
Thalamic system in apallic syndrome, 210-211
Thalamus
 electrical activity of, 235
 rostral reorganization at level of, 107
Theta coma, 407-409, 412
Thermodynamics, open systems and, 23-24
Thomas v. Anderson, 426
Total brain infarction, *see* Brain death
Transitory ischemia, *see* Ischemia
Transplantation, *see* Organ transplantation
Transtentorial hippocampal herniation, 174
Triceps reflex as criteria of brain death, 71, 85
Triphasic waves, in EEG, 131
Tucker v. Lower, 351, 371, 426-427
"Twilight states," in California Natural Death Act, 380

Uncontrolled seizures, treatment of, 410-411
Uniform Anatomical Gift Act, 46-50, 316, 430
Unresponsive coma, defined, 8

Value theory, 25-26
Vascular endothelium in defectively perfused brains, 270
Vascular filling in brain death, 161
Vegetative behavior, defined, 21
Vegetative state
 defined, 294
 early prediction of, 299-300
 nontraumatic causes of, 296
 prognosis, 293-303
 See also Persistent vegetative state
Verbal responses in vegetative state, 295, 297
Vertebral angiography, 253
Vestibular reflex
 cardiac arrest with, 88
 as criteria in brain death, 71, 74, 75, 79, 82-87
 in presumed brain death, 91, 92, 93
Vestibulo-ocular reflex in coma, 219
Virginia, 1973 statute in, 429
Visual responses (VER) in patients with ECS, 127
"Vital" body fluids and definition of death, 310
Vital signs, predictive value of, 113-114

Wakefulness, 218-219, 293
West Virginia, 1975 statute in, 430

¹³³**Xe** isotope technique, 185, 203, 205



Author Index

(Italicized page numbers refer to comments in discussions)

Abkowitz, M. A., 459-466

Akhtar, M., 726-736

Allen, W. N., 759-766

Amieli, J., 467-480

Andersen, Jan R., 293-300, 343-354

Anzai, Hiroyuki, 256-268

Ashwell, G. J., 417-441

Balch, Alan L., 651-662

Barton, Jacqueline K., 686-700

Baughman, R. H., 705-725, 775-787

Bechgaard, Klaus, 293-300, 467-480

Bloch, Aaron N., *165*, 209, 332, 366-368, 458

Bradley, Mark G., 588-593

Bray, J. W., 407-416

Brill, J. W., 459-466

Burlich, James, 799

Candela, G. A., 377-381

Cape, T., 377-381

Cava, M. P., 355-360

Chaikin, Pau! M., 128-144, 459-466

Chance, R. R., 705-725

Chartier, Duane, 788-799

Chen, C. H., 78

Chiang, C. K., 726-736

Clardy, J., 382-394

Clark, R. J. H., 495, 672-685

Cohen, M. J., 726-736

Coleman, Lawrence B., 316-332, 441, 458

Coler, M., 538

Comès, Robert, 234-243, 406

Conwell, Esther, 183-209, 458

Coppens, P., 60, 244-255, 538

Cornish, T. F., 525-538

Cowan, Dwaine O., 366-368

Craven, Robert A., 343-354

Cuellar, E., 580-587

Cutforth, Brent D., 788-799

Datars, W. Ross, 788-799

Dauplaise, D., 382-394

Davis, M., 744

Day, P., 9-24, 110, 495, 558

DeCorpo, J. J., 759-766

Delhaes, P., 467-480

Duke, C. B., 166-178, 315, 331

Elbaum, C., 745-758

Eley, D. D., 417-441

El Sharif, Mohammed, 663-671

Endres, Helmut, 617-632, 663-671

Engler, Edward M., *60*, 78, 293-300, 343-354

Epstein, Arthur J., *165*, 183-209, 233, 416, 458, 459-466

Etemad, Shahab, 343-354, 737-744

Fabre, J. M., 467-480

Ferguson, Richard, 822

Finnegan, T. F., 377-381

Fitchen, D. B., 771-774

Flandrois, S., 467-480

Froix, M. F., 459-466

Gamble, F. R., 86-110

Garito, A. F., 301-315

Geiss, R. H., 737-744

Geoffroy, Gregory L., 588-593

Gill, W. D., 737-744, 771-774

Gillespie, Ronald J., 788-799

Giral, L., 467-480

Glick, M., 377-381

Gliemann, Günter, 539-559

Goetz, Fred, 360, 736

Gordon, J. G., II, 580-587, 593

Grant, Paul, 291

Gray, H. B., 580-587

Green, Dennis C., 361-365

Greene, R. L., 737-744

Griffiths, C. H., 459-466

Gunning, W., 459-466

Hadek, V., 580-587

Haen, P., 701-704

Hart, H. R., Jr., 407-416

Hashmall, J. A., 377-381

Heeger, A. J., *331*, 332, 459-466, 726-736, 800-822

Hoffman, Brian, 538, 616

Hsu, C.-H., 580-587

Ilsley, W., 377-381

Interrante, L. V., 407-416, *616*

Iqbal, Z., 775-787

Isett, L. C., 61-78, 395-406, *416*

Jacobsen, C. S., 467-480

Johnson, P. L., 525-538

Junker, W. R., 745-758

Kao, H. I., 745-758

Kasper, J. S., 407-416
 Keeney, Mark E., 588-593
 Kelber, J., 525-538
 Keller Heimo J., 442-458, 617-632, 662, 663-671
 Keryer, G., 467-480
 Kistenmacher, Thomas J., 333-342, 538
 Klemm, Richard A., 144
 Kleppinger, J., 726-736, 775-787
 Kokoszka, G. F., 377-381
 Kommandeur, J., 315, 725
 Krug, William P., 366-368
 Kruger, A. A., 79-85
 Kutner, Włodzimierz, 767-770
 Kuyper, J., 737-744

Labes, M. M., 745-758
 Lakshminantham, M. V., 355-360
 LaPlaca, S. J., 369-376
 Lehmann, R., 617-632
 Lippard, Stephen J., 686-700
 Little, W. A., 459-466
 Louis, E. J., 726-736
 Love, P., 745-758

MacDiarmid, Alan G., 726-736, 757, 767-770, 775-787, 799, 800-822
 Mah, P. T., 759-766
 Mann, K., 580-587
 Mark, Harry B., Jr., 767-770
 Marks, Tobin J., 594-616, 822
 Martin, Reinhold, 663-671
 McGhie, A. R., 301-315
 Meerschaut, A., 701-704
 Mégnamisi-Bélombé, Michel, 633-650
 Megert, S., 234-243
 Meinwald, J., 382-394
 Metzger, Robert Melville, 145-165, 255, 292
 Meyer, Thomas J., 496-508
 Miller, Joel S., 1-8, 25-60, 183-209, 459-466, 616
 Milliken, J., 726-736
 Monceau, P., 701-704
 Moran, M. J., 726-736
 Morawitz, H., 179-182
 Moroni, W., 442-458
 Murakami, Mutsuaki, 269-292
 Myer, G., 745-758

Nigrey, P. J., 301-315
 Nöthe, D., 442-458
 Novatny, M., 459-466
 Nowak, Robert, 767-770

Ohno, Teruaki, 256-268
 Ong, N. P., 292

Pasquali, G., 525-538
 Patel, Vishnu V., 343-354
 Peebles, D. L., 726-736
 Perez-Albuerne, E. A., 395-406
 Perlstein, J. H., 61-78, 209, 291, 457, 616
 Peterson, Selmer W., 560-579
 Piacente, P. A., 407-416
 Poehler, Theodore O., 366-368
 Pouget, J. P., 234-243
 Poveda, Arnulfo, 617-632
 Putnik, C., 525-538

Reis, Arthur H., 110, 560-579
 Reynolds, G. A., 61-78
 Rouxel, Jean, 110, 701-704
 Row, T. N. Guru, 244-255

Saalfeld, F. E., 759-766
 Salomon, M. B., 525-538
 Samson, S., 580-587
 Saran, Mohan, 744
 Schaffman, M. J., 525-538
 Schechtman, Barry, 725
 Schultz, A. J., 509-515, 525-538
 Scott, Bruce A., 343-354, 369-376
 Scott, J. C., 382-394
 Shirakawa, H., 726-736
 Siedle, A. R., 232, 360, 377-381, 766
 Silverman, B. D., 165, 369-376
 Slade, M. L., 459-466
 Smith, R. D., 737-744
 Somoano, R., 110, 292, 441, 580-587
 Soos, Z. G., 127, 442-458, 725
 Stanley, George C., 593
 Street, G. B., 737-744, 771-774
 Stucky, Galen, 525-538

Takabe, Teruhiro, 256-268
 Tanaka, Chizuko, 256-268
 Tanaka, Jiro, 256-268
 Tanaka, Masashi, 256-268
 Tanner, D. B., 459-466
 Taube, Henry, 481-495
 Temkin, H., 382-394, 771-774
 Thomas, G. A., 79-85
 Träger, Ulrich, 663-671
 Tomkiewicz, Yaffa, 343-354
 Toreilles, E., 467-480
 Torrance, J., 24, 210-233, 369-376, 538, 559

Underhill, A. E., 516-524

Van Allen, J. A., 61-78
 Van de Sand, H., 617-632

Van Duyne, R. P., 377-381
Van Schyndel, André, 788-799
Vu, Dong, 617-632

Wallwork, S. C., 417-441
Washeck, D. M., 525-538
Watkins, G. D., 407-416
Welber, B., 369-376
Willett, Roger D., 111-127
Williams, Jack M., 509-515, 525-538
Williams, R., 580-587

Willis, M. R., 417-441
Wood, D. J., 516-524
Woodward, J., 417-441
Woyciech, P. M., 377-381
Wudl, F., 79-85, 360, 736
Wyatt, J. R., 759-766

Yamagishi, F. G., 301-315
Yersin, Hartmut, 539-559
Yoshimura, Susumu, 269-292

